#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Dysconnectivity of the medio-dorsal thalamic nucleus in drug-naïve first episode schizophrenia: diagnosis-specific or trans-diagnostic effect?
1-1	0-15	Dysconnectivity	_
1-2	16-18	of	_
1-3	19-22	the	_
1-4	23-35	medio-dorsal	_
1-5	36-44	thalamic	_
1-6	45-52	nucleus	_
1-7	53-55	in	_
1-8	56-66	drug-naïve	_
1-9	67-72	first	_
1-10	73-80	episode	_
1-11	81-94	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-12	94-95	:	_
1-13	96-114	diagnosis-specific	_
1-14	115-117	or	_
1-15	118-134	trans-diagnostic	_
1-16	135-141	effect	_
1-17	141-142	?	_

#Text=Converging lines of evidence implicate the thalamocortical network in schizophrenia.
2-1	143-153	Converging	_
2-2	154-159	lines	_
2-3	160-162	of	_
2-4	163-171	evidence	_
2-5	172-181	implicate	_
2-6	182-185	the	_
2-7	186-201	thalamocortical	_
2-8	202-209	network	_
2-9	210-212	in	_
2-10	213-226	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-11	226-227	.	_

#Text=In particular, the onset of the illness is associated with aberrant functional integration between the medio-dorsal thalamic nucleus (MDN) and widespread prefrontal, temporal and parietal cortical regions.
3-1	228-230	In	_
3-2	231-241	particular	_
3-3	241-242	,	_
3-4	243-246	the	_
3-5	247-252	onset	_
3-6	253-255	of	_
3-7	256-259	the	_
3-8	260-267	illness	_
3-9	268-270	is	_
3-10	271-281	associated	_
3-11	282-286	with	_
3-12	287-295	aberrant	_
3-13	296-306	functional	_
3-14	307-318	integration	_
3-15	319-326	between	_
3-16	327-330	the	_
3-17	331-343	medio-dorsal	_
3-18	344-352	thalamic	_
3-19	353-360	nucleus	_
3-20	361-362	(	_
3-21	362-365	MDN	_
3-22	365-366	)	_
3-23	367-370	and	_
3-24	371-381	widespread	_
3-25	382-392	prefrontal	_
3-26	392-393	,	_
3-27	394-402	temporal	_
3-28	403-406	and	_
3-29	407-415	parietal	_
3-30	416-424	cortical	_
3-31	425-432	regions	_
3-32	432-433	.	_

#Text=Because the thalamus is also implicated in other psychiatric illnesses including post-traumatic stress disorder (PTSD) and major depressive disorder (MDD), the diagnostic specificity of these alterations is unclear.
4-1	434-441	Because	_
4-2	442-445	the	_
4-3	446-454	thalamus	_
4-4	455-457	is	_
4-5	458-462	also	_
4-6	463-473	implicated	_
4-7	474-476	in	_
4-8	477-482	other	_
4-9	483-494	psychiatric	_
4-10	495-504	illnesses	_
4-11	505-514	including	_
4-12	515-529	post-traumatic	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[1]
4-13	530-536	stress	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[1]
4-14	537-545	disorder	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[1]
4-15	546-547	(	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[1]
4-16	547-551	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[1]
4-17	551-552	)	_
4-18	553-556	and	_
4-19	557-562	major	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[2]
4-20	563-573	depressive	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[2]
4-21	574-582	disorder	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[2]
4-22	583-584	(	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[2]
4-23	584-587	MDD	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[2]
4-24	587-588	)	_
4-25	588-589	,	_
4-26	590-593	the	_
4-27	594-604	diagnostic	_
4-28	605-616	specificity	_
4-29	617-619	of	_
4-30	620-625	these	_
4-31	626-637	alterations	_
4-32	638-640	is	_
4-33	641-648	unclear	_
4-34	648-649	.	_

#Text=Here, we determined whether aberrant functional integration between the MDN and the cortex is a specific feature of schizophrenia or a trans-diagnostic feature of psychiatric illness.
5-1	650-654	Here	_
5-2	654-655	,	_
5-3	656-658	we	_
5-4	659-669	determined	_
5-5	670-677	whether	_
5-6	678-686	aberrant	_
5-7	687-697	functional	_
5-8	698-709	integration	_
5-9	710-717	between	_
5-10	718-721	the	_
5-11	722-725	MDN	_
5-12	726-729	and	_
5-13	730-733	the	_
5-14	734-740	cortex	_
5-15	741-743	is	_
5-16	744-745	a	_
5-17	746-754	specific	_
5-18	755-762	feature	_
5-19	763-765	of	_
5-20	766-779	schizophrenia	_
5-21	780-782	or	_
5-22	783-784	a	_
5-23	785-801	trans-diagnostic	_
5-24	802-809	feature	_
5-25	810-812	of	_
5-26	813-824	psychiatric	_
5-27	825-832	illness	_
5-28	832-833	.	_

#Text=Effective connectivity (EC) between the MDN and rest of the cortex was measured by applying psychophysiological interaction analysis to resting-state functional magnetic resonance imaging data of 50 patients with first episode schizophrenia (FES), 50 patients with MDD, 50 patients with PTSD and 122 healthy controls.
6-1	834-843	Effective	_
6-2	844-856	connectivity	_
6-3	857-858	(	_
6-4	858-860	EC	_
6-5	860-861	)	_
6-6	862-869	between	_
6-7	870-873	the	_
6-8	874-877	MDN	_
6-9	878-881	and	_
6-10	882-886	rest	_
6-11	887-889	of	_
6-12	890-893	the	_
6-13	894-900	cortex	_
6-14	901-904	was	_
6-15	905-913	measured	_
6-16	914-916	by	_
6-17	917-925	applying	_
6-18	926-945	psychophysiological	_
6-19	946-957	interaction	_
6-20	958-966	analysis	_
6-21	967-969	to	_
6-22	970-983	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[3]
6-23	984-994	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[3]
6-24	995-1003	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[3]
6-25	1004-1013	resonance	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[3]
6-26	1014-1021	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[3]
6-27	1022-1026	data	_
6-28	1027-1029	of	_
6-29	1030-1032	50	_
6-30	1033-1041	patients	_
6-31	1042-1046	with	_
6-32	1047-1052	first	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]
6-33	1053-1060	episode	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]
6-34	1061-1074	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]
6-35	1075-1076	(	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]
6-36	1076-1079	FES	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]
6-37	1079-1080	)	_
6-38	1080-1081	,	_
6-39	1082-1084	50	_
6-40	1085-1093	patients	_
6-41	1094-1098	with	_
6-42	1099-1102	MDD	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
6-43	1102-1103	,	_
6-44	1104-1106	50	_
6-45	1107-1115	patients	_
6-46	1116-1120	with	_
6-47	1121-1125	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
6-48	1126-1129	and	_
6-49	1130-1133	122	_
6-50	1134-1141	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]
6-51	1142-1150	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]
6-52	1150-1151	.	_

#Text=All participants were medication-naïve.
7-1	1152-1155	All	_
7-2	1156-1168	participants	_
7-3	1169-1173	were	_
7-4	1174-1190	medication-naïve	_
7-5	1190-1191	.	_

#Text=The only significant schizophrenia-specific effect was increased EC between the right MDN and the right pallidum (p < 0.05 corrected).
8-1	1192-1195	The	_
8-2	1196-1200	only	_
8-3	1201-1212	significant	_
8-4	1213-1235	schizophrenia-specific	_
8-5	1236-1242	effect	_
8-6	1243-1246	was	_
8-7	1247-1256	increased	_
8-8	1257-1259	EC	_
8-9	1260-1267	between	_
8-10	1268-1271	the	_
8-11	1272-1277	right	_
8-12	1278-1281	MDN	_
8-13	1282-1285	and	_
8-14	1286-1289	the	_
8-15	1290-1295	right	_
8-16	1296-1304	pallidum	_
8-17	1305-1306	(	_
8-18	1306-1307	p	_
8-19	1308-1309	<	_
8-20	1310-1314	0.05	_
8-21	1315-1324	corrected	_
8-22	1324-1325	)	_
8-23	1325-1326	.	_

#Text=In contrast, there were a number of significant trans-diagnostic alterations, with both right and left MDN displaying trans-diagnostic increased EC with several prefrontal and parietal regions bilaterally (p < 0.05 corrected).
9-1	1327-1329	In	_
9-2	1330-1338	contrast	_
9-3	1338-1339	,	_
9-4	1340-1345	there	_
9-5	1346-1350	were	_
9-6	1351-1352	a	_
9-7	1353-1359	number	_
9-8	1360-1362	of	_
9-9	1363-1374	significant	_
9-10	1375-1391	trans-diagnostic	_
9-11	1392-1403	alterations	_
9-12	1403-1404	,	_
9-13	1405-1409	with	_
9-14	1410-1414	both	_
9-15	1415-1420	right	_
9-16	1421-1424	and	_
9-17	1425-1429	left	_
9-18	1430-1433	MDN	_
9-19	1434-1444	displaying	_
9-20	1445-1461	trans-diagnostic	_
9-21	1462-1471	increased	_
9-22	1472-1474	EC	_
9-23	1475-1479	with	_
9-24	1480-1487	several	_
9-25	1488-1498	prefrontal	_
9-26	1499-1502	and	_
9-27	1503-1511	parietal	_
9-28	1512-1519	regions	_
9-29	1520-1531	bilaterally	_
9-30	1532-1533	(	_
9-31	1533-1534	p	_
9-32	1535-1536	<	_
9-33	1537-1541	0.05	_
9-34	1542-1551	corrected	_
9-35	1551-1552	)	_
9-36	1552-1553	.	_

#Text=EC alterations between the MDN and the cortex are not specific to schizophrenia but are a trans-diagnostic feature of psychiatric disorders, consistent with emerging conceptualizations of mental illness based on a single general psychopathology factor.
10-1	1554-1556	EC	_
10-2	1557-1568	alterations	_
10-3	1569-1576	between	_
10-4	1577-1580	the	_
10-5	1581-1584	MDN	_
10-6	1585-1588	and	_
10-7	1589-1592	the	_
10-8	1593-1599	cortex	_
10-9	1600-1603	are	_
10-10	1604-1607	not	_
10-11	1608-1616	specific	_
10-12	1617-1619	to	_
10-13	1620-1633	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-14	1634-1637	but	_
10-15	1638-1641	are	_
10-16	1642-1643	a	_
10-17	1644-1660	trans-diagnostic	_
10-18	1661-1668	feature	_
10-19	1669-1671	of	_
10-20	1672-1683	psychiatric	_
10-21	1684-1693	disorders	_
10-22	1693-1694	,	_
10-23	1695-1705	consistent	_
10-24	1706-1710	with	_
10-25	1711-1719	emerging	_
10-26	1720-1738	conceptualizations	_
10-27	1739-1741	of	_
10-28	1742-1748	mental	_
10-29	1749-1756	illness	_
10-30	1757-1762	based	_
10-31	1763-1765	on	_
10-32	1766-1767	a	_
10-33	1768-1774	single	_
10-34	1775-1782	general	_
10-35	1783-1798	psychopathology	_
10-36	1799-1805	factor	_
10-37	1805-1806	.	_

#Text=Therefore, dysconnectivity of the MDN could potentially be used to assess the presence of general psychopathology above and beyond traditional diagnostic boundaries.
11-1	1807-1816	Therefore	_
11-2	1816-1817	,	_
11-3	1818-1833	dysconnectivity	_
11-4	1834-1836	of	_
11-5	1837-1840	the	_
11-6	1841-1844	MDN	_
11-7	1845-1850	could	_
11-8	1851-1862	potentially	_
11-9	1863-1865	be	_
11-10	1866-1870	used	_
11-11	1871-1873	to	_
11-12	1874-1880	assess	_
11-13	1881-1884	the	_
11-14	1885-1893	presence	_
11-15	1894-1896	of	_
11-16	1897-1904	general	_
11-17	1905-1920	psychopathology	_
11-18	1921-1926	above	_
11-19	1927-1930	and	_
11-20	1931-1937	beyond	_
11-21	1938-1949	traditional	_
11-22	1950-1960	diagnostic	_
11-23	1961-1971	boundaries	_
11-24	1971-1972	.	_

#Text=Introduction
#Text=Schizophrenia, a severe psychiatric illness involving delusions, hallucinations and disorganized thinking, is one of the greatest causes of disability worldwide.
12-1	1973-1985	Introduction	_
12-2	1986-1999	Schizophrenia	_
12-3	1999-2000	,	_
12-4	2001-2002	a	_
12-5	2003-2009	severe	_
12-6	2010-2021	psychiatric	_
12-7	2022-2029	illness	_
12-8	2030-2039	involving	_
12-9	2040-2049	delusions	_
12-10	2049-2050	,	_
12-11	2051-2065	hallucinations	_
12-12	2066-2069	and	_
12-13	2070-2082	disorganized	_
12-14	2083-2091	thinking	_
12-15	2091-2092	,	_
12-16	2093-2095	is	_
12-17	2096-2099	one	_
12-18	2100-2102	of	_
12-19	2103-2106	the	_
12-20	2107-2115	greatest	_
12-21	2116-2122	causes	_
12-22	2123-2125	of	_
12-23	2126-2136	disability	_
12-24	2137-2146	worldwide	_
12-25	2146-2147	.	_

#Text=Over the past two decades, magnetic resonance imaging (MRI) techniques such as resting-state functional MRI (rs-fMRI) have allowed the investigation of the neurobiological alterations underlying this disease in vivo.
13-1	2148-2152	Over	_
13-2	2153-2156	the	_
13-3	2157-2161	past	_
13-4	2162-2165	two	_
13-5	2166-2173	decades	_
13-6	2173-2174	,	_
13-7	2175-2183	magnetic	_
13-8	2184-2193	resonance	_
13-9	2194-2201	imaging	_
13-10	2202-2203	(	_
13-11	2203-2206	MRI	_
13-12	2206-2207	)	_
13-13	2208-2218	techniques	_
13-14	2219-2223	such	_
13-15	2224-2226	as	_
13-16	2227-2240	resting-state	_
13-17	2241-2251	functional	_
13-18	2252-2255	MRI	_
13-19	2256-2257	(	_
13-20	2257-2264	rs-fMRI	_
13-21	2264-2265	)	_
13-22	2266-2270	have	_
13-23	2271-2278	allowed	_
13-24	2279-2282	the	_
13-25	2283-2296	investigation	_
13-26	2297-2299	of	_
13-27	2300-2303	the	_
13-28	2304-2319	neurobiological	_
13-29	2320-2331	alterations	_
13-30	2332-2342	underlying	_
13-31	2343-2347	this	_
13-32	2348-2355	disease	_
13-33	2356-2358	in	_
13-34	2359-2363	vivo	_
13-35	2363-2364	.	_

#Text=These studies have revealed widespread alterations within cortical-subcortical-cerebellar networks, and in particular have identified the thalamus as a key structure implicated in the onset and progression of the illness.
14-1	2365-2370	These	_
14-2	2371-2378	studies	_
14-3	2379-2383	have	_
14-4	2384-2392	revealed	_
14-5	2393-2403	widespread	_
14-6	2404-2415	alterations	_
14-7	2416-2422	within	_
14-8	2423-2454	cortical-subcortical-cerebellar	_
14-9	2455-2463	networks	_
14-10	2463-2464	,	_
14-11	2465-2468	and	_
14-12	2469-2471	in	_
14-13	2472-2482	particular	_
14-14	2483-2487	have	_
14-15	2488-2498	identified	_
14-16	2499-2502	the	_
14-17	2503-2511	thalamus	_
14-18	2512-2514	as	_
14-19	2515-2516	a	_
14-20	2517-2520	key	_
14-21	2521-2530	structure	_
14-22	2531-2541	implicated	_
14-23	2542-2544	in	_
14-24	2545-2548	the	_
14-25	2549-2554	onset	_
14-26	2555-2558	and	_
14-27	2559-2570	progression	_
14-28	2571-2573	of	_
14-29	2574-2577	the	_
14-30	2578-2585	illness	_
14-31	2585-2586	.	_

#Text=Within this region, the medio-dorsal thalamic nucleus (MDN) has received particular attention due to its prominent connections to the prefrontal cortex, a region known to be implicated in the illness.
15-1	2587-2593	Within	_
15-2	2594-2598	this	_
15-3	2599-2605	region	_
15-4	2605-2606	,	_
15-5	2607-2610	the	_
15-6	2611-2623	medio-dorsal	_
15-7	2624-2632	thalamic	_
15-8	2633-2640	nucleus	_
15-9	2641-2642	(	_
15-10	2642-2645	MDN	_
15-11	2645-2646	)	_
15-12	2647-2650	has	_
15-13	2651-2659	received	_
15-14	2660-2670	particular	_
15-15	2671-2680	attention	_
15-16	2681-2684	due	_
15-17	2685-2687	to	_
15-18	2688-2691	its	_
15-19	2692-2701	prominent	_
15-20	2702-2713	connections	_
15-21	2714-2716	to	_
15-22	2717-2720	the	_
15-23	2721-2731	prefrontal	_
15-24	2732-2738	cortex	_
15-25	2738-2739	,	_
15-26	2740-2741	a	_
15-27	2742-2748	region	_
15-28	2749-2754	known	_
15-29	2755-2757	to	_
15-30	2758-2760	be	_
15-31	2761-2771	implicated	_
15-32	2772-2774	in	_
15-33	2775-2778	the	_
15-34	2779-2786	illness	_
15-35	2786-2787	.	_

#Text=Task-based studies have reported decreased activation in the MDN of patients during a range of cognitive processes including episodic memory, working memory and attention, whilst resting-state studies have found aberrant functional integration between the MDN and widespread cortical networks including prefrontal, temporal, and parietal regions.
16-1	2788-2798	Task-based	_
16-2	2799-2806	studies	_
16-3	2807-2811	have	_
16-4	2812-2820	reported	_
16-5	2821-2830	decreased	_
16-6	2831-2841	activation	_
16-7	2842-2844	in	_
16-8	2845-2848	the	_
16-9	2849-2852	MDN	_
16-10	2853-2855	of	_
16-11	2856-2864	patients	_
16-12	2865-2871	during	_
16-13	2872-2873	a	_
16-14	2874-2879	range	_
16-15	2880-2882	of	_
16-16	2883-2892	cognitive	_
16-17	2893-2902	processes	_
16-18	2903-2912	including	_
16-19	2913-2921	episodic	_
16-20	2922-2928	memory	_
16-21	2928-2929	,	_
16-22	2930-2937	working	_
16-23	2938-2944	memory	_
16-24	2945-2948	and	_
16-25	2949-2958	attention	_
16-26	2958-2959	,	_
16-27	2960-2966	whilst	_
16-28	2967-2980	resting-state	_
16-29	2981-2988	studies	_
16-30	2989-2993	have	_
16-31	2994-2999	found	_
16-32	3000-3008	aberrant	_
16-33	3009-3019	functional	_
16-34	3020-3031	integration	_
16-35	3032-3039	between	_
16-36	3040-3043	the	_
16-37	3044-3047	MDN	_
16-38	3048-3051	and	_
16-39	3052-3062	widespread	_
16-40	3063-3071	cortical	_
16-41	3072-3080	networks	_
16-42	3081-3090	including	_
16-43	3091-3101	prefrontal	_
16-44	3101-3102	,	_
16-45	3103-3111	temporal	_
16-46	3111-3112	,	_
16-47	3113-3116	and	_
16-48	3117-3125	parietal	_
16-49	3126-3133	regions	_
16-50	3133-3134	.	_

#Text=In addition to schizophrenia, the thalamus has also been implicated in other psychiatric illnesses including post-traumatic stress disorder (PTSD) and major depressive disorder (MDD).
17-1	3135-3137	In	_
17-2	3138-3146	addition	_
17-3	3147-3149	to	_
17-4	3150-3163	schizophrenia	_
17-5	3163-3164	,	_
17-6	3165-3168	the	_
17-7	3169-3177	thalamus	_
17-8	3178-3181	has	_
17-9	3182-3186	also	_
17-10	3187-3191	been	_
17-11	3192-3202	implicated	_
17-12	3203-3205	in	_
17-13	3206-3211	other	_
17-14	3212-3223	psychiatric	_
17-15	3224-3233	illnesses	_
17-16	3234-3243	including	_
17-17	3244-3258	post-traumatic	_
17-18	3259-3265	stress	_
17-19	3266-3274	disorder	_
17-20	3275-3276	(	_
17-21	3276-3280	PTSD	_
17-22	3280-3281	)	_
17-23	3282-3285	and	_
17-24	3286-3291	major	_
17-25	3292-3302	depressive	_
17-26	3303-3311	disorder	_
17-27	3312-3313	(	_
17-28	3313-3316	MDD	_
17-29	3316-3317	)	_
17-30	3317-3318	.	_

#Text=In PTSD, thalamic functional abnormalities are thought to underlie dysregulation of sensory filtering, circadian rhythms, level of alertness and consciousness.
18-1	3319-3321	In	_
18-2	3322-3326	PTSD	_
18-3	3326-3327	,	_
18-4	3328-3336	thalamic	_
18-5	3337-3347	functional	_
18-6	3348-3361	abnormalities	_
18-7	3362-3365	are	_
18-8	3366-3373	thought	_
18-9	3374-3376	to	_
18-10	3377-3385	underlie	_
18-11	3386-3399	dysregulation	_
18-12	3400-3402	of	_
18-13	3403-3410	sensory	_
18-14	3411-3420	filtering	_
18-15	3420-3421	,	_
18-16	3422-3431	circadian	_
18-17	3432-3439	rhythms	_
18-18	3439-3440	,	_
18-19	3441-3446	level	_
18-20	3447-3449	of	_
18-21	3450-3459	alertness	_
18-22	3460-3463	and	_
18-23	3464-3477	consciousness	_
18-24	3477-3478	.	_

#Text=Moreover, with the thalamus being a fundamental component of the mood regulating circuit, functional abnormalities in this region are thought to contribute to emotional dysregulation in MDD.
19-1	3479-3487	Moreover	_
19-2	3487-3488	,	_
19-3	3489-3493	with	_
19-4	3494-3497	the	_
19-5	3498-3506	thalamus	_
19-6	3507-3512	being	_
19-7	3513-3514	a	_
19-8	3515-3526	fundamental	_
19-9	3527-3536	component	_
19-10	3537-3539	of	_
19-11	3540-3543	the	_
19-12	3544-3548	mood	_
19-13	3549-3559	regulating	_
19-14	3560-3567	circuit	_
19-15	3567-3568	,	_
19-16	3569-3579	functional	_
19-17	3580-3593	abnormalities	_
19-18	3594-3596	in	_
19-19	3597-3601	this	_
19-20	3602-3608	region	_
19-21	3609-3612	are	_
19-22	3613-3620	thought	_
19-23	3621-3623	to	_
19-24	3624-3634	contribute	_
19-25	3635-3637	to	_
19-26	3638-3647	emotional	_
19-27	3648-3661	dysregulation	_
19-28	3662-3664	in	_
19-29	3665-3668	MDD	_
19-30	3668-3669	.	_

#Text=A critical limitation of the existing literature is that the diagnostic specificity of the findings is unclear, since previous studies have compared a single group of patients with a certain diagnosis against a group of healthy controls.
20-1	3670-3671	A	_
20-2	3672-3680	critical	_
20-3	3681-3691	limitation	_
20-4	3692-3694	of	_
20-5	3695-3698	the	_
20-6	3699-3707	existing	_
20-7	3708-3718	literature	_
20-8	3719-3721	is	_
20-9	3722-3726	that	_
20-10	3727-3730	the	_
20-11	3731-3741	diagnostic	_
20-12	3742-3753	specificity	_
20-13	3754-3756	of	_
20-14	3757-3760	the	_
20-15	3761-3769	findings	_
20-16	3770-3772	is	_
20-17	3773-3780	unclear	_
20-18	3780-3781	,	_
20-19	3782-3787	since	_
20-20	3788-3796	previous	_
20-21	3797-3804	studies	_
20-22	3805-3809	have	_
20-23	3810-3818	compared	_
20-24	3819-3820	a	_
20-25	3821-3827	single	_
20-26	3828-3833	group	_
20-27	3834-3836	of	_
20-28	3837-3845	patients	_
20-29	3846-3850	with	_
20-30	3851-3852	a	_
20-31	3853-3860	certain	_
20-32	3861-3870	diagnosis	_
20-33	3871-3878	against	_
20-34	3879-3880	a	_
20-35	3881-3886	group	_
20-36	3887-3889	of	_
20-37	3890-3897	healthy	_
20-38	3898-3906	controls	_
20-39	3906-3907	.	_

#Text=Additionally, studies have typically analyzed chronic patients under pharmacological treatment, raising the possibility that the observed alterations reflect a consequence of medication rather than an intrinsic feature of psychopathology.
21-1	3908-3920	Additionally	_
21-2	3920-3921	,	_
21-3	3922-3929	studies	_
21-4	3930-3934	have	_
21-5	3935-3944	typically	_
21-6	3945-3953	analyzed	_
21-7	3954-3961	chronic	_
21-8	3962-3970	patients	_
21-9	3971-3976	under	_
21-10	3977-3992	pharmacological	_
21-11	3993-4002	treatment	_
21-12	4002-4003	,	_
21-13	4004-4011	raising	_
21-14	4012-4015	the	_
21-15	4016-4027	possibility	_
21-16	4028-4032	that	_
21-17	4033-4036	the	_
21-18	4037-4045	observed	_
21-19	4046-4057	alterations	_
21-20	4058-4065	reflect	_
21-21	4066-4067	a	_
21-22	4068-4079	consequence	_
21-23	4080-4082	of	_
21-24	4083-4093	medication	_
21-25	4094-4100	rather	_
21-26	4101-4105	than	_
21-27	4106-4108	an	_
21-28	4109-4118	intrinsic	_
21-29	4119-4126	feature	_
21-30	4127-4129	of	_
21-31	4130-4145	psychopathology	_
21-32	4145-4146	.	_

#Text=In particular, antipsychotic treatment represents a potential major confound in light of previous studies suggesting that it can influence resting-state thalamocortical functional integration.
22-1	4147-4149	In	_
22-2	4150-4160	particular	_
22-3	4160-4161	,	_
22-4	4162-4175	antipsychotic	_
22-5	4176-4185	treatment	_
22-6	4186-4196	represents	_
22-7	4197-4198	a	_
22-8	4199-4208	potential	_
22-9	4209-4214	major	_
22-10	4215-4223	confound	_
22-11	4224-4226	in	_
22-12	4227-4232	light	_
22-13	4233-4235	of	_
22-14	4236-4244	previous	_
22-15	4245-4252	studies	_
22-16	4253-4263	suggesting	_
22-17	4264-4268	that	_
22-18	4269-4271	it	_
22-19	4272-4275	can	_
22-20	4276-4285	influence	_
22-21	4286-4299	resting-state	_
22-22	4300-4315	thalamocortical	_
22-23	4316-4326	functional	_
22-24	4327-4338	integration	_
22-25	4338-4339	.	_

#Text=The aim of the present investigation was therefore to examine the diagnostic specificity of alterations in thalamocortical functional integration in schizophrenia without the confounding effects of medication.
23-1	4340-4343	The	_
23-2	4344-4347	aim	_
23-3	4348-4350	of	_
23-4	4351-4354	the	_
23-5	4355-4362	present	_
23-6	4363-4376	investigation	_
23-7	4377-4380	was	_
23-8	4381-4390	therefore	_
23-9	4391-4393	to	_
23-10	4394-4401	examine	_
23-11	4402-4405	the	_
23-12	4406-4416	diagnostic	_
23-13	4417-4428	specificity	_
23-14	4429-4431	of	_
23-15	4432-4443	alterations	_
23-16	4444-4446	in	_
23-17	4447-4462	thalamocortical	_
23-18	4463-4473	functional	_
23-19	4474-4485	integration	_
23-20	4486-4488	in	_
23-21	4489-4502	schizophrenia	_
23-22	4503-4510	without	_
23-23	4511-4514	the	_
23-24	4515-4526	confounding	_
23-25	4527-4534	effects	_
23-26	4535-4537	of	_
23-27	4538-4548	medication	_
23-28	4548-4549	.	_

#Text=In light of the number of previous studies in patients with schizophrenia reporting alterations in the MDN specifically, the present investigation focused on this section of the thalamus.
24-1	4550-4552	In	_
24-2	4553-4558	light	_
24-3	4559-4561	of	_
24-4	4562-4565	the	_
24-5	4566-4572	number	_
24-6	4573-4575	of	_
24-7	4576-4584	previous	_
24-8	4585-4592	studies	_
24-9	4593-4595	in	_
24-10	4596-4604	patients	_
24-11	4605-4609	with	_
24-12	4610-4623	schizophrenia	_
24-13	4624-4633	reporting	_
24-14	4634-4645	alterations	_
24-15	4646-4648	in	_
24-16	4649-4652	the	_
24-17	4653-4656	MDN	_
24-18	4657-4669	specifically	_
24-19	4669-4670	,	_
24-20	4671-4674	the	_
24-21	4675-4682	present	_
24-22	4683-4696	investigation	_
24-23	4697-4704	focused	_
24-24	4705-4707	on	_
24-25	4708-4712	this	_
24-26	4713-4720	section	_
24-27	4721-4723	of	_
24-28	4724-4727	the	_
24-29	4728-4736	thalamus	_
24-30	4736-4737	.	_

#Text=By comparing effective connectivity alterations in medication-naïve patients with schizophrenia, PTSD, and MDD, we were able to differentiate between effects that are specific to psychotic illness and effects that represent a generic, trans-diagnostic feature of psychiatric disease.
25-1	4738-4740	By	_
25-2	4741-4750	comparing	_
25-3	4751-4760	effective	_
25-4	4761-4773	connectivity	_
25-5	4774-4785	alterations	_
25-6	4786-4788	in	_
25-7	4789-4805	medication-naïve	_
25-8	4806-4814	patients	_
25-9	4815-4819	with	_
25-10	4820-4833	schizophrenia	_
25-11	4833-4834	,	_
25-12	4835-4839	PTSD	_
25-13	4839-4840	,	_
25-14	4841-4844	and	_
25-15	4845-4848	MDD	_
25-16	4848-4849	,	_
25-17	4850-4852	we	_
25-18	4853-4857	were	_
25-19	4858-4862	able	_
25-20	4863-4865	to	_
25-21	4866-4879	differentiate	_
25-22	4880-4887	between	_
25-23	4888-4895	effects	_
25-24	4896-4900	that	_
25-25	4901-4904	are	_
25-26	4905-4913	specific	_
25-27	4914-4916	to	_
25-28	4917-4926	psychotic	_
25-29	4927-4934	illness	_
25-30	4935-4938	and	_
25-31	4939-4946	effects	_
25-32	4947-4951	that	_
25-33	4952-4961	represent	_
25-34	4962-4963	a	_
25-35	4964-4971	generic	_
25-36	4971-4972	,	_
25-37	4973-4989	trans-diagnostic	_
25-38	4990-4997	feature	_
25-39	4998-5000	of	_
25-40	5001-5012	psychiatric	_
25-41	5013-5020	disease	_
25-42	5020-5021	.	_

#Text=We used rs-fMRI in a total of 272 un-medicated participants including 50 with first episode schizophrenia (FES), 50 with a diagnosis of PTSD, 50 with a diagnosis of MDD and 122 healthy controls (HC).
26-1	5022-5024	We	_
26-2	5025-5029	used	_
26-3	5030-5037	rs-fMRI	_
26-4	5038-5040	in	_
26-5	5041-5042	a	_
26-6	5043-5048	total	_
26-7	5049-5051	of	_
26-8	5052-5055	272	_
26-9	5056-5068	un-medicated	_
26-10	5069-5081	participants	_
26-11	5082-5091	including	_
26-12	5092-5094	50	_
26-13	5095-5099	with	_
26-14	5100-5105	first	_
26-15	5106-5113	episode	_
26-16	5114-5127	schizophrenia	_
26-17	5128-5129	(	_
26-18	5129-5132	FES	_
26-19	5132-5133	)	_
26-20	5133-5134	,	_
26-21	5135-5137	50	_
26-22	5138-5142	with	_
26-23	5143-5144	a	_
26-24	5145-5154	diagnosis	_
26-25	5155-5157	of	_
26-26	5158-5162	PTSD	_
26-27	5162-5163	,	_
26-28	5164-5166	50	_
26-29	5167-5171	with	_
26-30	5172-5173	a	_
26-31	5174-5183	diagnosis	_
26-32	5184-5186	of	_
26-33	5187-5190	MDD	_
26-34	5191-5194	and	_
26-35	5195-5198	122	_
26-36	5199-5206	healthy	_
26-37	5207-5215	controls	_
26-38	5216-5217	(	_
26-39	5217-5219	HC	_
26-40	5219-5220	)	_
26-41	5220-5221	.	_

#Text=We hypothesized the presence of thalamocortical alterations specific to schizophrenia, reflecting the unique clinical presentation of this illness.
27-1	5222-5224	We	_
27-2	5225-5237	hypothesized	_
27-3	5238-5241	the	_
27-4	5242-5250	presence	_
27-5	5251-5253	of	_
27-6	5254-5269	thalamocortical	_
27-7	5270-5281	alterations	_
27-8	5282-5290	specific	_
27-9	5291-5293	to	_
27-10	5294-5307	schizophrenia	_
27-11	5307-5308	,	_
27-12	5309-5319	reflecting	_
27-13	5320-5323	the	_
27-14	5324-5330	unique	_
27-15	5331-5339	clinical	_
27-16	5340-5352	presentation	_
27-17	5353-5355	of	_
27-18	5356-5360	this	_
27-19	5361-5368	illness	_
27-20	5368-5369	.	_

#Text=Furthermore, we hypothesized the presence of trans-diagnostic thalamocortical alterations, reflecting shared psychopathological features of the three diseases including general psychopathology.
28-1	5370-5381	Furthermore	_
28-2	5381-5382	,	_
28-3	5383-5385	we	_
28-4	5386-5398	hypothesized	_
28-5	5399-5402	the	_
28-6	5403-5411	presence	_
28-7	5412-5414	of	_
28-8	5415-5431	trans-diagnostic	_
28-9	5432-5447	thalamocortical	_
28-10	5448-5459	alterations	_
28-11	5459-5460	,	_
28-12	5461-5471	reflecting	_
28-13	5472-5478	shared	_
28-14	5479-5497	psychopathological	_
28-15	5498-5506	features	_
28-16	5507-5509	of	_
28-17	5510-5513	the	_
28-18	5514-5519	three	_
28-19	5520-5528	diseases	_
28-20	5529-5538	including	_
28-21	5539-5546	general	_
28-22	5547-5562	psychopathology	_
28-23	5562-5563	.	_

#Text=The results would inform current neurobiological models of psychiatric disease and support the development of differential biomarkers to help classify patients between alternative diagnoses in clinical practice.
29-1	5564-5567	The	_
29-2	5568-5575	results	_
29-3	5576-5581	would	_
29-4	5582-5588	inform	_
29-5	5589-5596	current	_
29-6	5597-5612	neurobiological	_
29-7	5613-5619	models	_
29-8	5620-5622	of	_
29-9	5623-5634	psychiatric	_
29-10	5635-5642	disease	_
29-11	5643-5646	and	_
29-12	5647-5654	support	_
29-13	5655-5658	the	_
29-14	5659-5670	development	_
29-15	5671-5673	of	_
29-16	5674-5686	differential	_
29-17	5687-5697	biomarkers	_
29-18	5698-5700	to	_
29-19	5701-5705	help	_
29-20	5706-5714	classify	_
29-21	5715-5723	patients	_
29-22	5724-5731	between	_
29-23	5732-5743	alternative	_
29-24	5744-5753	diagnoses	_
29-25	5754-5756	in	_
29-26	5757-5765	clinical	_
29-27	5766-5774	practice	_
29-28	5774-5775	.	_

#Text=Materials and methods
#Text=Participants
#Text=The study was approved by the Medical Ethics Committee of West China Hospital of Sichuan University and all participants provided written informed consent.
30-1	5776-5785	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[6]
30-2	5786-5789	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[6]
30-3	5790-5797	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[6]
30-4	5798-5810	Participants	_
30-5	5811-5814	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
30-6	5815-5820	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
30-7	5821-5824	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
30-8	5825-5833	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
30-9	5834-5836	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
30-10	5837-5840	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
30-11	5841-5848	Medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
30-12	5849-5855	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
30-13	5856-5865	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
30-14	5866-5868	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
30-15	5869-5873	West	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
30-16	5874-5879	China	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
30-17	5880-5888	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
30-18	5889-5891	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
30-19	5892-5899	Sichuan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
30-20	5900-5910	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
30-21	5911-5914	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
30-22	5915-5918	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
30-23	5919-5931	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
30-24	5932-5940	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
30-25	5941-5948	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
30-26	5949-5957	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
30-27	5958-5965	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
30-28	5965-5966	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]

#Text=Subsets of the data used here have been used in previous studies.
31-1	5967-5974	Subsets	_
31-2	5975-5977	of	_
31-3	5978-5981	the	_
31-4	5982-5986	data	_
31-5	5987-5991	used	_
31-6	5992-5996	here	_
31-7	5997-6001	have	_
31-8	6002-6006	been	_
31-9	6007-6011	used	_
31-10	6012-6014	in	_
31-11	6015-6023	previous	_
31-12	6024-6031	studies	_
31-13	6031-6032	.	_

#Text=While in a recent article we consider functional integration within and between three networks of interest (default mode, central exectutive, and salience), in the present investigation we focus on the EC between the MDN and the cortex.
32-1	6033-6038	While	_
32-2	6039-6041	in	_
32-3	6042-6043	a	_
32-4	6044-6050	recent	_
32-5	6051-6058	article	_
32-6	6059-6061	we	_
32-7	6062-6070	consider	_
32-8	6071-6081	functional	_
32-9	6082-6093	integration	_
32-10	6094-6100	within	_
32-11	6101-6104	and	_
32-12	6105-6112	between	_
32-13	6113-6118	three	_
32-14	6119-6127	networks	_
32-15	6128-6130	of	_
32-16	6131-6139	interest	_
32-17	6140-6141	(	_
32-18	6141-6148	default	_
32-19	6149-6153	mode	_
32-20	6153-6154	,	_
32-21	6155-6162	central	_
32-22	6163-6173	exectutive	_
32-23	6173-6174	,	_
32-24	6175-6178	and	_
32-25	6179-6187	salience	_
32-26	6187-6188	)	_
32-27	6188-6189	,	_
32-28	6190-6192	in	_
32-29	6193-6196	the	_
32-30	6197-6204	present	_
32-31	6205-6218	investigation	_
32-32	6219-6221	we	_
32-33	6222-6227	focus	_
32-34	6228-6230	on	_
32-35	6231-6234	the	_
32-36	6235-6237	EC	_
32-37	6238-6245	between	_
32-38	6246-6249	the	_
32-39	6250-6253	MDN	_
32-40	6254-6257	and	_
32-41	6258-6261	the	_
32-42	6262-6268	cortex	_
32-43	6268-6269	.	_

#Text=All patients were recruited as they presented to the West China Hospital of Sichuan University, and were came from the inner city of Chengdu with the exception of the PTSD group who tended to come from surrounding rural areas (see below) Exclusion criteria applicable to all participants included (i) history of drug or alcohol abuse, (ii) pregnancy and (iii) any physical illness such as hepatitis, cardiovascular disease, or neurological disorder, as assessed by interview and review of medical records.
33-1	6270-6273	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-2	6274-6282	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-3	6283-6287	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-4	6288-6297	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-5	6298-6300	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-6	6301-6305	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-7	6306-6315	presented	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-8	6316-6318	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-9	6319-6322	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-10	6323-6327	West	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-11	6328-6333	China	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-12	6334-6342	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-13	6343-6345	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-14	6346-6353	Sichuan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-15	6354-6364	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-16	6364-6365	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-17	6366-6369	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-18	6370-6374	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-19	6375-6379	came	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-20	6380-6384	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-21	6385-6388	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-22	6389-6394	inner	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-23	6395-6399	city	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-24	6400-6402	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-25	6403-6410	Chengdu	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-26	6411-6415	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-27	6416-6419	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-28	6420-6429	exception	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-29	6430-6432	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-30	6433-6436	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-31	6437-6441	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[9]
33-32	6442-6447	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-33	6448-6451	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-34	6452-6458	tended	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-35	6459-6461	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-36	6462-6466	come	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-37	6467-6471	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-38	6472-6483	surrounding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-39	6484-6489	rural	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-40	6490-6495	areas	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-41	6496-6497	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-42	6497-6500	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-43	6501-6506	below	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-44	6506-6507	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-45	6508-6517	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-46	6518-6526	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-47	6527-6537	applicable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-48	6538-6540	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-49	6541-6544	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-50	6545-6557	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-51	6558-6566	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-52	6567-6568	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-53	6568-6569	i	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-54	6569-6570	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-55	6571-6578	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-56	6579-6581	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-57	6582-6586	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-58	6587-6589	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-59	6590-6597	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-60	6598-6603	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-61	6603-6604	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-62	6605-6606	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-63	6606-6608	ii	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-64	6608-6609	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-65	6610-6619	pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-66	6620-6623	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-67	6624-6625	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-68	6625-6628	iii	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-69	6628-6629	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-70	6630-6633	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-71	6634-6642	physical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-72	6643-6650	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-73	6651-6655	such	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-74	6656-6658	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-75	6659-6668	hepatitis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-76	6668-6669	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-77	6670-6684	cardiovascular	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-78	6685-6692	disease	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-79	6692-6693	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-80	6694-6696	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-81	6697-6709	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-82	6710-6718	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-83	6718-6719	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-84	6720-6722	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-85	6723-6731	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-86	6732-6734	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-87	6735-6744	interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-88	6745-6748	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-89	6749-6755	review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-90	6756-6758	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-91	6759-6766	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-92	6767-6774	records	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
33-93	6774-6775	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]

#Text=Further information on each group are provided below.
34-1	6776-6783	Further	_
34-2	6784-6795	information	_
34-3	6796-6798	on	_
34-4	6799-6803	each	_
34-5	6804-6809	group	_
34-6	6810-6813	are	_
34-7	6814-6822	provided	_
34-8	6823-6828	below	_
34-9	6828-6829	.	_

#Text=First episode schizophrenia
#Text=Characteristics of subject cohorts
#Text=Measure\tFES\tPTSD\tMDD\tHC\t \t\t(n = 50)\t(n = 50)\t(n = 50)\t(n = 122)\t \t\tn\tMean\tSD\tn\tMean\tSD\tn\tMean\tSD\tn\tMean\tSD\t \tAge\t–\t32.72\t7.27\t–\t43.10\t10.79\t–\t38.89\t11.63\t–\t29.61\t14.36\t \tGender (M:F)\t16:34\t–\t–\t16:34\t–\t–\t16:34\t–\t–\t58:64\t–\t–\t \tEducation years\t–\t13.28\t4.12\t–\t6.90\t3.44\t–\t12.83\t3.93\t–\t12.33\t3.08\t \tPANSS positive\t\t24.84\t6.86\t\t\t\t\t\t\t\t\t\t \tPANSS negative\t–\t16.84\t8.66\t–\t–\t–\t–\t–\t–\t–\t–\t–\t \tPANSS general\t\t46.62\t9.35\t\t\t\t\t\t\t\t\t\t \tPANSS total\t\t88.30\t19.61\t\t\t\t\t\t\t\t\t\t \tPCL\t–\t–\t–\t–\t51.20\t10.44\t–\t–\t–\t–\t–\t–\t \tHAM-D\t–\t–\t–\t–\t–\t–\t–\t23.22\t4.53\t–\t–\t–\t \t
#Text=PANSS positive and negative syndrome scale, PCL PTSD Checklist, HAM-D Hamilton depression rating scale, SD standard deviation, M males, F females
#Text=Fifty patients with FES were included (see Table 1).
35-1	6830-6835	First	_
35-2	6836-6843	episode	_
35-3	6844-6857	schizophrenia	_
35-4	6858-6873	Characteristics	_
35-5	6874-6876	of	_
35-6	6877-6884	subject	_
35-7	6885-6892	cohorts	_
35-8	6893-6900	Measure	_
35-9	6901-6904	FES	_
35-10	6905-6909	PTSD	_
35-11	6910-6913	MDD	_
35-12	6914-6916	HC	_
35-13	6920-6921	(	_
35-14	6921-6922	n	_
35-15	6923-6924	=	_
35-16	6925-6927	50	_
35-17	6927-6928	)	_
35-18	6929-6930	(	_
35-19	6930-6931	n	_
35-20	6932-6933	=	_
35-21	6934-6936	50	_
35-22	6936-6937	)	_
35-23	6938-6939	(	_
35-24	6939-6940	n	_
35-25	6941-6942	=	_
35-26	6943-6945	50	_
35-27	6945-6946	)	_
35-28	6947-6948	(	_
35-29	6948-6949	n	_
35-30	6950-6951	=	_
35-31	6952-6955	122	_
35-32	6955-6956	)	_
35-33	6960-6961	n	_
35-34	6962-6966	Mean	_
35-35	6967-6969	SD	_
35-36	6970-6971	n	_
35-37	6972-6976	Mean	_
35-38	6977-6979	SD	_
35-39	6980-6981	n	_
35-40	6982-6986	Mean	_
35-41	6987-6989	SD	_
35-42	6990-6991	n	_
35-43	6992-6996	Mean	_
35-44	6997-6999	SD	_
35-45	7002-7005	Age	_
35-46	7006-7007	–	_
35-47	7008-7013	32.72	_
35-48	7014-7018	7.27	_
35-49	7019-7020	–	_
35-50	7021-7026	43.10	_
35-51	7027-7032	10.79	_
35-52	7033-7034	–	_
35-53	7035-7040	38.89	_
35-54	7041-7046	11.63	_
35-55	7047-7048	–	_
35-56	7049-7054	29.61	_
35-57	7055-7060	14.36	_
35-58	7063-7069	Gender	_
35-59	7070-7071	(	_
35-60	7071-7072	M	_
35-61	7072-7073	:	_
35-62	7073-7074	F	_
35-63	7074-7075	)	_
35-64	7076-7078	16	_
35-65	7078-7079	:	_
35-66	7079-7081	34	_
35-67	7082-7083	–	_
35-68	7084-7085	–	_
35-69	7086-7088	16	_
35-70	7088-7089	:	_
35-71	7089-7091	34	_
35-72	7092-7093	–	_
35-73	7094-7095	–	_
35-74	7096-7098	16	_
35-75	7098-7099	:	_
35-76	7099-7101	34	_
35-77	7102-7103	–	_
35-78	7104-7105	–	_
35-79	7106-7108	58	_
35-80	7108-7109	:	_
35-81	7109-7111	64	_
35-82	7112-7113	–	_
35-83	7114-7115	–	_
35-84	7118-7127	Education	_
35-85	7128-7133	years	_
35-86	7134-7135	–	_
35-87	7136-7141	13.28	_
35-88	7142-7146	4.12	_
35-89	7147-7148	–	_
35-90	7149-7153	6.90	_
35-91	7154-7158	3.44	_
35-92	7159-7160	–	_
35-93	7161-7166	12.83	_
35-94	7167-7171	3.93	_
35-95	7172-7173	–	_
35-96	7174-7179	12.33	_
35-97	7180-7184	3.08	_
35-98	7187-7192	PANSS	_
35-99	7193-7201	positive	_
35-100	7203-7208	24.84	_
35-101	7209-7213	6.86	_
35-102	7225-7230	PANSS	_
35-103	7231-7239	negative	_
35-104	7240-7241	–	_
35-105	7242-7247	16.84	_
35-106	7248-7252	8.66	_
35-107	7253-7254	–	_
35-108	7255-7256	–	_
35-109	7257-7258	–	_
35-110	7259-7260	–	_
35-111	7261-7262	–	_
35-112	7263-7264	–	_
35-113	7265-7266	–	_
35-114	7267-7268	–	_
35-115	7269-7270	–	_
35-116	7273-7278	PANSS	_
35-117	7279-7286	general	_
35-118	7288-7293	46.62	_
35-119	7294-7298	9.35	_
35-120	7310-7315	PANSS	_
35-121	7316-7321	total	_
35-122	7323-7328	88.30	_
35-123	7329-7334	19.61	_
35-124	7346-7349	PCL	_
35-125	7350-7351	–	_
35-126	7352-7353	–	_
35-127	7354-7355	–	_
35-128	7356-7357	–	_
35-129	7358-7363	51.20	_
35-130	7364-7369	10.44	_
35-131	7370-7371	–	_
35-132	7372-7373	–	_
35-133	7374-7375	–	_
35-134	7376-7377	–	_
35-135	7378-7379	–	_
35-136	7380-7381	–	_
35-137	7384-7389	HAM-D	_
35-138	7390-7391	–	_
35-139	7392-7393	–	_
35-140	7394-7395	–	_
35-141	7396-7397	–	_
35-142	7398-7399	–	_
35-143	7400-7401	–	_
35-144	7402-7403	–	_
35-145	7404-7409	23.22	_
35-146	7410-7414	4.53	_
35-147	7415-7416	–	_
35-148	7417-7418	–	_
35-149	7419-7420	–	_
35-150	7424-7429	PANSS	_
35-151	7430-7438	positive	_
35-152	7439-7442	and	_
35-153	7443-7451	negative	_
35-154	7452-7460	syndrome	_
35-155	7461-7466	scale	_
35-156	7466-7467	,	_
35-157	7468-7471	PCL	_
35-158	7472-7476	PTSD	_
35-159	7477-7486	Checklist	_
35-160	7486-7487	,	_
35-161	7488-7493	HAM-D	_
35-162	7494-7502	Hamilton	_
35-163	7503-7513	depression	_
35-164	7514-7520	rating	_
35-165	7521-7526	scale	_
35-166	7526-7527	,	_
35-167	7528-7530	SD	_
35-168	7531-7539	standard	_
35-169	7540-7549	deviation	_
35-170	7549-7550	,	_
35-171	7551-7552	M	_
35-172	7553-7558	males	_
35-173	7558-7559	,	_
35-174	7560-7561	F	_
35-175	7562-7569	females	_
35-176	7570-7575	Fifty	_
35-177	7576-7584	patients	_
35-178	7585-7589	with	_
35-179	7590-7593	FES	_
35-180	7594-7598	were	_
35-181	7599-7607	included	_
35-182	7608-7609	(	_
35-183	7609-7612	see	_
35-184	7613-7618	Table	_
35-185	7619-7620	1	_
35-186	7620-7621	)	_
35-187	7621-7622	.	_

#Text=The presence of psychotic illness was determined by the consensus of two experienced psychiatrists using the Structured Interview for the DSM-IV Axis I Disorder, Patient Edition (SCID).
36-1	7623-7626	The	_
36-2	7627-7635	presence	_
36-3	7636-7638	of	_
36-4	7639-7648	psychotic	_
36-5	7649-7656	illness	_
36-6	7657-7660	was	_
36-7	7661-7671	determined	_
36-8	7672-7674	by	_
36-9	7675-7678	the	_
36-10	7679-7688	consensus	_
36-11	7689-7691	of	_
36-12	7692-7695	two	_
36-13	7696-7707	experienced	_
36-14	7708-7721	psychiatrists	_
36-15	7722-7727	using	_
36-16	7728-7731	the	_
36-17	7732-7742	Structured	_
36-18	7743-7752	Interview	_
36-19	7753-7756	for	_
36-20	7757-7760	the	_
36-21	7761-7767	DSM-IV	_
36-22	7768-7772	Axis	_
36-23	7773-7774	I	_
36-24	7775-7783	Disorder	_
36-25	7783-7784	,	_
36-26	7785-7792	Patient	_
36-27	7793-7800	Edition	_
36-28	7801-7802	(	_
36-29	7802-7806	SCID	_
36-30	7806-7807	)	_
36-31	7807-7808	.	_

#Text=Psychopathology was measured on the day of scanning using the Positive and Negative Syndrome Scale (PANSS).
37-1	7809-7824	Psychopathology	_
37-2	7825-7828	was	_
37-3	7829-7837	measured	_
37-4	7838-7840	on	_
37-5	7841-7844	the	_
37-6	7845-7848	day	_
37-7	7849-7851	of	_
37-8	7852-7860	scanning	_
37-9	7861-7866	using	_
37-10	7867-7870	the	_
37-11	7871-7879	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[10]
37-12	7880-7883	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[10]
37-13	7884-7892	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[10]
37-14	7893-7901	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[10]
37-15	7902-7907	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[10]
37-16	7908-7909	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[10]
37-17	7909-7914	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[10]
37-18	7914-7915	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[10]
37-19	7915-7916	.	_

#Text=The use of these clinical instruments indicated that all patients met criteria for schizophrenia—a diagnosis that was confirmed in subsequent clinical follow-ups.
38-1	7917-7920	The	_
38-2	7921-7924	use	_
38-3	7925-7927	of	_
38-4	7928-7933	these	_
38-5	7934-7942	clinical	_
38-6	7943-7954	instruments	_
38-7	7955-7964	indicated	_
38-8	7965-7969	that	_
38-9	7970-7973	all	_
38-10	7974-7982	patients	_
38-11	7983-7986	met	_
38-12	7987-7995	criteria	_
38-13	7996-7999	for	_
38-14	8000-8015	schizophrenia—a	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
38-15	8016-8025	diagnosis	_
38-16	8026-8030	that	_
38-17	8031-8034	was	_
38-18	8035-8044	confirmed	_
38-19	8045-8047	in	_
38-20	8048-8058	subsequent	_
38-21	8059-8067	clinical	_
38-22	8068-8078	follow-ups	_
38-23	8078-8079	.	_

#Text=At the time of scanning, all patients were medication-naïve.
39-1	8080-8082	At	_
39-2	8083-8086	the	_
39-3	8087-8091	time	_
39-4	8092-8094	of	_
39-5	8095-8103	scanning	_
39-6	8103-8104	,	_
39-7	8105-8108	all	_
39-8	8109-8117	patients	_
39-9	8118-8122	were	_
39-10	8123-8139	medication-naïve	_
39-11	8139-8140	.	_

#Text=Major depressive disorder
#Text=Fifty participants with MDD were included (see Table 1).
40-1	8141-8146	Major	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
40-2	8147-8157	depressive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
40-3	8158-8166	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
40-4	8167-8172	Fifty	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
40-5	8173-8185	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
40-6	8186-8190	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
40-7	8191-8194	MDD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[12]
40-8	8195-8199	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
40-9	8200-8208	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
40-10	8209-8210	(	_
40-11	8210-8213	see	_
40-12	8214-8219	Table	_
40-13	8220-8221	1	_
40-14	8221-8222	)	_
40-15	8222-8223	.	_

#Text=These participants were part of a larger cohort study of depression in the Chinese population of Han nationality.
41-1	8224-8229	These	_
41-2	8230-8242	participants	_
41-3	8243-8247	were	_
41-4	8248-8252	part	_
41-5	8253-8255	of	_
41-6	8256-8257	a	_
41-7	8258-8264	larger	_
41-8	8265-8271	cohort	_
41-9	8272-8277	study	_
41-10	8278-8280	of	_
41-11	8281-8291	depression	_
41-12	8292-8294	in	_
41-13	8295-8298	the	_
41-14	8299-8306	Chinese	_
41-15	8307-8317	population	_
41-16	8318-8320	of	_
41-17	8321-8324	Han	_
41-18	8325-8336	nationality	_
41-19	8336-8337	.	_

#Text=Diagnosis of MDD was made with the SCID; although psychotic symptoms can occur during depressive episodes, none of the participants reported suffering from them.
42-1	8338-8347	Diagnosis	_
42-2	8348-8350	of	_
42-3	8351-8354	MDD	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
42-4	8355-8358	was	_
42-5	8359-8363	made	_
42-6	8364-8368	with	_
42-7	8369-8372	the	_
42-8	8373-8377	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder
42-9	8377-8378	;	_
42-10	8379-8387	although	_
42-11	8388-8397	psychotic	_
42-12	8398-8406	symptoms	_
42-13	8407-8410	can	_
42-14	8411-8416	occur	_
42-15	8417-8423	during	_
42-16	8424-8434	depressive	_
42-17	8435-8443	episodes	_
42-18	8443-8444	,	_
42-19	8445-8449	none	_
42-20	8450-8452	of	_
42-21	8453-8456	the	_
42-22	8457-8469	participants	_
42-23	8470-8478	reported	_
42-24	8479-8488	suffering	_
42-25	8489-8493	from	_
42-26	8494-8498	them	_
42-27	8498-8499	.	_

#Text=On the day of scanning, severity of depression was quantified using the 17-item Hamilton depression rating scale (HAM-D) and all participants had a total HAM-D score ≥18.
43-1	8500-8502	On	_
43-2	8503-8506	the	_
43-3	8507-8510	day	_
43-4	8511-8513	of	_
43-5	8514-8522	scanning	_
43-6	8522-8523	,	_
43-7	8524-8532	severity	_
43-8	8533-8535	of	_
43-9	8536-8546	depression	_
43-10	8547-8550	was	_
43-11	8551-8561	quantified	_
43-12	8562-8567	using	_
43-13	8568-8571	the	_
43-14	8572-8574	17	_
43-15	8574-8575	-	_
43-16	8575-8579	item	_
43-17	8580-8588	Hamilton	_
43-18	8589-8599	depression	_
43-19	8600-8606	rating	_
43-20	8607-8612	scale	_
43-21	8613-8614	(	_
43-22	8614-8619	HAM-D	_
43-23	8619-8620	)	_
43-24	8621-8624	and	_
43-25	8625-8628	all	_
43-26	8629-8641	participants	_
43-27	8642-8645	had	_
43-28	8646-8647	a	_
43-29	8648-8653	total	_
43-30	8654-8659	HAM-D	_
43-31	8660-8665	score	_
43-32	8666-8667	≥	_
43-33	8667-8669	18	_
43-34	8669-8670	.	_

#Text=All patients were medication-naïve at the time of scanning.
44-1	8671-8674	All	_
44-2	8675-8683	patients	_
44-3	8684-8688	were	_
44-4	8689-8705	medication-naïve	_
44-5	8706-8708	at	_
44-6	8709-8712	the	_
44-7	8713-8717	time	_
44-8	8718-8720	of	_
44-9	8721-8729	scanning	_
44-10	8729-8730	.	_

#Text=Post-traumatic stress disorder
#Text=Fifty participants with PTSD were included (see Table 1).
45-1	8731-8745	Post-traumatic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-2	8746-8752	stress	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-3	8753-8761	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-4	8762-8767	Fifty	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-5	8768-8780	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-6	8781-8785	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-7	8786-8790	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[14]
45-8	8791-8795	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-9	8796-8804	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-10	8805-8806	(	_
45-11	8806-8809	see	_
45-12	8810-8815	Table	_
45-13	8816-8817	1	_
45-14	8817-8818	)	_
45-15	8818-8819	.	_

#Text=These participants were survivors of the 2008 Sichuan earthquake who lived in rural areas, had all physically experienced the earthquake, personally witnessed death, serious injury or the collapse of buildings and not suffered any physical injury; because these patients were recruited in the aftermath of the earthquake, they came from rural areas (where the Earthquake was strongest) and were older relative to the other clinical groups.
46-1	8820-8825	These	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-2	8826-8838	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-3	8839-8843	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-4	8844-8853	survivors	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-5	8854-8856	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-6	8857-8860	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-7	8861-8865	2008	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-8	8866-8873	Sichuan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-9	8874-8884	earthquake	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-10	8885-8888	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-11	8889-8894	lived	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-12	8895-8897	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-13	8898-8903	rural	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-14	8904-8909	areas	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-15	8909-8910	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-16	8911-8914	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-17	8915-8918	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-18	8919-8929	physically	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-19	8930-8941	experienced	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-20	8942-8945	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-21	8946-8956	earthquake	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-22	8956-8957	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-23	8958-8968	personally	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-24	8969-8978	witnessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-25	8979-8984	death	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-26	8984-8985	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-27	8986-8993	serious	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-28	8994-9000	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-29	9001-9003	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-30	9004-9007	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-31	9008-9016	collapse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-32	9017-9019	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-33	9020-9029	buildings	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-34	9030-9033	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-35	9034-9037	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-36	9038-9046	suffered	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-37	9047-9050	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-38	9051-9059	physical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-39	9060-9066	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-40	9066-9067	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-41	9068-9075	because	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-42	9076-9081	these	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-43	9082-9090	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-44	9091-9095	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-45	9096-9105	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-46	9106-9108	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-47	9109-9112	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-48	9113-9122	aftermath	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-49	9123-9125	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-50	9126-9129	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-51	9130-9140	earthquake	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-52	9140-9141	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-53	9142-9146	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-54	9147-9151	came	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-55	9152-9156	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-56	9157-9162	rural	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-57	9163-9168	areas	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-58	9169-9170	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-59	9170-9175	where	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-60	9176-9179	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-61	9180-9190	Earthquake	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-62	9191-9194	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-63	9195-9204	strongest	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-64	9204-9205	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-65	9206-9209	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-66	9210-9214	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-67	9215-9220	older	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-68	9221-9229	relative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-69	9230-9232	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-70	9233-9236	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-71	9237-9242	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-72	9243-9251	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-73	9252-9258	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-74	9258-9259	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]

#Text=All participants were assessed using the PTSD Checklist (PCL) and met threshold criteria (PCL score ≥ 35) for diagnosis of PTSD on the day of scanning.
47-1	9260-9263	All	_
47-2	9264-9276	participants	_
47-3	9277-9281	were	_
47-4	9282-9290	assessed	_
47-5	9291-9296	using	_
47-6	9297-9300	the	_
47-7	9301-9305	PTSD	_
47-8	9306-9315	Checklist	_
47-9	9316-9317	(	_
47-10	9317-9320	PCL	_
47-11	9320-9321	)	_
47-12	9322-9325	and	_
47-13	9326-9329	met	_
47-14	9330-9339	threshold	_
47-15	9340-9348	criteria	_
47-16	9349-9350	(	_
47-17	9350-9353	PCL	_
47-18	9354-9359	score	_
47-19	9360-9361	≥	_
47-20	9362-9364	35	_
47-21	9364-9365	)	_
47-22	9366-9369	for	_
47-23	9370-9379	diagnosis	_
47-24	9380-9382	of	_
47-25	9383-9387	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
47-26	9388-9390	on	_
47-27	9391-9394	the	_
47-28	9395-9398	day	_
47-29	9399-9401	of	_
47-30	9402-9410	scanning	_
47-31	9410-9411	.	_

#Text=At the time of scanning, all patients were medication-naïve.
48-1	9412-9414	At	_
48-2	9415-9418	the	_
48-3	9419-9423	time	_
48-4	9424-9426	of	_
48-5	9427-9435	scanning	_
48-6	9435-9436	,	_
48-7	9437-9440	all	_
48-8	9441-9449	patients	_
48-9	9450-9454	were	_
48-10	9455-9471	medication-naïve	_
48-11	9471-9472	.	_

#Text=Healthy controls
#Text=One hundred and twenty two HC were included (Table 1).
49-1	9473-9480	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[17]
49-2	9481-9489	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[17]
49-3	9490-9493	One	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
49-4	9494-9501	hundred	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
49-5	9502-9505	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
49-6	9506-9512	twenty	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
49-7	9513-9516	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
49-8	9517-9519	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[18]
49-9	9520-9524	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
49-10	9525-9533	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
49-11	9534-9535	(	_
49-12	9535-9540	Table	_
49-13	9541-9542	1	_
49-14	9542-9543	)	_
49-15	9543-9544	.	_

#Text=All were recruited by poster advertisement, and screened using the non-patient edition of the SCID to confirm the lifetime absence of psychiatric illnesses.
50-1	9545-9548	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
50-2	9549-9553	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
50-3	9554-9563	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
50-4	9564-9566	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
50-5	9567-9573	poster	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
50-6	9574-9587	advertisement	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
50-7	9587-9588	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
50-8	9589-9592	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
50-9	9593-9601	screened	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
50-10	9602-9607	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
50-11	9608-9611	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
50-12	9612-9623	non-patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
50-13	9624-9631	edition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
50-14	9632-9634	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
50-15	9635-9638	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
50-16	9639-9643	SCID	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[20]
50-17	9644-9646	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
50-18	9647-9654	confirm	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
50-19	9655-9658	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
50-20	9659-9667	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
50-21	9668-9675	absence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
50-22	9676-9678	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
50-23	9679-9690	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
50-24	9691-9700	illnesses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
50-25	9700-9701	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]

#Text=In addition, all were interviewed to exclude individuals with a known history of psychiatric illness in first-degree relatives.
51-1	9702-9704	In	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
51-2	9705-9713	addition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
51-3	9713-9714	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
51-4	9715-9718	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
51-5	9719-9723	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
51-6	9724-9735	interviewed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
51-7	9736-9738	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
51-8	9739-9746	exclude	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
51-9	9747-9758	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
51-10	9759-9763	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
51-11	9764-9765	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
51-12	9766-9771	known	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
51-13	9772-9779	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
51-14	9780-9782	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
51-15	9783-9794	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
51-16	9795-9802	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
51-17	9803-9805	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
51-18	9806-9818	first-degree	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
51-19	9819-9828	relatives	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
51-20	9828-9829	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]

#Text=Data acquisition
#Text=All neuroimaging data was acquired from a 3T MRI scanner (EXCITE; General Electric, Milwaukee, Wisconsin) with an 8-channel phased array head coil.
52-1	9830-9834	Data	_
52-2	9835-9846	acquisition	_
52-3	9847-9850	All	_
52-4	9851-9863	neuroimaging	_
52-5	9864-9868	data	_
52-6	9869-9872	was	_
52-7	9873-9881	acquired	_
52-8	9882-9886	from	_
52-9	9887-9888	a	_
52-10	9889-9891	3T	_
52-11	9892-9895	MRI	_
52-12	9896-9903	scanner	_
52-13	9904-9905	(	_
52-14	9905-9911	EXCITE	_
52-15	9911-9912	;	_
52-16	9913-9920	General	_
52-17	9921-9929	Electric	_
52-18	9929-9930	,	_
52-19	9931-9940	Milwaukee	_
52-20	9940-9941	,	_
52-21	9942-9951	Wisconsin	_
52-22	9951-9952	)	_
52-23	9953-9957	with	_
52-24	9958-9960	an	_
52-25	9961-9962	8	_
52-26	9962-9963	-	_
52-27	9963-9970	channel	_
52-28	9971-9977	phased	_
52-29	9978-9983	array	_
52-30	9984-9988	head	_
52-31	9989-9993	coil	_
52-32	9993-9994	.	_

#Text=Images were acquired using a gradient-echo echo-planar imaging sequence with a repetition time (TR) = 2000 ms, an echo time (TE) = 30 ms, flip-angle = 90°, slice thickness = 5 mm (no slice gap), 64 × 64 matrix and field of view = 24 cm2 resulting in a voxel size of 3.75 × 3.75 × 5 mm3.
53-1	9995-10001	Images	_
53-2	10002-10006	were	_
53-3	10007-10015	acquired	_
53-4	10016-10021	using	_
53-5	10022-10023	a	_
53-6	10024-10037	gradient-echo	_
53-7	10038-10049	echo-planar	_
53-8	10050-10057	imaging	_
53-9	10058-10066	sequence	_
53-10	10067-10071	with	_
53-11	10072-10073	a	_
53-12	10074-10084	repetition	_
53-13	10085-10089	time	_
53-14	10090-10091	(	_
53-15	10091-10093	TR	_
53-16	10093-10094	)	_
53-17	10095-10096	=	_
53-18	10097-10101	2000	_
53-19	10102-10104	ms	_
53-20	10104-10105	,	_
53-21	10106-10108	an	_
53-22	10109-10113	echo	_
53-23	10114-10118	time	_
53-24	10119-10120	(	_
53-25	10120-10122	TE	_
53-26	10122-10123	)	_
53-27	10124-10125	=	_
53-28	10126-10128	30	_
53-29	10129-10131	ms	_
53-30	10131-10132	,	_
53-31	10133-10143	flip-angle	_
53-32	10144-10145	=	_
53-33	10146-10148	90	_
53-34	10148-10149	°	_
53-35	10149-10150	,	_
53-36	10151-10156	slice	_
53-37	10157-10166	thickness	_
53-38	10167-10168	=	_
53-39	10169-10170	5	_
53-40	10171-10173	mm	_
53-41	10174-10175	(	_
53-42	10175-10177	no	_
53-43	10178-10183	slice	_
53-44	10184-10187	gap	_
53-45	10187-10188	)	_
53-46	10188-10189	,	_
53-47	10190-10192	64	_
53-48	10193-10194	×	_
53-49	10195-10197	64	_
53-50	10198-10204	matrix	_
53-51	10205-10208	and	_
53-52	10209-10214	field	_
53-53	10215-10217	of	_
53-54	10218-10222	view	_
53-55	10223-10224	=	_
53-56	10225-10227	24	_
53-57	10228-10231	cm2	_
53-58	10232-10241	resulting	_
53-59	10242-10244	in	_
53-60	10245-10246	a	_
53-61	10247-10252	voxel	_
53-62	10253-10257	size	_
53-63	10258-10260	of	_
53-64	10261-10265	3.75	_
53-65	10266-10267	×	_
53-66	10268-10272	3.75	_
53-67	10273-10274	×	_
53-68	10275-10276	5	_
53-69	10277-10280	mm3	_
53-70	10280-10281	.	_

#Text=Scanning lasted for 410 s, with each brain volume comprising 30 axial slices and each functional run containing 205 image volumes.
54-1	10282-10290	Scanning	_
54-2	10291-10297	lasted	_
54-3	10298-10301	for	_
54-4	10302-10305	410	_
54-5	10306-10307	s	_
54-6	10307-10308	,	_
54-7	10309-10313	with	_
54-8	10314-10318	each	_
54-9	10319-10324	brain	_
54-10	10325-10331	volume	_
54-11	10332-10342	comprising	_
54-12	10343-10345	30	_
54-13	10346-10351	axial	_
54-14	10352-10358	slices	_
54-15	10359-10362	and	_
54-16	10363-10367	each	_
54-17	10368-10378	functional	_
54-18	10379-10382	run	_
54-19	10383-10393	containing	_
54-20	10394-10397	205	_
54-21	10398-10403	image	_
54-22	10404-10411	volumes	_
54-23	10411-10412	.	_

#Text=During scanning, participants were instructed to relax with their eyes closed without falling asleep.
55-1	10413-10419	During	_
55-2	10420-10428	scanning	_
55-3	10428-10429	,	_
55-4	10430-10442	participants	_
55-5	10443-10447	were	_
55-6	10448-10458	instructed	_
55-7	10459-10461	to	_
55-8	10462-10467	relax	_
55-9	10468-10472	with	_
55-10	10473-10478	their	_
55-11	10479-10483	eyes	_
55-12	10484-10490	closed	_
55-13	10491-10498	without	_
55-14	10499-10506	falling	_
55-15	10507-10513	asleep	_
55-16	10513-10514	.	_

#Text=After the experiment, each participant confirmed as to not having fallen asleep during scanning.
56-1	10515-10520	After	_
56-2	10521-10524	the	_
56-3	10525-10535	experiment	_
56-4	10535-10536	,	_
56-5	10537-10541	each	_
56-6	10542-10553	participant	_
56-7	10554-10563	confirmed	_
56-8	10564-10566	as	_
56-9	10567-10569	to	_
56-10	10570-10573	not	_
56-11	10574-10580	having	_
56-12	10581-10587	fallen	_
56-13	10588-10594	asleep	_
56-14	10595-10601	during	_
56-15	10602-10610	scanning	_
56-16	10610-10611	.	_

#Text=Data analysis
#Text=Preprocessing
#Text=Functional images were pre-processed using SPM12 software (http://www.fil.ion.ucl.ac.uk/spm) running under Matlab 7.1 (Math Works, USA).
57-1	10612-10616	Data	_
57-2	10617-10625	analysis	_
57-3	10626-10639	Preprocessing	_
57-4	10640-10650	Functional	_
57-5	10651-10657	images	_
57-6	10658-10662	were	_
57-7	10663-10676	pre-processed	_
57-8	10677-10682	using	_
57-9	10683-10688	SPM12	_
57-10	10689-10697	software	_
57-11	10698-10699	(	_
57-12	10699-10703	http	_
57-13	10703-10704	:	_
57-14	10704-10705	/	_
57-15	10705-10706	/	_
57-16	10706-10727	www.fil.ion.ucl.ac.uk	_
57-17	10727-10728	/	_
57-18	10728-10731	spm	_
57-19	10731-10732	)	_
57-20	10733-10740	running	_
57-21	10741-10746	under	_
57-22	10747-10753	Matlab	_
57-23	10754-10757	7.1	_
57-24	10758-10759	(	_
57-25	10759-10763	Math	_
57-26	10764-10769	Works	_
57-27	10769-10770	,	_
57-28	10771-10774	USA	_
57-29	10774-10775	)	_
57-30	10775-10776	.	_

#Text=For each participant, the first five scans were discarded to remove the impact of magnetization stabilization, and the images were realigned to the first of the run and resliced with sinc interpolation.
58-1	10777-10780	For	_
58-2	10781-10785	each	_
58-3	10786-10797	participant	_
58-4	10797-10798	,	_
58-5	10799-10802	the	_
58-6	10803-10808	first	_
58-7	10809-10813	five	_
58-8	10814-10819	scans	_
58-9	10820-10824	were	_
58-10	10825-10834	discarded	_
58-11	10835-10837	to	_
58-12	10838-10844	remove	_
58-13	10845-10848	the	_
58-14	10849-10855	impact	_
58-15	10856-10858	of	_
58-16	10859-10872	magnetization	_
58-17	10873-10886	stabilization	_
58-18	10886-10887	,	_
58-19	10888-10891	and	_
58-20	10892-10895	the	_
58-21	10896-10902	images	_
58-22	10903-10907	were	_
58-23	10908-10917	realigned	_
58-24	10918-10920	to	_
58-25	10921-10924	the	_
58-26	10925-10930	first	_
58-27	10931-10933	of	_
58-28	10934-10937	the	_
58-29	10938-10941	run	_
58-30	10942-10945	and	_
58-31	10946-10954	resliced	_
58-32	10955-10959	with	_
58-33	10960-10964	sinc	_
58-34	10965-10978	interpolation	_
58-35	10978-10979	.	_

#Text=The resulting images were normalized to the Montreal Neurological Institute (MNI) 152 template and then linearly de-trended and band pass filtered (0.01–0.08 Hz) to remove low-frequency drift and high-frequency physiological noise.
59-1	10980-10983	The	_
59-2	10984-10993	resulting	_
59-3	10994-11000	images	_
59-4	11001-11005	were	_
59-5	11006-11016	normalized	_
59-6	11017-11019	to	_
59-7	11020-11023	the	_
59-8	11024-11032	Montreal	_
59-9	11033-11045	Neurological	_
59-10	11046-11055	Institute	_
59-11	11056-11057	(	_
59-12	11057-11060	MNI	_
59-13	11060-11061	)	_
59-14	11062-11065	152	_
59-15	11066-11074	template	_
59-16	11075-11078	and	_
59-17	11079-11083	then	_
59-18	11084-11092	linearly	_
59-19	11093-11103	de-trended	_
59-20	11104-11107	and	_
59-21	11108-11112	band	_
59-22	11113-11117	pass	_
59-23	11118-11126	filtered	_
59-24	11127-11128	(	_
59-25	11128-11132	0.01	_
59-26	11132-11133	–	_
59-27	11133-11137	0.08	_
59-28	11138-11140	Hz	_
59-29	11140-11141	)	_
59-30	11142-11144	to	_
59-31	11145-11151	remove	_
59-32	11152-11165	low-frequency	_
59-33	11166-11171	drift	_
59-34	11172-11175	and	_
59-35	11176-11190	high-frequency	_
59-36	11191-11204	physiological	_
59-37	11205-11210	noise	_
59-38	11210-11211	.	_

#Text=Finally the normalized images were smoothed with an 8-mm full width at half maximum isotropic Gaussian kernel, and the global signal, the white matter signal and the cerebrospinal fluid signal were regressed out.
60-1	11212-11219	Finally	_
60-2	11220-11223	the	_
60-3	11224-11234	normalized	_
60-4	11235-11241	images	_
60-5	11242-11246	were	_
60-6	11247-11255	smoothed	_
60-7	11256-11260	with	_
60-8	11261-11263	an	_
60-9	11264-11265	8	_
60-10	11265-11266	-	_
60-11	11266-11268	mm	_
60-12	11269-11273	full	_
60-13	11274-11279	width	_
60-14	11280-11282	at	_
60-15	11283-11287	half	_
60-16	11288-11295	maximum	_
60-17	11296-11305	isotropic	_
60-18	11306-11314	Gaussian	_
60-19	11315-11321	kernel	_
60-20	11321-11322	,	_
60-21	11323-11326	and	_
60-22	11327-11330	the	_
60-23	11331-11337	global	_
60-24	11338-11344	signal	_
60-25	11344-11345	,	_
60-26	11346-11349	the	_
60-27	11350-11355	white	_
60-28	11356-11362	matter	_
60-29	11363-11369	signal	_
60-30	11370-11373	and	_
60-31	11374-11377	the	_
60-32	11378-11391	cerebrospinal	_
60-33	11392-11397	fluid	_
60-34	11398-11404	signal	_
60-35	11405-11409	were	_
60-36	11410-11419	regressed	_
60-37	11420-11423	out	_
60-38	11423-11424	.	_

#Text=None of the subjects who enrolled on the study had to be excluded due to excessive head motion during scanning (defined as translational movement >1.5 mm and/or rotation >1.5°).
61-1	11425-11429	None	_
61-2	11430-11432	of	_
61-3	11433-11436	the	_
61-4	11437-11445	subjects	_
61-5	11446-11449	who	_
61-6	11450-11458	enrolled	_
61-7	11459-11461	on	_
61-8	11462-11465	the	_
61-9	11466-11471	study	_
61-10	11472-11475	had	_
61-11	11476-11478	to	_
61-12	11479-11481	be	_
61-13	11482-11490	excluded	_
61-14	11491-11494	due	_
61-15	11495-11497	to	_
61-16	11498-11507	excessive	_
61-17	11508-11512	head	_
61-18	11513-11519	motion	_
61-19	11520-11526	during	_
61-20	11527-11535	scanning	_
61-21	11536-11537	(	_
61-22	11537-11544	defined	_
61-23	11545-11547	as	_
61-24	11548-11561	translational	_
61-25	11562-11570	movement	_
61-26	11571-11572	>	_
61-27	11572-11575	1.5	_
61-28	11576-11578	mm	_
61-29	11579-11582	and	_
61-30	11582-11583	/	_
61-31	11583-11585	or	_
61-32	11586-11594	rotation	_
61-33	11595-11596	>	_
61-34	11596-11599	1.5	_
61-35	11599-11600	°	_
61-36	11600-11601	)	_
61-37	11601-11602	.	_

#Text=In order to test for differences in head movement, we estimated the framewise displacement of each subject—a measure of head movement from one volume to the next calculated as the sum of the absolute values of the realignment estimates at every time point; an ANOVA did not reveal significant differences across the four groups (df = 3, F = 1.903, p = 0.129).
62-1	11603-11605	In	_
62-2	11606-11611	order	_
62-3	11612-11614	to	_
62-4	11615-11619	test	_
62-5	11620-11623	for	_
62-6	11624-11635	differences	_
62-7	11636-11638	in	_
62-8	11639-11643	head	_
62-9	11644-11652	movement	_
62-10	11652-11653	,	_
62-11	11654-11656	we	_
62-12	11657-11666	estimated	_
62-13	11667-11670	the	_
62-14	11671-11680	framewise	_
62-15	11681-11693	displacement	_
62-16	11694-11696	of	_
62-17	11697-11701	each	_
62-18	11702-11711	subject—a	_
62-19	11712-11719	measure	_
62-20	11720-11722	of	_
62-21	11723-11727	head	_
62-22	11728-11736	movement	_
62-23	11737-11741	from	_
62-24	11742-11745	one	_
62-25	11746-11752	volume	_
62-26	11753-11755	to	_
62-27	11756-11759	the	_
62-28	11760-11764	next	_
62-29	11765-11775	calculated	_
62-30	11776-11778	as	_
62-31	11779-11782	the	_
62-32	11783-11786	sum	_
62-33	11787-11789	of	_
62-34	11790-11793	the	_
62-35	11794-11802	absolute	_
62-36	11803-11809	values	_
62-37	11810-11812	of	_
62-38	11813-11816	the	_
62-39	11817-11828	realignment	_
62-40	11829-11838	estimates	_
62-41	11839-11841	at	_
62-42	11842-11847	every	_
62-43	11848-11852	time	_
62-44	11853-11858	point	_
62-45	11858-11859	;	_
62-46	11860-11862	an	_
62-47	11863-11868	ANOVA	_
62-48	11869-11872	did	_
62-49	11873-11876	not	_
62-50	11877-11883	reveal	_
62-51	11884-11895	significant	_
62-52	11896-11907	differences	_
62-53	11908-11914	across	_
62-54	11915-11918	the	_
62-55	11919-11923	four	_
62-56	11924-11930	groups	_
62-57	11931-11932	(	_
62-58	11932-11934	df	_
62-59	11935-11936	=	_
62-60	11937-11938	3	_
62-61	11938-11939	,	_
62-62	11940-11941	F	_
62-63	11942-11943	=	_
62-64	11944-11949	1.903	_
62-65	11949-11950	,	_
62-66	11951-11952	p	_
62-67	11953-11954	=	_
62-68	11955-11960	0.129	_
62-69	11960-11961	)	_
62-70	11961-11962	.	_

#Text=Psychophysiological interaction analysis
#Text=Psychophysiological interaction analysis was conducted using SPM12 software running under MATLAB 8.6.
63-1	11963-11982	Psychophysiological	_
63-2	11983-11994	interaction	_
63-3	11995-12003	analysis	_
63-4	12004-12023	Psychophysiological	_
63-5	12024-12035	interaction	_
63-6	12036-12044	analysis	_
63-7	12045-12048	was	_
63-8	12049-12058	conducted	_
63-9	12059-12064	using	_
63-10	12065-12070	SPM12	_
63-11	12071-12079	software	_
63-12	12080-12087	running	_
63-13	12088-12093	under	_
63-14	12094-12100	MATLAB	_
63-15	12101-12104	8.6	_
63-16	12104-12105	.	_

#Text=Firstly, the left and right MDN were selected as regions of interest and anatomically identified using the Talairach Daemon Brodmann Areas + atlas on WFU_PickAtlas 3.0.5 software.
64-1	12106-12113	Firstly	_
64-2	12113-12114	,	_
64-3	12115-12118	the	_
64-4	12119-12123	left	_
64-5	12124-12127	and	_
64-6	12128-12133	right	_
64-7	12134-12137	MDN	_
64-8	12138-12142	were	_
64-9	12143-12151	selected	_
64-10	12152-12154	as	_
64-11	12155-12162	regions	_
64-12	12163-12165	of	_
64-13	12166-12174	interest	_
64-14	12175-12178	and	_
64-15	12179-12191	anatomically	_
64-16	12192-12202	identified	_
64-17	12203-12208	using	_
64-18	12209-12212	the	_
64-19	12213-12222	Talairach	_
64-20	12223-12229	Daemon	_
64-21	12230-12238	Brodmann	_
64-22	12239-12244	Areas	_
64-23	12245-12246	+	_
64-24	12247-12252	atlas	_
64-25	12253-12255	on	_
64-26	12256-12269	WFU_PickAtlas	_
64-27	12270-12275	3.0.5	_
64-28	12276-12284	software	_
64-29	12284-12285	.	_

#Text=The left MDN centered on (−6.15, −17, 7.85; MNI co-ordinates) and the right MDN centered on (6.31, −17, 7.85).
65-1	12286-12289	The	_
65-2	12290-12294	left	_
65-3	12295-12298	MDN	_
65-4	12299-12307	centered	_
65-5	12308-12310	on	_
65-6	12311-12312	(	_
65-7	12312-12313	−	_
65-8	12313-12317	6.15	_
65-9	12317-12318	,	_
65-10	12319-12320	−	_
65-11	12320-12322	17	_
65-12	12322-12323	,	_
65-13	12324-12328	7.85	_
65-14	12328-12329	;	_
65-15	12330-12333	MNI	_
65-16	12334-12346	co-ordinates	_
65-17	12346-12347	)	_
65-18	12348-12351	and	_
65-19	12352-12355	the	_
65-20	12356-12361	right	_
65-21	12362-12365	MDN	_
65-22	12366-12374	centered	_
65-23	12375-12377	on	_
65-24	12378-12379	(	_
65-25	12379-12383	6.31	_
65-26	12383-12384	,	_
65-27	12385-12386	−	_
65-28	12386-12388	17	_
65-29	12388-12389	,	_
65-30	12390-12394	7.85	_
65-31	12394-12395	)	_
65-32	12395-12396	.	_

#Text=The raw mean time-series of voxels in each region of interest were then extracted for each subject using the MarsBaR toolbox for SPM.
66-1	12397-12400	The	_
66-2	12401-12404	raw	_
66-3	12405-12409	mean	_
66-4	12410-12421	time-series	_
66-5	12422-12424	of	_
66-6	12425-12431	voxels	_
66-7	12432-12434	in	_
66-8	12435-12439	each	_
66-9	12440-12446	region	_
66-10	12447-12449	of	_
66-11	12450-12458	interest	_
66-12	12459-12463	were	_
66-13	12464-12468	then	_
66-14	12469-12478	extracted	_
66-15	12479-12482	for	_
66-16	12483-12487	each	_
66-17	12488-12495	subject	_
66-18	12496-12501	using	_
66-19	12502-12505	the	_
66-20	12506-12513	MarsBaR	_
66-21	12514-12521	toolbox	_
66-22	12522-12525	for	_
66-23	12526-12529	SPM	_
66-24	12529-12530	.	_

#Text=For each subject, the extracted values were correlated with all other voxels in the brain using linear regression with the subject head motion parameters modeled as co-variates of no interest.
67-1	12531-12534	For	_
67-2	12535-12539	each	_
67-3	12540-12547	subject	_
67-4	12547-12548	,	_
67-5	12549-12552	the	_
67-6	12553-12562	extracted	_
67-7	12563-12569	values	_
67-8	12570-12574	were	_
67-9	12575-12585	correlated	_
67-10	12586-12590	with	_
67-11	12591-12594	all	_
67-12	12595-12600	other	_
67-13	12601-12607	voxels	_
67-14	12608-12610	in	_
67-15	12611-12614	the	_
67-16	12615-12620	brain	_
67-17	12621-12626	using	_
67-18	12627-12633	linear	_
67-19	12634-12644	regression	_
67-20	12645-12649	with	_
67-21	12650-12653	the	_
67-22	12654-12661	subject	_
67-23	12662-12666	head	_
67-24	12667-12673	motion	_
67-25	12674-12684	parameters	_
67-26	12685-12692	modeled	_
67-27	12693-12695	as	_
67-28	12696-12707	co-variates	_
67-29	12708-12710	of	_
67-30	12711-12713	no	_
67-31	12714-12722	interest	_
67-32	12722-12723	.	_

#Text=Subject-level t-contrast maps were combined into a group-level analysis of variance (ANOVA) with age and gender modeled as covariates of no interest.
68-1	12724-12737	Subject-level	_
68-2	12738-12748	t-contrast	_
68-3	12749-12753	maps	_
68-4	12754-12758	were	_
68-5	12759-12767	combined	_
68-6	12768-12772	into	_
68-7	12773-12774	a	_
68-8	12775-12786	group-level	_
68-9	12787-12795	analysis	_
68-10	12796-12798	of	_
68-11	12799-12807	variance	_
68-12	12808-12809	(	_
68-13	12809-12814	ANOVA	_
68-14	12814-12815	)	_
68-15	12816-12820	with	_
68-16	12821-12824	age	_
68-17	12825-12828	and	_
68-18	12829-12835	gender	_
68-19	12836-12843	modeled	_
68-20	12844-12846	as	_
68-21	12847-12857	covariates	_
68-22	12858-12860	of	_
68-23	12861-12863	no	_
68-24	12864-12872	interest	_
68-25	12872-12873	.	_

#Text=Effectively, this seed-based approach conforms to a psychophysiological interaction analysis.
69-1	12874-12885	Effectively	_
69-2	12885-12886	,	_
69-3	12887-12891	this	_
69-4	12892-12902	seed-based	_
69-5	12903-12911	approach	_
69-6	12912-12920	conforms	_
69-7	12921-12923	to	_
69-8	12924-12925	a	_
69-9	12926-12945	psychophysiological	_
69-10	12946-12957	interaction	_
69-11	12958-12966	analysis	_
69-12	12966-12967	.	_

#Text=In other words, we use the regression slope of activity in any given voxel on activity in the (thalamic) seed region as a measure of direct (linear) coupling and then compared this measure between diagnostic groups.
70-1	12968-12970	In	_
70-2	12971-12976	other	_
70-3	12977-12982	words	_
70-4	12982-12983	,	_
70-5	12984-12986	we	_
70-6	12987-12990	use	_
70-7	12991-12994	the	_
70-8	12995-13005	regression	_
70-9	13006-13011	slope	_
70-10	13012-13014	of	_
70-11	13015-13023	activity	_
70-12	13024-13026	in	_
70-13	13027-13030	any	_
70-14	13031-13036	given	_
70-15	13037-13042	voxel	_
70-16	13043-13045	on	_
70-17	13046-13054	activity	_
70-18	13055-13057	in	_
70-19	13058-13061	the	_
70-20	13062-13063	(	_
70-21	13063-13071	thalamic	_
70-22	13071-13072	)	_
70-23	13073-13077	seed	_
70-24	13078-13084	region	_
70-25	13085-13087	as	_
70-26	13088-13089	a	_
70-27	13090-13097	measure	_
70-28	13098-13100	of	_
70-29	13101-13107	direct	_
70-30	13108-13109	(	_
70-31	13109-13115	linear	_
70-32	13115-13116	)	_
70-33	13117-13125	coupling	_
70-34	13126-13129	and	_
70-35	13130-13134	then	_
70-36	13135-13143	compared	_
70-37	13144-13148	this	_
70-38	13149-13156	measure	_
70-39	13157-13164	between	_
70-40	13165-13175	diagnostic	_
70-41	13176-13182	groups	_
70-42	13182-13183	.	_

#Text=This psychophysiological interaction analysis has the advantage of not conflating coupling with the amplitude of error terms—a recognized methodological issue in the statistical analysis of (Z-transformed) functional correlation measures.
71-1	13184-13188	This	_
71-2	13189-13208	psychophysiological	_
71-3	13209-13220	interaction	_
71-4	13221-13229	analysis	_
71-5	13230-13233	has	_
71-6	13234-13237	the	_
71-7	13238-13247	advantage	_
71-8	13248-13250	of	_
71-9	13251-13254	not	_
71-10	13255-13265	conflating	_
71-11	13266-13274	coupling	_
71-12	13275-13279	with	_
71-13	13280-13283	the	_
71-14	13284-13293	amplitude	_
71-15	13294-13296	of	_
71-16	13297-13302	error	_
71-17	13303-13310	terms—a	_
71-18	13311-13321	recognized	_
71-19	13322-13336	methodological	_
71-20	13337-13342	issue	_
71-21	13343-13345	in	_
71-22	13346-13349	the	_
71-23	13350-13361	statistical	_
71-24	13362-13370	analysis	_
71-25	13371-13373	of	_
71-26	13374-13375	(	_
71-27	13375-13388	Z-transformed	_
71-28	13388-13389	)	_
71-29	13390-13400	functional	_
71-30	13401-13412	correlation	_
71-31	13413-13421	measures	_
71-32	13421-13422	.	_

#Text=Alterations specific to schizophrenia were identified by comparing this group against the other three groups (e.g., schizophrenia vs.
72-1	13423-13434	Alterations	_
72-2	13435-13443	specific	_
72-3	13444-13446	to	_
72-4	13447-13460	schizophrenia	_
72-5	13461-13465	were	_
72-6	13466-13476	identified	_
72-7	13477-13479	by	_
72-8	13480-13489	comparing	_
72-9	13490-13494	this	_
72-10	13495-13500	group	_
72-11	13501-13508	against	_
72-12	13509-13512	the	_
72-13	13513-13518	other	_
72-14	13519-13524	three	_
72-15	13525-13531	groups	_
72-16	13532-13533	(	_
72-17	13533-13536	e.g	_
72-18	13536-13537	.	_
72-19	13537-13538	,	_
72-20	13539-13552	schizophrenia	_
72-21	13553-13555	vs	_
72-22	13555-13556	.	_

#Text=HC, PTSD, and MDD) and then using the inclusive masking option (at p < 0.05 uncorrected) in SPM12 software to identify those regions that survived the individual comparisons (i.e., schizophrenia vs.
73-1	13557-13559	HC	_
73-2	13559-13560	,	_
73-3	13561-13565	PTSD	_
73-4	13565-13566	,	_
73-5	13567-13570	and	_
73-6	13571-13574	MDD	_
73-7	13574-13575	)	_
73-8	13576-13579	and	_
73-9	13580-13584	then	_
73-10	13585-13590	using	_
73-11	13591-13594	the	_
73-12	13595-13604	inclusive	_
73-13	13605-13612	masking	_
73-14	13613-13619	option	_
73-15	13620-13621	(	_
73-16	13621-13623	at	_
73-17	13624-13625	p	_
73-18	13626-13627	<	_
73-19	13628-13632	0.05	_
73-20	13633-13644	uncorrected	_
73-21	13644-13645	)	_
73-22	13646-13648	in	_
73-23	13649-13654	SPM12	_
73-24	13655-13663	software	_
73-25	13664-13666	to	_
73-26	13667-13675	identify	_
73-27	13676-13681	those	_
73-28	13682-13689	regions	_
73-29	13690-13694	that	_
73-30	13695-13703	survived	_
73-31	13704-13707	the	_
73-32	13708-13718	individual	_
73-33	13719-13730	comparisons	_
73-34	13731-13732	(	_
73-35	13732-13735	i.e	_
73-36	13735-13736	.	_
73-37	13736-13737	,	_
73-38	13738-13751	schizophrenia	_
73-39	13752-13754	vs	_
73-40	13754-13755	.	_

#Text=HC; schizophrenia vs.
74-1	13756-13758	HC	_
74-2	13758-13759	;	_
74-3	13760-13773	schizophrenia	_
74-4	13774-13776	vs	_
74-5	13776-13777	.	_

#Text=PTSD; schizophrenia vs.
75-1	13778-13782	PTSD	_
75-2	13782-13783	;	_
75-3	13784-13797	schizophrenia	_
75-4	13798-13800	vs	_
75-5	13800-13801	.	_

#Text=MDD).
76-1	13802-13805	MDD	_
76-2	13805-13806	)	_
76-3	13806-13807	.	_

#Text=Here the use of inclusive masking enabled a simple form of conjunction analysis that allowed us to identify alterations specific to the schizophrenia group.
77-1	13808-13812	Here	_
77-2	13813-13816	the	_
77-3	13817-13820	use	_
77-4	13821-13823	of	_
77-5	13824-13833	inclusive	_
77-6	13834-13841	masking	_
77-7	13842-13849	enabled	_
77-8	13850-13851	a	_
77-9	13852-13858	simple	_
77-10	13859-13863	form	_
77-11	13864-13866	of	_
77-12	13867-13878	conjunction	_
77-13	13879-13887	analysis	_
77-14	13888-13892	that	_
77-15	13893-13900	allowed	_
77-16	13901-13903	us	_
77-17	13904-13906	to	_
77-18	13907-13915	identify	_
77-19	13916-13927	alterations	_
77-20	13928-13936	specific	_
77-21	13937-13939	to	_
77-22	13940-13943	the	_
77-23	13944-13957	schizophrenia	_
77-24	13958-13963	group	_
77-25	13963-13964	.	_

#Text=Alterations common to the three diagnostic groups were identified by comparing schizophrenia, PTSD, and MDD patients against HC (e.g., schizophrenia, PTSD and MDD vs.
78-1	13965-13976	Alterations	_
78-2	13977-13983	common	_
78-3	13984-13986	to	_
78-4	13987-13990	the	_
78-5	13991-13996	three	_
78-6	13997-14007	diagnostic	_
78-7	14008-14014	groups	_
78-8	14015-14019	were	_
78-9	14020-14030	identified	_
78-10	14031-14033	by	_
78-11	14034-14043	comparing	_
78-12	14044-14057	schizophrenia	_
78-13	14057-14058	,	_
78-14	14059-14063	PTSD	_
78-15	14063-14064	,	_
78-16	14065-14068	and	_
78-17	14069-14072	MDD	_
78-18	14073-14081	patients	_
78-19	14082-14089	against	_
78-20	14090-14092	HC	_
78-21	14093-14094	(	_
78-22	14094-14097	e.g	_
78-23	14097-14098	.	_
78-24	14098-14099	,	_
78-25	14100-14113	schizophrenia	_
78-26	14113-14114	,	_
78-27	14115-14119	PTSD	_
78-28	14120-14123	and	_
78-29	14124-14127	MDD	_
78-30	14128-14130	vs	_
78-31	14130-14131	.	_

#Text=HC) and then using the inclusive masking option (at p < 0.05 uncorrected) in SPM12 software to identify those regions that survived the diagnosis-specific comparisons (i.e., schizophrenia vs.
79-1	14132-14134	HC	_
79-2	14134-14135	)	_
79-3	14136-14139	and	_
79-4	14140-14144	then	_
79-5	14145-14150	using	_
79-6	14151-14154	the	_
79-7	14155-14164	inclusive	_
79-8	14165-14172	masking	_
79-9	14173-14179	option	_
79-10	14180-14181	(	_
79-11	14181-14183	at	_
79-12	14184-14185	p	_
79-13	14186-14187	<	_
79-14	14188-14192	0.05	_
79-15	14193-14204	uncorrected	_
79-16	14204-14205	)	_
79-17	14206-14208	in	_
79-18	14209-14214	SPM12	_
79-19	14215-14223	software	_
79-20	14224-14226	to	_
79-21	14227-14235	identify	_
79-22	14236-14241	those	_
79-23	14242-14249	regions	_
79-24	14250-14254	that	_
79-25	14255-14263	survived	_
79-26	14264-14267	the	_
79-27	14268-14286	diagnosis-specific	_
79-28	14287-14298	comparisons	_
79-29	14299-14300	(	_
79-30	14300-14303	i.e	_
79-31	14303-14304	.	_
79-32	14304-14305	,	_
79-33	14306-14319	schizophrenia	_
79-34	14320-14322	vs	_
79-35	14322-14323	.	_

#Text=HC; PTSD vs.
80-1	14324-14326	HC	_
80-2	14326-14327	;	_
80-3	14328-14332	PTSD	_
80-4	14333-14335	vs	_
80-5	14335-14336	.	_

#Text=HC; and MDD vs.
81-1	14337-14339	HC	_
81-2	14339-14340	;	_
81-3	14341-14344	and	_
81-4	14345-14348	MDD	_
81-5	14349-14351	vs	_
81-6	14351-14352	.	_

#Text=HC).
82-1	14353-14355	HC	_
82-2	14355-14356	)	_
82-3	14356-14357	.	_

#Text=Here the use of inclusive masking enabled us to detect alterations in schizophrenia group that reflect a trans-diagnostic feature of psychiatric illness.
83-1	14358-14362	Here	_
83-2	14363-14366	the	_
83-3	14367-14370	use	_
83-4	14371-14373	of	_
83-5	14374-14383	inclusive	_
83-6	14384-14391	masking	_
83-7	14392-14399	enabled	_
83-8	14400-14402	us	_
83-9	14403-14405	to	_
83-10	14406-14412	detect	_
83-11	14413-14424	alterations	_
83-12	14425-14427	in	_
83-13	14428-14441	schizophrenia	_
83-14	14442-14447	group	_
83-15	14448-14452	that	_
83-16	14453-14460	reflect	_
83-17	14461-14462	a	_
83-18	14463-14479	trans-diagnostic	_
83-19	14480-14487	feature	_
83-20	14488-14490	of	_
83-21	14491-14502	psychiatric	_
83-22	14503-14510	illness	_
83-23	14510-14511	.	_

#Text=Statistical inferences were made at p < 0.05 after family-wise error (FWE) correction with a minimum extent threshold of 5 voxels.
84-1	14512-14523	Statistical	_
84-2	14524-14534	inferences	_
84-3	14535-14539	were	_
84-4	14540-14544	made	_
84-5	14545-14547	at	_
84-6	14548-14549	p	_
84-7	14550-14551	<	_
84-8	14552-14556	0.05	_
84-9	14557-14562	after	_
84-10	14563-14574	family-wise	_
84-11	14575-14580	error	_
84-12	14581-14582	(	_
84-13	14582-14585	FWE	_
84-14	14585-14586	)	_
84-15	14587-14597	correction	_
84-16	14598-14602	with	_
84-17	14603-14604	a	_
84-18	14605-14612	minimum	_
84-19	14613-14619	extent	_
84-20	14620-14629	threshold	_
84-21	14630-14632	of	_
84-22	14633-14634	5	_
84-23	14635-14641	voxels	_
84-24	14641-14642	.	_

#Text=Results
#Text=Thalamic effective connectivity alterations specific to schizophrenia
#Text=Region showing schizophrenia-specific effective connectivity increases with the right MDN.
85-1	14643-14650	Results	_
85-2	14651-14659	Thalamic	_
85-3	14660-14669	effective	_
85-4	14670-14682	connectivity	_
85-5	14683-14694	alterations	_
85-6	14695-14703	specific	_
85-7	14704-14706	to	_
85-8	14707-14720	schizophrenia	_
85-9	14721-14727	Region	_
85-10	14728-14735	showing	_
85-11	14736-14758	schizophrenia-specific	_
85-12	14759-14768	effective	_
85-13	14769-14781	connectivity	_
85-14	14782-14791	increases	_
85-15	14792-14796	with	_
85-16	14797-14800	the	_
85-17	14801-14806	right	_
85-18	14807-14810	MDN	_
85-19	14810-14811	.	_

#Text=Left: region of the right pallidum showing EC increases with the right MDN in the schizophrenia group relative to the HC, PTSD and MDD groups.
86-1	14812-14816	Left	_
86-2	14816-14817	:	_
86-3	14818-14824	region	_
86-4	14825-14827	of	_
86-5	14828-14831	the	_
86-6	14832-14837	right	_
86-7	14838-14846	pallidum	_
86-8	14847-14854	showing	_
86-9	14855-14857	EC	_
86-10	14858-14867	increases	_
86-11	14868-14872	with	_
86-12	14873-14876	the	_
86-13	14877-14882	right	_
86-14	14883-14886	MDN	_
86-15	14887-14889	in	_
86-16	14890-14893	the	_
86-17	14894-14907	schizophrenia	_
86-18	14908-14913	group	_
86-19	14914-14922	relative	_
86-20	14923-14925	to	_
86-21	14926-14929	the	_
86-22	14930-14932	HC	_
86-23	14932-14933	,	_
86-24	14934-14938	PTSD	_
86-25	14939-14942	and	_
86-26	14943-14946	MDD	_
86-27	14947-14953	groups	_
86-28	14953-14954	.	_

#Text=Right: mean right MDN-right pallidum effective connectivity for the FEP, MDD, PTSD, and HC groups (standard error in brackets).
87-1	14955-14960	Right	_
87-2	14960-14961	:	_
87-3	14962-14966	mean	_
87-4	14967-14972	right	_
87-5	14973-14982	MDN-right	_
87-6	14983-14991	pallidum	_
87-7	14992-15001	effective	_
87-8	15002-15014	connectivity	_
87-9	15015-15018	for	_
87-10	15019-15022	the	_
87-11	15023-15026	FEP	_
87-12	15026-15027	,	_
87-13	15028-15031	MDD	_
87-14	15031-15032	,	_
87-15	15033-15037	PTSD	_
87-16	15037-15038	,	_
87-17	15039-15042	and	_
87-18	15043-15045	HC	_
87-19	15046-15052	groups	_
87-20	15053-15054	(	_
87-21	15054-15062	standard	_
87-22	15063-15068	error	_
87-23	15069-15071	in	_
87-24	15072-15080	brackets	_
87-25	15080-15081	)	_
87-26	15081-15082	.	_

#Text=FES, first episode schizophrenia, PTSD, post-traumatic stress disorder, MDD, major depressive disorder, HC, healthy controls
#Text=For the left MDN, no regions exhibited significant schizophrenia-specific EC alterations.
88-1	15083-15086	FES	_
88-2	15086-15087	,	_
88-3	15088-15093	first	_
88-4	15094-15101	episode	_
88-5	15102-15115	schizophrenia	_
88-6	15115-15116	,	_
88-7	15117-15121	PTSD	_
88-8	15121-15122	,	_
88-9	15123-15137	post-traumatic	_
88-10	15138-15144	stress	_
88-11	15145-15153	disorder	_
88-12	15153-15154	,	_
88-13	15155-15158	MDD	_
88-14	15158-15159	,	_
88-15	15160-15165	major	_
88-16	15166-15176	depressive	_
88-17	15177-15185	disorder	_
88-18	15185-15186	,	_
88-19	15187-15189	HC	_
88-20	15189-15190	,	_
88-21	15191-15198	healthy	_
88-22	15199-15207	controls	_
88-23	15208-15211	For	_
88-24	15212-15215	the	_
88-25	15216-15220	left	_
88-26	15221-15224	MDN	_
88-27	15224-15225	,	_
88-28	15226-15228	no	_
88-29	15229-15236	regions	_
88-30	15237-15246	exhibited	_
88-31	15247-15258	significant	_
88-32	15259-15281	schizophrenia-specific	_
88-33	15282-15284	EC	_
88-34	15285-15296	alterations	_
88-35	15296-15297	.	_

#Text=In contrast, the right MDN displayed schizophrenia-specific increased EC with the right pallidum (MNI co-ordinates: x = 15 y = 5 z = 4; Z-score = 5.23 p-value after FWE correction = 0.018, cluster size: 9 voxels; see Fig. 1).
89-1	15298-15300	In	_
89-2	15301-15309	contrast	_
89-3	15309-15310	,	_
89-4	15311-15314	the	_
89-5	15315-15320	right	_
89-6	15321-15324	MDN	_
89-7	15325-15334	displayed	_
89-8	15335-15357	schizophrenia-specific	_
89-9	15358-15367	increased	_
89-10	15368-15370	EC	_
89-11	15371-15375	with	_
89-12	15376-15379	the	_
89-13	15380-15385	right	_
89-14	15386-15394	pallidum	_
89-15	15395-15396	(	_
89-16	15396-15399	MNI	_
89-17	15400-15412	co-ordinates	_
89-18	15412-15413	:	_
89-19	15414-15415	x	_
89-20	15416-15417	=	_
89-21	15418-15420	15	_
89-22	15421-15422	y	_
89-23	15423-15424	=	_
89-24	15425-15426	5	_
89-25	15427-15428	z	_
89-26	15429-15430	=	_
89-27	15431-15432	4	_
89-28	15432-15433	;	_
89-29	15434-15441	Z-score	_
89-30	15442-15443	=	_
89-31	15444-15448	5.23	_
89-32	15449-15456	p-value	_
89-33	15457-15462	after	_
89-34	15463-15466	FWE	_
89-35	15467-15477	correction	_
89-36	15478-15479	=	_
89-37	15480-15485	0.018	_
89-38	15485-15486	,	_
89-39	15487-15494	cluster	_
89-40	15495-15499	size	_
89-41	15499-15500	:	_
89-42	15501-15502	9	_
89-43	15503-15509	voxels	_
89-44	15509-15510	;	_
89-45	15511-15514	see	_
89-46	15515-15518	Fig	_
89-47	15518-15519	.	_
89-48	15520-15521	1	_
89-49	15521-15522	)	_
89-50	15522-15523	.	_

#Text=Trans-diagnostic thalamic effective connectivity alterations
#Text=Regions showing trans-diagnostic effective connectivity increases with the left medio-dorsal thalamic nucleus
#Text=Region\tHemisphere\tCo-ordinates (MNI)\tCluster size\tZ score\tp value (FWE corrected)\t \tX\tY\tZ\t \tPostcentral gyrus\tRight\t60\t−10\t31\t59\t5.05\t0.002\t \tSupramarginal gyrus\tLeft\t−60\t−34\t37\t9\t4.84\t0.019\t \tPutamen\tRight\t33\t2\t1\t9\t4.66\t0.019\t \tSupramarginal/Angular gyrus\tRight\t57\t−52\t43\t11\t4.63\t0.016\t \tMedial superior frontal gyrus\tRight\t3\t29\t40\t16\t4.58\t0.012\t \t
#Text=Regions showing trans-diagnostic effective connectivity increases with the left MDN.
90-1	15524-15540	Trans-diagnostic	_
90-2	15541-15549	thalamic	_
90-3	15550-15559	effective	_
90-4	15560-15572	connectivity	_
90-5	15573-15584	alterations	_
90-6	15585-15592	Regions	_
90-7	15593-15600	showing	_
90-8	15601-15617	trans-diagnostic	_
90-9	15618-15627	effective	_
90-10	15628-15640	connectivity	_
90-11	15641-15650	increases	_
90-12	15651-15655	with	_
90-13	15656-15659	the	_
90-14	15660-15664	left	_
90-15	15665-15677	medio-dorsal	_
90-16	15678-15686	thalamic	_
90-17	15687-15694	nucleus	_
90-18	15695-15701	Region	_
90-19	15702-15712	Hemisphere	_
90-20	15713-15725	Co-ordinates	_
90-21	15726-15727	(	_
90-22	15727-15730	MNI	_
90-23	15730-15731	)	_
90-24	15732-15739	Cluster	_
90-25	15740-15744	size	_
90-26	15745-15746	Z	_
90-27	15747-15752	score	_
90-28	15753-15754	p	_
90-29	15755-15760	value	_
90-30	15761-15762	(	_
90-31	15762-15765	FWE	_
90-32	15766-15775	corrected	_
90-33	15775-15776	)	_
90-34	15779-15780	X	_
90-35	15781-15782	Y	_
90-36	15783-15784	Z	_
90-37	15787-15798	Postcentral	_
90-38	15799-15804	gyrus	_
90-39	15805-15810	Right	_
90-40	15811-15813	60	_
90-41	15814-15815	−	_
90-42	15815-15817	10	_
90-43	15818-15820	31	_
90-44	15821-15823	59	_
90-45	15824-15828	5.05	_
90-46	15829-15834	0.002	_
90-47	15837-15850	Supramarginal	_
90-48	15851-15856	gyrus	_
90-49	15857-15861	Left	_
90-50	15862-15863	−	_
90-51	15863-15865	60	_
90-52	15866-15867	−	_
90-53	15867-15869	34	_
90-54	15870-15872	37	_
90-55	15873-15874	9	_
90-56	15875-15879	4.84	_
90-57	15880-15885	0.019	_
90-58	15888-15895	Putamen	_
90-59	15896-15901	Right	_
90-60	15902-15904	33	_
90-61	15905-15906	2	_
90-62	15907-15908	1	_
90-63	15909-15910	9	_
90-64	15911-15915	4.66	_
90-65	15916-15921	0.019	_
90-66	15924-15937	Supramarginal	_
90-67	15937-15938	/	_
90-68	15938-15945	Angular	_
90-69	15946-15951	gyrus	_
90-70	15952-15957	Right	_
90-71	15958-15960	57	_
90-72	15961-15962	−	_
90-73	15962-15964	52	_
90-74	15965-15967	43	_
90-75	15968-15970	11	_
90-76	15971-15975	4.63	_
90-77	15976-15981	0.016	_
90-78	15984-15990	Medial	_
90-79	15991-15999	superior	_
90-80	16000-16007	frontal	_
90-81	16008-16013	gyrus	_
90-82	16014-16019	Right	_
90-83	16020-16021	3	_
90-84	16022-16024	29	_
90-85	16025-16027	40	_
90-86	16028-16030	16	_
90-87	16031-16035	4.58	_
90-88	16036-16041	0.012	_
90-89	16045-16052	Regions	_
90-90	16053-16060	showing	_
90-91	16061-16077	trans-diagnostic	_
90-92	16078-16087	effective	_
90-93	16088-16100	connectivity	_
90-94	16101-16110	increases	_
90-95	16111-16115	with	_
90-96	16116-16119	the	_
90-97	16120-16124	left	_
90-98	16125-16128	MDN	_
90-99	16128-16129	.	_

#Text=Left: Regions showing EC increases with the left MDN in the schizophrenia, PTSD, and MDD groups relative to the HC group.
91-1	16130-16134	Left	_
91-2	16134-16135	:	_
91-3	16136-16143	Regions	_
91-4	16144-16151	showing	_
91-5	16152-16154	EC	_
91-6	16155-16164	increases	_
91-7	16165-16169	with	_
91-8	16170-16173	the	_
91-9	16174-16178	left	_
91-10	16179-16182	MDN	_
91-11	16183-16185	in	_
91-12	16186-16189	the	_
91-13	16190-16203	schizophrenia	_
91-14	16203-16204	,	_
91-15	16205-16209	PTSD	_
91-16	16209-16210	,	_
91-17	16211-16214	and	_
91-18	16215-16218	MDD	_
91-19	16219-16225	groups	_
91-20	16226-16234	relative	_
91-21	16235-16237	to	_
91-22	16238-16241	the	_
91-23	16242-16244	HC	_
91-24	16245-16250	group	_
91-25	16250-16251	.	_

#Text=Right: mean effective connectivity for each group (standard error in brackets).
92-1	16252-16257	Right	_
92-2	16257-16258	:	_
92-3	16259-16263	mean	_
92-4	16264-16273	effective	_
92-5	16274-16286	connectivity	_
92-6	16287-16290	for	_
92-7	16291-16295	each	_
92-8	16296-16301	group	_
92-9	16302-16303	(	_
92-10	16303-16311	standard	_
92-11	16312-16317	error	_
92-12	16318-16320	in	_
92-13	16321-16329	brackets	_
92-14	16329-16330	)	_
92-15	16330-16331	.	_

#Text=FES, first episode schizophrenia; PTSD, post-traumatic stress disorder; MDD, major depressive disorder; HC, healthy controls
#Text=The left MDN displayed significant trans-diagnostic EC increases with five regions including the right postcentral gyrus, left supramarginal gyrus, right putamen, right supramarginal/angular gyrus and right medial superior frontal gyrus (p < 0.05, FWE corrected, see Table 2; Fig. 2).
93-1	16332-16335	FES	_
93-2	16335-16336	,	_
93-3	16337-16342	first	_
93-4	16343-16350	episode	_
93-5	16351-16364	schizophrenia	_
93-6	16364-16365	;	_
93-7	16366-16370	PTSD	_
93-8	16370-16371	,	_
93-9	16372-16386	post-traumatic	_
93-10	16387-16393	stress	_
93-11	16394-16402	disorder	_
93-12	16402-16403	;	_
93-13	16404-16407	MDD	_
93-14	16407-16408	,	_
93-15	16409-16414	major	_
93-16	16415-16425	depressive	_
93-17	16426-16434	disorder	_
93-18	16434-16435	;	_
93-19	16436-16438	HC	_
93-20	16438-16439	,	_
93-21	16440-16447	healthy	_
93-22	16448-16456	controls	_
93-23	16457-16460	The	_
93-24	16461-16465	left	_
93-25	16466-16469	MDN	_
93-26	16470-16479	displayed	_
93-27	16480-16491	significant	_
93-28	16492-16508	trans-diagnostic	_
93-29	16509-16511	EC	_
93-30	16512-16521	increases	_
93-31	16522-16526	with	_
93-32	16527-16531	five	_
93-33	16532-16539	regions	_
93-34	16540-16549	including	_
93-35	16550-16553	the	_
93-36	16554-16559	right	_
93-37	16560-16571	postcentral	_
93-38	16572-16577	gyrus	_
93-39	16577-16578	,	_
93-40	16579-16583	left	_
93-41	16584-16597	supramarginal	_
93-42	16598-16603	gyrus	_
93-43	16603-16604	,	_
93-44	16605-16610	right	_
93-45	16611-16618	putamen	_
93-46	16618-16619	,	_
93-47	16620-16625	right	_
93-48	16626-16639	supramarginal	_
93-49	16639-16640	/	_
93-50	16640-16647	angular	_
93-51	16648-16653	gyrus	_
93-52	16654-16657	and	_
93-53	16658-16663	right	_
93-54	16664-16670	medial	_
93-55	16671-16679	superior	_
93-56	16680-16687	frontal	_
93-57	16688-16693	gyrus	_
93-58	16694-16695	(	_
93-59	16695-16696	p	_
93-60	16697-16698	<	_
93-61	16699-16703	0.05	_
93-62	16703-16704	,	_
93-63	16705-16708	FWE	_
93-64	16709-16718	corrected	_
93-65	16718-16719	,	_
93-66	16720-16723	see	_
93-67	16724-16729	Table	_
93-68	16730-16731	2	_
93-69	16731-16732	;	_
93-70	16733-16736	Fig	_
93-71	16736-16737	.	_
93-72	16738-16739	2	_
93-73	16739-16740	)	_
93-74	16740-16741	.	_

#Text=Regions showing trans-diagnostic effective connectivity increases with the right medio-dorsal thalamic nucleus
#Text=Region\tHemisphere\tCo-ordinates (MNI)\tCluster size\tZ score\tp value (FWE corrected)\t \tX\tY\tZ\t \tSupramarginal gyrus\tLeft\t−60\t−37\t37\t14\t5.17\t0.012\t \tSupramarginal gyrus\tRight\t51\t−43\t37\t31\t4.91\t0.005\t \tPostcentral gyrus\tRight\t60\t−10\t31\t28\t4.83\t0.005\t \tMedial superior frontal gyrus\tRight\t9\t26\t43\t28\t4.80\t0.005\t \tMiddle cingulate cortex\tLeft\t−9\t−40\t52\t8\t4.67\t0.019\t \t
#Text=Regions showing trans-diagnostic effective connectivity increases with the right MDN.
94-1	16742-16749	Regions	_
94-2	16750-16757	showing	_
94-3	16758-16774	trans-diagnostic	_
94-4	16775-16784	effective	_
94-5	16785-16797	connectivity	_
94-6	16798-16807	increases	_
94-7	16808-16812	with	_
94-8	16813-16816	the	_
94-9	16817-16822	right	_
94-10	16823-16835	medio-dorsal	_
94-11	16836-16844	thalamic	_
94-12	16845-16852	nucleus	_
94-13	16853-16859	Region	_
94-14	16860-16870	Hemisphere	_
94-15	16871-16883	Co-ordinates	_
94-16	16884-16885	(	_
94-17	16885-16888	MNI	_
94-18	16888-16889	)	_
94-19	16890-16897	Cluster	_
94-20	16898-16902	size	_
94-21	16903-16904	Z	_
94-22	16905-16910	score	_
94-23	16911-16912	p	_
94-24	16913-16918	value	_
94-25	16919-16920	(	_
94-26	16920-16923	FWE	_
94-27	16924-16933	corrected	_
94-28	16933-16934	)	_
94-29	16937-16938	X	_
94-30	16939-16940	Y	_
94-31	16941-16942	Z	_
94-32	16945-16958	Supramarginal	_
94-33	16959-16964	gyrus	_
94-34	16965-16969	Left	_
94-35	16970-16971	−	_
94-36	16971-16973	60	_
94-37	16974-16975	−	_
94-38	16975-16977	37	_
94-39	16978-16980	37	_
94-40	16981-16983	14	_
94-41	16984-16988	5.17	_
94-42	16989-16994	0.012	_
94-43	16997-17010	Supramarginal	_
94-44	17011-17016	gyrus	_
94-45	17017-17022	Right	_
94-46	17023-17025	51	_
94-47	17026-17027	−	_
94-48	17027-17029	43	_
94-49	17030-17032	37	_
94-50	17033-17035	31	_
94-51	17036-17040	4.91	_
94-52	17041-17046	0.005	_
94-53	17049-17060	Postcentral	_
94-54	17061-17066	gyrus	_
94-55	17067-17072	Right	_
94-56	17073-17075	60	_
94-57	17076-17077	−	_
94-58	17077-17079	10	_
94-59	17080-17082	31	_
94-60	17083-17085	28	_
94-61	17086-17090	4.83	_
94-62	17091-17096	0.005	_
94-63	17099-17105	Medial	_
94-64	17106-17114	superior	_
94-65	17115-17122	frontal	_
94-66	17123-17128	gyrus	_
94-67	17129-17134	Right	_
94-68	17135-17136	9	_
94-69	17137-17139	26	_
94-70	17140-17142	43	_
94-71	17143-17145	28	_
94-72	17146-17150	4.80	_
94-73	17151-17156	0.005	_
94-74	17159-17165	Middle	_
94-75	17166-17175	cingulate	_
94-76	17176-17182	cortex	_
94-77	17183-17187	Left	_
94-78	17188-17189	−	_
94-79	17189-17190	9	_
94-80	17191-17192	−	_
94-81	17192-17194	40	_
94-82	17195-17197	52	_
94-83	17198-17199	8	_
94-84	17200-17204	4.67	_
94-85	17205-17210	0.019	_
94-86	17214-17221	Regions	_
94-87	17222-17229	showing	_
94-88	17230-17246	trans-diagnostic	_
94-89	17247-17256	effective	_
94-90	17257-17269	connectivity	_
94-91	17270-17279	increases	_
94-92	17280-17284	with	_
94-93	17285-17288	the	_
94-94	17289-17294	right	_
94-95	17295-17298	MDN	_
94-96	17298-17299	.	_

#Text=Left: Regions showing EC increases with the right MDN in the schizophrenia, PTSD, and MDD groups relative to the HC group.
95-1	17300-17304	Left	_
95-2	17304-17305	:	_
95-3	17306-17313	Regions	_
95-4	17314-17321	showing	_
95-5	17322-17324	EC	_
95-6	17325-17334	increases	_
95-7	17335-17339	with	_
95-8	17340-17343	the	_
95-9	17344-17349	right	_
95-10	17350-17353	MDN	_
95-11	17354-17356	in	_
95-12	17357-17360	the	_
95-13	17361-17374	schizophrenia	_
95-14	17374-17375	,	_
95-15	17376-17380	PTSD	_
95-16	17380-17381	,	_
95-17	17382-17385	and	_
95-18	17386-17389	MDD	_
95-19	17390-17396	groups	_
95-20	17397-17405	relative	_
95-21	17406-17408	to	_
95-22	17409-17412	the	_
95-23	17413-17415	HC	_
95-24	17416-17421	group	_
95-25	17421-17422	.	_

#Text=Right: mean effectivity connectivity for each group (standard error in brackets).
96-1	17423-17428	Right	_
96-2	17428-17429	:	_
96-3	17430-17434	mean	_
96-4	17435-17446	effectivity	_
96-5	17447-17459	connectivity	_
96-6	17460-17463	for	_
96-7	17464-17468	each	_
96-8	17469-17474	group	_
96-9	17475-17476	(	_
96-10	17476-17484	standard	_
96-11	17485-17490	error	_
96-12	17491-17493	in	_
96-13	17494-17502	brackets	_
96-14	17502-17503	)	_
96-15	17503-17504	.	_

#Text=FES, first episode schizophrenia; PTSD, post-traumatic stress disorder; MDD, major depressive disorder; HC, healthy controls
#Text=In addition, the right MDN displayed significant trans-diagnostic EC increases with five significant regions including the bilateral supramarginal gyrus, right postcentral gyrus, right medial superior frontal gyrus and left middle cingulate cortex (p < 0.05, FWE corrected, see Table 3; Fig. 3).
97-1	17505-17508	FES	_
97-2	17508-17509	,	_
97-3	17510-17515	first	_
97-4	17516-17523	episode	_
97-5	17524-17537	schizophrenia	_
97-6	17537-17538	;	_
97-7	17539-17543	PTSD	_
97-8	17543-17544	,	_
97-9	17545-17559	post-traumatic	_
97-10	17560-17566	stress	_
97-11	17567-17575	disorder	_
97-12	17575-17576	;	_
97-13	17577-17580	MDD	_
97-14	17580-17581	,	_
97-15	17582-17587	major	_
97-16	17588-17598	depressive	_
97-17	17599-17607	disorder	_
97-18	17607-17608	;	_
97-19	17609-17611	HC	_
97-20	17611-17612	,	_
97-21	17613-17620	healthy	_
97-22	17621-17629	controls	_
97-23	17630-17632	In	_
97-24	17633-17641	addition	_
97-25	17641-17642	,	_
97-26	17643-17646	the	_
97-27	17647-17652	right	_
97-28	17653-17656	MDN	_
97-29	17657-17666	displayed	_
97-30	17667-17678	significant	_
97-31	17679-17695	trans-diagnostic	_
97-32	17696-17698	EC	_
97-33	17699-17708	increases	_
97-34	17709-17713	with	_
97-35	17714-17718	five	_
97-36	17719-17730	significant	_
97-37	17731-17738	regions	_
97-38	17739-17748	including	_
97-39	17749-17752	the	_
97-40	17753-17762	bilateral	_
97-41	17763-17776	supramarginal	_
97-42	17777-17782	gyrus	_
97-43	17782-17783	,	_
97-44	17784-17789	right	_
97-45	17790-17801	postcentral	_
97-46	17802-17807	gyrus	_
97-47	17807-17808	,	_
97-48	17809-17814	right	_
97-49	17815-17821	medial	_
97-50	17822-17830	superior	_
97-51	17831-17838	frontal	_
97-52	17839-17844	gyrus	_
97-53	17845-17848	and	_
97-54	17849-17853	left	_
97-55	17854-17860	middle	_
97-56	17861-17870	cingulate	_
97-57	17871-17877	cortex	_
97-58	17878-17879	(	_
97-59	17879-17880	p	_
97-60	17881-17882	<	_
97-61	17883-17887	0.05	_
97-62	17887-17888	,	_
97-63	17889-17892	FWE	_
97-64	17893-17902	corrected	_
97-65	17902-17903	,	_
97-66	17904-17907	see	_
97-67	17908-17913	Table	_
97-68	17914-17915	3	_
97-69	17915-17916	;	_
97-70	17917-17920	Fig	_
97-71	17920-17921	.	_
97-72	17922-17923	3	_
97-73	17923-17924	)	_
97-74	17924-17925	.	_

#Text=Post hoc correlation analysis in schizophrenia
#Text=To further elucidate the above alterations, a series of exploratory post hoc correlation analyses were performed with clinical scores in patients with schizophrenia using IBM SPSS version 21.0 (IBM Corp, Armonk, NY, USA).
98-1	17926-17930	Post	_
98-2	17931-17934	hoc	_
98-3	17935-17946	correlation	_
98-4	17947-17955	analysis	_
98-5	17956-17958	in	_
98-6	17959-17972	schizophrenia	_
98-7	17973-17975	To	_
98-8	17976-17983	further	_
98-9	17984-17993	elucidate	_
98-10	17994-17997	the	_
98-11	17998-18003	above	_
98-12	18004-18015	alterations	_
98-13	18015-18016	,	_
98-14	18017-18018	a	_
98-15	18019-18025	series	_
98-16	18026-18028	of	_
98-17	18029-18040	exploratory	_
98-18	18041-18045	post	_
98-19	18046-18049	hoc	_
98-20	18050-18061	correlation	_
98-21	18062-18070	analyses	_
98-22	18071-18075	were	_
98-23	18076-18085	performed	_
98-24	18086-18090	with	_
98-25	18091-18099	clinical	_
98-26	18100-18106	scores	_
98-27	18107-18109	in	_
98-28	18110-18118	patients	_
98-29	18119-18123	with	_
98-30	18124-18137	schizophrenia	_
98-31	18138-18143	using	_
98-32	18144-18147	IBM	_
98-33	18148-18152	SPSS	_
98-34	18153-18160	version	_
98-35	18161-18165	21.0	_
98-36	18166-18167	(	_
98-37	18167-18170	IBM	_
98-38	18171-18175	Corp	_
98-39	18175-18176	,	_
98-40	18177-18183	Armonk	_
98-41	18183-18184	,	_
98-42	18185-18187	NY	_
98-43	18187-18188	,	_
98-44	18189-18192	USA	_
98-45	18192-18193	)	_
98-46	18193-18194	.	_

#Text=This identified three significant correlations with clinical scores.
99-1	18195-18199	This	_
99-2	18200-18210	identified	_
99-3	18211-18216	three	_
99-4	18217-18228	significant	_
99-5	18229-18241	correlations	_
99-6	18242-18246	with	_
99-7	18247-18255	clinical	_
99-8	18256-18262	scores	_
99-9	18262-18263	.	_

#Text=First, the trans-diagnostic EC increase between the left MDN and the right medial superior frontal gyrus was negatively correlated with the PANSS negative score (Pearson correlation = −0.328; two-tailed p-value: 0.020).
100-1	18264-18269	First	_
100-2	18269-18270	,	_
100-3	18271-18274	the	_
100-4	18275-18291	trans-diagnostic	_
100-5	18292-18294	EC	_
100-6	18295-18303	increase	_
100-7	18304-18311	between	_
100-8	18312-18315	the	_
100-9	18316-18320	left	_
100-10	18321-18324	MDN	_
100-11	18325-18328	and	_
100-12	18329-18332	the	_
100-13	18333-18338	right	_
100-14	18339-18345	medial	_
100-15	18346-18354	superior	_
100-16	18355-18362	frontal	_
100-17	18363-18368	gyrus	_
100-18	18369-18372	was	_
100-19	18373-18383	negatively	_
100-20	18384-18394	correlated	_
100-21	18395-18399	with	_
100-22	18400-18403	the	_
100-23	18404-18409	PANSS	_
100-24	18410-18418	negative	_
100-25	18419-18424	score	_
100-26	18425-18426	(	_
100-27	18426-18433	Pearson	_
100-28	18434-18445	correlation	_
100-29	18446-18447	=	_
100-30	18448-18449	−	_
100-31	18449-18454	0.328	_
100-32	18454-18455	;	_
100-33	18456-18466	two-tailed	_
100-34	18467-18474	p-value	_
100-35	18474-18475	:	_
100-36	18476-18481	0.020	_
100-37	18481-18482	)	_
100-38	18482-18483	.	_

#Text=Second, the trans-diagnostic EC increase between the left MDN and the right putamen was positively correlated with the Global Assessment of Functioning scores (Pearson correlation = 0.389; two-tailed p-value: 0.005).
101-1	18484-18490	Second	_
101-2	18490-18491	,	_
101-3	18492-18495	the	_
101-4	18496-18512	trans-diagnostic	_
101-5	18513-18515	EC	_
101-6	18516-18524	increase	_
101-7	18525-18532	between	_
101-8	18533-18536	the	_
101-9	18537-18541	left	_
101-10	18542-18545	MDN	_
101-11	18546-18549	and	_
101-12	18550-18553	the	_
101-13	18554-18559	right	_
101-14	18560-18567	putamen	_
101-15	18568-18571	was	_
101-16	18572-18582	positively	_
101-17	18583-18593	correlated	_
101-18	18594-18598	with	_
101-19	18599-18602	the	_
101-20	18603-18609	Global	_
101-21	18610-18620	Assessment	_
101-22	18621-18623	of	_
101-23	18624-18635	Functioning	_
101-24	18636-18642	scores	_
101-25	18643-18644	(	_
101-26	18644-18651	Pearson	_
101-27	18652-18663	correlation	_
101-28	18664-18665	=	_
101-29	18666-18671	0.389	_
101-30	18671-18672	;	_
101-31	18673-18683	two-tailed	_
101-32	18684-18691	p-value	_
101-33	18691-18692	:	_
101-34	18693-18698	0.005	_
101-35	18698-18699	)	_
101-36	18699-18700	.	_

#Text=Third, the trans-diagnostic EC increase between the right MDN and the right medial superior frontal gyrus was negatively associated with the PANSS general psychopathology score (Pearson correlation = −0.323; two-tailed p-value: 0.022).
102-1	18701-18706	Third	_
102-2	18706-18707	,	_
102-3	18708-18711	the	_
102-4	18712-18728	trans-diagnostic	_
102-5	18729-18731	EC	_
102-6	18732-18740	increase	_
102-7	18741-18748	between	_
102-8	18749-18752	the	_
102-9	18753-18758	right	_
102-10	18759-18762	MDN	_
102-11	18763-18766	and	_
102-12	18767-18770	the	_
102-13	18771-18776	right	_
102-14	18777-18783	medial	_
102-15	18784-18792	superior	_
102-16	18793-18800	frontal	_
102-17	18801-18806	gyrus	_
102-18	18807-18810	was	_
102-19	18811-18821	negatively	_
102-20	18822-18832	associated	_
102-21	18833-18837	with	_
102-22	18838-18841	the	_
102-23	18842-18847	PANSS	_
102-24	18848-18855	general	_
102-25	18856-18871	psychopathology	_
102-26	18872-18877	score	_
102-27	18878-18879	(	_
102-28	18879-18886	Pearson	_
102-29	18887-18898	correlation	_
102-30	18899-18900	=	_
102-31	18901-18902	−	_
102-32	18902-18907	0.323	_
102-33	18907-18908	;	_
102-34	18909-18919	two-tailed	_
102-35	18920-18927	p-value	_
102-36	18927-18928	:	_
102-37	18929-18934	0.022	_
102-38	18934-18935	)	_
102-39	18935-18936	.	_

#Text=Discussion
#Text=The aim of this study was to differentiate between alterations in MDN EC patterns that are a specific feature of schizophrenia and trans-diagnostic alterations that can also be found in other psychiatric illnesses including MDD and PTSD.
103-1	18937-18947	Discussion	_
103-2	18948-18951	The	_
103-3	18952-18955	aim	_
103-4	18956-18958	of	_
103-5	18959-18963	this	_
103-6	18964-18969	study	_
103-7	18970-18973	was	_
103-8	18974-18976	to	_
103-9	18977-18990	differentiate	_
103-10	18991-18998	between	_
103-11	18999-19010	alterations	_
103-12	19011-19013	in	_
103-13	19014-19017	MDN	_
103-14	19018-19020	EC	_
103-15	19021-19029	patterns	_
103-16	19030-19034	that	_
103-17	19035-19038	are	_
103-18	19039-19040	a	_
103-19	19041-19049	specific	_
103-20	19050-19057	feature	_
103-21	19058-19060	of	_
103-22	19061-19074	schizophrenia	_
103-23	19075-19078	and	_
103-24	19079-19095	trans-diagnostic	_
103-25	19096-19107	alterations	_
103-26	19108-19112	that	_
103-27	19113-19116	can	_
103-28	19117-19121	also	_
103-29	19122-19124	be	_
103-30	19125-19130	found	_
103-31	19131-19133	in	_
103-32	19134-19139	other	_
103-33	19140-19151	psychiatric	_
103-34	19152-19161	illnesses	_
103-35	19162-19171	including	_
103-36	19172-19175	MDD	_
103-37	19176-19179	and	_
103-38	19180-19184	PTSD	_
103-39	19184-19185	.	_

#Text=By investigating medication-naïve participants experiencing their first episode of schizophrenia, we were able to assess thalamocortical dysconnectivity without confounds of antipsychotic medication and prolonged exposure to the illness.
104-1	19186-19188	By	_
104-2	19189-19202	investigating	_
104-3	19203-19219	medication-naïve	_
104-4	19220-19232	participants	_
104-5	19233-19245	experiencing	_
104-6	19246-19251	their	_
104-7	19252-19257	first	_
104-8	19258-19265	episode	_
104-9	19266-19268	of	_
104-10	19269-19282	schizophrenia	_
104-11	19282-19283	,	_
104-12	19284-19286	we	_
104-13	19287-19291	were	_
104-14	19292-19296	able	_
104-15	19297-19299	to	_
104-16	19300-19306	assess	_
104-17	19307-19322	thalamocortical	_
104-18	19323-19338	dysconnectivity	_
104-19	19339-19346	without	_
104-20	19347-19356	confounds	_
104-21	19357-19359	of	_
104-22	19360-19373	antipsychotic	_
104-23	19374-19384	medication	_
104-24	19385-19388	and	_
104-25	19389-19398	prolonged	_
104-26	19399-19407	exposure	_
104-27	19408-19410	to	_
104-28	19411-19414	the	_
104-29	19415-19422	illness	_
104-30	19422-19423	.	_

#Text=In particular, we focused on the MDN—a section of the thalamus that has been found to be functionally impaired in previous task-based and resting-state studies of psychosis.
105-1	19424-19426	In	_
105-2	19427-19437	particular	_
105-3	19437-19438	,	_
105-4	19439-19441	we	_
105-5	19442-19449	focused	_
105-6	19450-19452	on	_
105-7	19453-19456	the	_
105-8	19457-19462	MDN—a	_
105-9	19463-19470	section	_
105-10	19471-19473	of	_
105-11	19474-19477	the	_
105-12	19478-19486	thalamus	_
105-13	19487-19491	that	_
105-14	19492-19495	has	_
105-15	19496-19500	been	_
105-16	19501-19506	found	_
105-17	19507-19509	to	_
105-18	19510-19512	be	_
105-19	19513-19525	functionally	_
105-20	19526-19534	impaired	_
105-21	19535-19537	in	_
105-22	19538-19546	previous	_
105-23	19547-19557	task-based	_
105-24	19558-19561	and	_
105-25	19562-19575	resting-state	_
105-26	19576-19583	studies	_
105-27	19584-19586	of	_
105-28	19587-19596	psychosis	_
105-29	19596-19597	.	_

#Text=Our first finding of note was increased EC between the right MDN and the right pallidum in the schizophrenia group relative to the HC, PTSD and MDD groups.
106-1	19598-19601	Our	_
106-2	19602-19607	first	_
106-3	19608-19615	finding	_
106-4	19616-19618	of	_
106-5	19619-19623	note	_
106-6	19624-19627	was	_
106-7	19628-19637	increased	_
106-8	19638-19640	EC	_
106-9	19641-19648	between	_
106-10	19649-19652	the	_
106-11	19653-19658	right	_
106-12	19659-19662	MDN	_
106-13	19663-19666	and	_
106-14	19667-19670	the	_
106-15	19671-19676	right	_
106-16	19677-19685	pallidum	_
106-17	19686-19688	in	_
106-18	19689-19692	the	_
106-19	19693-19706	schizophrenia	_
106-20	19707-19712	group	_
106-21	19713-19721	relative	_
106-22	19722-19724	to	_
106-23	19725-19728	the	_
106-24	19729-19731	HC	_
106-25	19731-19732	,	_
106-26	19733-19737	PTSD	_
106-27	19738-19741	and	_
106-28	19742-19745	MDD	_
106-29	19746-19752	groups	_
106-30	19752-19753	.	_

#Text=Although our psychophysiological interaction analysis would suggest greatest sensitivity of the pallidum to thalamic activity in the schizophrenia group, a complementary interpretation is that the sensitivity of the thalamus to afferents from the pallidum was reduced; indeed this is the preferred interpretation given the prevalence of polysynaptic projections from the pallidum to the thalamus (as opposed to the reciprocal direction).
107-1	19754-19762	Although	_
107-2	19763-19766	our	_
107-3	19767-19786	psychophysiological	_
107-4	19787-19798	interaction	_
107-5	19799-19807	analysis	_
107-6	19808-19813	would	_
107-7	19814-19821	suggest	_
107-8	19822-19830	greatest	_
107-9	19831-19842	sensitivity	_
107-10	19843-19845	of	_
107-11	19846-19849	the	_
107-12	19850-19858	pallidum	_
107-13	19859-19861	to	_
107-14	19862-19870	thalamic	_
107-15	19871-19879	activity	_
107-16	19880-19882	in	_
107-17	19883-19886	the	_
107-18	19887-19900	schizophrenia	_
107-19	19901-19906	group	_
107-20	19906-19907	,	_
107-21	19908-19909	a	_
107-22	19910-19923	complementary	_
107-23	19924-19938	interpretation	_
107-24	19939-19941	is	_
107-25	19942-19946	that	_
107-26	19947-19950	the	_
107-27	19951-19962	sensitivity	_
107-28	19963-19965	of	_
107-29	19966-19969	the	_
107-30	19970-19978	thalamus	_
107-31	19979-19981	to	_
107-32	19982-19991	afferents	_
107-33	19992-19996	from	_
107-34	19997-20000	the	_
107-35	20001-20009	pallidum	_
107-36	20010-20013	was	_
107-37	20014-20021	reduced	_
107-38	20021-20022	;	_
107-39	20023-20029	indeed	_
107-40	20030-20034	this	_
107-41	20035-20037	is	_
107-42	20038-20041	the	_
107-43	20042-20051	preferred	_
107-44	20052-20066	interpretation	_
107-45	20067-20072	given	_
107-46	20073-20076	the	_
107-47	20077-20087	prevalence	_
107-48	20088-20090	of	_
107-49	20091-20103	polysynaptic	_
107-50	20104-20115	projections	_
107-51	20116-20120	from	_
107-52	20121-20124	the	_
107-53	20125-20133	pallidum	_
107-54	20134-20136	to	_
107-55	20137-20140	the	_
107-56	20141-20149	thalamus	_
107-57	20150-20151	(	_
107-58	20151-20153	as	_
107-59	20154-20161	opposed	_
107-60	20162-20164	to	_
107-61	20165-20168	the	_
107-62	20169-20179	reciprocal	_
107-63	20180-20189	direction	_
107-64	20189-20190	)	_
107-65	20190-20191	.	_

#Text=Exploration of the group-specific parameters revealed that, although the EC between the right MDN and the right pallidum was greatest in the schizophrenia group suggesting some diagnostic specificity, a non-significant trend was also evident in the PTSD group relative to the HC and MDD groups (Fig. 1).
108-1	20192-20203	Exploration	_
108-2	20204-20206	of	_
108-3	20207-20210	the	_
108-4	20211-20225	group-specific	_
108-5	20226-20236	parameters	_
108-6	20237-20245	revealed	_
108-7	20246-20250	that	_
108-8	20250-20251	,	_
108-9	20252-20260	although	_
108-10	20261-20264	the	_
108-11	20265-20267	EC	_
108-12	20268-20275	between	_
108-13	20276-20279	the	_
108-14	20280-20285	right	_
108-15	20286-20289	MDN	_
108-16	20290-20293	and	_
108-17	20294-20297	the	_
108-18	20298-20303	right	_
108-19	20304-20312	pallidum	_
108-20	20313-20316	was	_
108-21	20317-20325	greatest	_
108-22	20326-20328	in	_
108-23	20329-20332	the	_
108-24	20333-20346	schizophrenia	_
108-25	20347-20352	group	_
108-26	20353-20363	suggesting	_
108-27	20364-20368	some	_
108-28	20369-20379	diagnostic	_
108-29	20380-20391	specificity	_
108-30	20391-20392	,	_
108-31	20393-20394	a	_
108-32	20395-20410	non-significant	_
108-33	20411-20416	trend	_
108-34	20417-20420	was	_
108-35	20421-20425	also	_
108-36	20426-20433	evident	_
108-37	20434-20436	in	_
108-38	20437-20440	the	_
108-39	20441-20445	PTSD	_
108-40	20446-20451	group	_
108-41	20452-20460	relative	_
108-42	20461-20463	to	_
108-43	20464-20467	the	_
108-44	20468-20470	HC	_
108-45	20471-20474	and	_
108-46	20475-20478	MDD	_
108-47	20479-20485	groups	_
108-48	20486-20487	(	_
108-49	20487-20490	Fig	_
108-50	20490-20491	.	_
108-51	20492-20493	1	_
108-52	20493-20494	)	_
108-53	20494-20495	.	_

#Text=Multiple lines of evidence implicate the pallidum in schizophrenia.
109-1	20496-20504	Multiple	_
109-2	20505-20510	lines	_
109-3	20511-20513	of	_
109-4	20514-20522	evidence	_
109-5	20523-20532	implicate	_
109-6	20533-20536	the	_
109-7	20537-20545	pallidum	_
109-8	20546-20548	in	_
109-9	20549-20562	schizophrenia	_
109-10	20562-20563	.	_

#Text=For example, gray matter volume in this region has been found to be positively related with genetic risk for the illness, whilst abnormal resting-state interhemispheric EC between left and right pallidum has been shown to be associated with negative symptoms, illness duration, and cognitive impairments in patients.
110-1	20564-20567	For	_
110-2	20568-20575	example	_
110-3	20575-20576	,	_
110-4	20577-20581	gray	_
110-5	20582-20588	matter	_
110-6	20589-20595	volume	_
110-7	20596-20598	in	_
110-8	20599-20603	this	_
110-9	20604-20610	region	_
110-10	20611-20614	has	_
110-11	20615-20619	been	_
110-12	20620-20625	found	_
110-13	20626-20628	to	_
110-14	20629-20631	be	_
110-15	20632-20642	positively	_
110-16	20643-20650	related	_
110-17	20651-20655	with	_
110-18	20656-20663	genetic	_
110-19	20664-20668	risk	_
110-20	20669-20672	for	_
110-21	20673-20676	the	_
110-22	20677-20684	illness	_
110-23	20684-20685	,	_
110-24	20686-20692	whilst	_
110-25	20693-20701	abnormal	_
110-26	20702-20715	resting-state	_
110-27	20716-20732	interhemispheric	_
110-28	20733-20735	EC	_
110-29	20736-20743	between	_
110-30	20744-20748	left	_
110-31	20749-20752	and	_
110-32	20753-20758	right	_
110-33	20759-20767	pallidum	_
110-34	20768-20771	has	_
110-35	20772-20776	been	_
110-36	20777-20782	shown	_
110-37	20783-20785	to	_
110-38	20786-20788	be	_
110-39	20789-20799	associated	_
110-40	20800-20804	with	_
110-41	20805-20813	negative	_
110-42	20814-20822	symptoms	_
110-43	20822-20823	,	_
110-44	20824-20831	illness	_
110-45	20832-20840	duration	_
110-46	20840-20841	,	_
110-47	20842-20845	and	_
110-48	20846-20855	cognitive	_
110-49	20856-20867	impairments	_
110-50	20868-20870	in	_
110-51	20871-20879	patients	_
110-52	20879-20880	.	_

#Text=In the present study, however, there was no statistically significant association between the strength of the right MDN-right pallidum EC and clinical variables.
111-1	20881-20883	In	_
111-2	20884-20887	the	_
111-3	20888-20895	present	_
111-4	20896-20901	study	_
111-5	20901-20902	,	_
111-6	20903-20910	however	_
111-7	20910-20911	,	_
111-8	20912-20917	there	_
111-9	20918-20921	was	_
111-10	20922-20924	no	_
111-11	20925-20938	statistically	_
111-12	20939-20950	significant	_
111-13	20951-20962	association	_
111-14	20963-20970	between	_
111-15	20971-20974	the	_
111-16	20975-20983	strength	_
111-17	20984-20986	of	_
111-18	20987-20990	the	_
111-19	20991-20996	right	_
111-20	20997-21006	MDN-right	_
111-21	21007-21015	pallidum	_
111-22	21016-21018	EC	_
111-23	21019-21022	and	_
111-24	21023-21031	clinical	_
111-25	21032-21041	variables	_
111-26	21041-21042	.	_

#Text=Based on the increasing evidence for a role of the pallidum in cognition, we speculate that the increased EC between the right MDN and right pallidum could potentially underlie the widely reported cognitive deficits in schizophrenia; this interpretation is consistent with the diagnostic specificity of such deficits that tend to be minimally present in PTSD and MDD.
112-1	21043-21048	Based	_
112-2	21049-21051	on	_
112-3	21052-21055	the	_
112-4	21056-21066	increasing	_
112-5	21067-21075	evidence	_
112-6	21076-21079	for	_
112-7	21080-21081	a	_
112-8	21082-21086	role	_
112-9	21087-21089	of	_
112-10	21090-21093	the	_
112-11	21094-21102	pallidum	_
112-12	21103-21105	in	_
112-13	21106-21115	cognition	_
112-14	21115-21116	,	_
112-15	21117-21119	we	_
112-16	21120-21129	speculate	_
112-17	21130-21134	that	_
112-18	21135-21138	the	_
112-19	21139-21148	increased	_
112-20	21149-21151	EC	_
112-21	21152-21159	between	_
112-22	21160-21163	the	_
112-23	21164-21169	right	_
112-24	21170-21173	MDN	_
112-25	21174-21177	and	_
112-26	21178-21183	right	_
112-27	21184-21192	pallidum	_
112-28	21193-21198	could	_
112-29	21199-21210	potentially	_
112-30	21211-21219	underlie	_
112-31	21220-21223	the	_
112-32	21224-21230	widely	_
112-33	21231-21239	reported	_
112-34	21240-21249	cognitive	_
112-35	21250-21258	deficits	_
112-36	21259-21261	in	_
112-37	21262-21275	schizophrenia	_
112-38	21275-21276	;	_
112-39	21277-21281	this	_
112-40	21282-21296	interpretation	_
112-41	21297-21299	is	_
112-42	21300-21310	consistent	_
112-43	21311-21315	with	_
112-44	21316-21319	the	_
112-45	21320-21330	diagnostic	_
112-46	21331-21342	specificity	_
112-47	21343-21345	of	_
112-48	21346-21350	such	_
112-49	21351-21359	deficits	_
112-50	21360-21364	that	_
112-51	21365-21369	tend	_
112-52	21370-21372	to	_
112-53	21373-21375	be	_
112-54	21376-21385	minimally	_
112-55	21386-21393	present	_
112-56	21394-21396	in	_
112-57	21397-21401	PTSD	_
112-58	21402-21405	and	_
112-59	21406-21409	MDD	_
112-60	21409-21410	.	_

#Text=Our second finding of note was widespread trans-diagnostic EC increases in MDN.
113-1	21411-21414	Our	_
113-2	21415-21421	second	_
113-3	21422-21429	finding	_
113-4	21430-21432	of	_
113-5	21433-21437	note	_
113-6	21438-21441	was	_
113-7	21442-21452	widespread	_
113-8	21453-21469	trans-diagnostic	_
113-9	21470-21472	EC	_
113-10	21473-21482	increases	_
113-11	21483-21485	in	_
113-12	21486-21489	MDN	_
113-13	21489-21490	.	_

#Text=Specifically, the left MDN displayed significant trans-diagnostic EC increases with the right postcentral gyrus, left supramarginal gyrus, right putamen, right supramarginal/angular gyrus, and right medial superior frontal gyrus, whereas the right MDN displayed significant trans-diagnostic EC increases with the bilateral supramarginal gyrus, right postcentral gyrus, right medial superior frontal gyrus, and left middle cingulate cortex.
114-1	21491-21503	Specifically	_
114-2	21503-21504	,	_
114-3	21505-21508	the	_
114-4	21509-21513	left	_
114-5	21514-21517	MDN	_
114-6	21518-21527	displayed	_
114-7	21528-21539	significant	_
114-8	21540-21556	trans-diagnostic	_
114-9	21557-21559	EC	_
114-10	21560-21569	increases	_
114-11	21570-21574	with	_
114-12	21575-21578	the	_
114-13	21579-21584	right	_
114-14	21585-21596	postcentral	_
114-15	21597-21602	gyrus	_
114-16	21602-21603	,	_
114-17	21604-21608	left	_
114-18	21609-21622	supramarginal	_
114-19	21623-21628	gyrus	_
114-20	21628-21629	,	_
114-21	21630-21635	right	_
114-22	21636-21643	putamen	_
114-23	21643-21644	,	_
114-24	21645-21650	right	_
114-25	21651-21664	supramarginal	_
114-26	21664-21665	/	_
114-27	21665-21672	angular	_
114-28	21673-21678	gyrus	_
114-29	21678-21679	,	_
114-30	21680-21683	and	_
114-31	21684-21689	right	_
114-32	21690-21696	medial	_
114-33	21697-21705	superior	_
114-34	21706-21713	frontal	_
114-35	21714-21719	gyrus	_
114-36	21719-21720	,	_
114-37	21721-21728	whereas	_
114-38	21729-21732	the	_
114-39	21733-21738	right	_
114-40	21739-21742	MDN	_
114-41	21743-21752	displayed	_
114-42	21753-21764	significant	_
114-43	21765-21781	trans-diagnostic	_
114-44	21782-21784	EC	_
114-45	21785-21794	increases	_
114-46	21795-21799	with	_
114-47	21800-21803	the	_
114-48	21804-21813	bilateral	_
114-49	21814-21827	supramarginal	_
114-50	21828-21833	gyrus	_
114-51	21833-21834	,	_
114-52	21835-21840	right	_
114-53	21841-21852	postcentral	_
114-54	21853-21858	gyrus	_
114-55	21858-21859	,	_
114-56	21860-21865	right	_
114-57	21866-21872	medial	_
114-58	21873-21881	superior	_
114-59	21882-21889	frontal	_
114-60	21890-21895	gyrus	_
114-61	21895-21896	,	_
114-62	21897-21900	and	_
114-63	21901-21905	left	_
114-64	21906-21912	middle	_
114-65	21913-21922	cingulate	_
114-66	21923-21929	cortex	_
114-67	21929-21930	.	_

#Text=The finding of widespread trans-diagnostic increases, observed above and beyond traditional diagnostic boundaries, is potentially consistent with emerging conceptualizations of mental illness based on a single general psychopathology factor.
115-1	21931-21934	The	_
115-2	21935-21942	finding	_
115-3	21943-21945	of	_
115-4	21946-21956	widespread	_
115-5	21957-21973	trans-diagnostic	_
115-6	21974-21983	increases	_
115-7	21983-21984	,	_
115-8	21985-21993	observed	_
115-9	21994-21999	above	_
115-10	22000-22003	and	_
115-11	22004-22010	beyond	_
115-12	22011-22022	traditional	_
115-13	22023-22033	diagnostic	_
115-14	22034-22044	boundaries	_
115-15	22044-22045	,	_
115-16	22046-22048	is	_
115-17	22049-22060	potentially	_
115-18	22061-22071	consistent	_
115-19	22072-22076	with	_
115-20	22077-22085	emerging	_
115-21	22086-22104	conceptualizations	_
115-22	22105-22107	of	_
115-23	22108-22114	mental	_
115-24	22115-22122	illness	_
115-25	22123-22128	based	_
115-26	22129-22131	on	_
115-27	22132-22133	a	_
115-28	22134-22140	single	_
115-29	22141-22148	general	_
115-30	22149-22164	psychopathology	_
115-31	22165-22171	factor	_
115-32	22171-22172	.	_

#Text=The observation of increased EC between the bilateral MDN and the right postcentral gyrus during the resting state is consistent with the results of several previous studies of psychosis.
116-1	22173-22176	The	_
116-2	22177-22188	observation	_
116-3	22189-22191	of	_
116-4	22192-22201	increased	_
116-5	22202-22204	EC	_
116-6	22205-22212	between	_
116-7	22213-22216	the	_
116-8	22217-22226	bilateral	_
116-9	22227-22230	MDN	_
116-10	22231-22234	and	_
116-11	22235-22238	the	_
116-12	22239-22244	right	_
116-13	22245-22256	postcentral	_
116-14	22257-22262	gyrus	_
116-15	22263-22269	during	_
116-16	22270-22273	the	_
116-17	22274-22281	resting	_
116-18	22282-22287	state	_
116-19	22288-22290	is	_
116-20	22291-22301	consistent	_
116-21	22302-22306	with	_
116-22	22307-22310	the	_
116-23	22311-22318	results	_
116-24	22319-22321	of	_
116-25	22322-22329	several	_
116-26	22330-22338	previous	_
116-27	22339-22346	studies	_
116-28	22347-22349	of	_
116-29	22350-22359	psychosis	_
116-30	22359-22360	.	_

#Text=In particular, it has been suggested that impaired inhibitory interactions between the MDN and primary somatosensory cortex (i.e., the postcentral gyrus) may result in aberrant processing of somatosensory information.
117-1	22361-22363	In	_
117-2	22364-22374	particular	_
117-3	22374-22375	,	_
117-4	22376-22378	it	_
117-5	22379-22382	has	_
117-6	22383-22387	been	_
117-7	22388-22397	suggested	_
117-8	22398-22402	that	_
117-9	22403-22411	impaired	_
117-10	22412-22422	inhibitory	_
117-11	22423-22435	interactions	_
117-12	22436-22443	between	_
117-13	22444-22447	the	_
117-14	22448-22451	MDN	_
117-15	22452-22455	and	_
117-16	22456-22463	primary	_
117-17	22464-22477	somatosensory	_
117-18	22478-22484	cortex	_
117-19	22485-22486	(	_
117-20	22486-22489	i.e	_
117-21	22489-22490	.	_
117-22	22490-22491	,	_
117-23	22492-22495	the	_
117-24	22496-22507	postcentral	_
117-25	22508-22513	gyrus	_
117-26	22513-22514	)	_
117-27	22515-22518	may	_
117-28	22519-22525	result	_
117-29	22526-22528	in	_
117-30	22529-22537	aberrant	_
117-31	22538-22548	processing	_
117-32	22549-22551	of	_
117-33	22552-22565	somatosensory	_
117-34	22566-22577	information	_
117-35	22577-22578	.	_

#Text=Here, we speculate that the increased EC between the bilateral MDN and right postcentral gyrus could reflect altered sensory processing in schizophrenia, PTSD, and MDD, contributing to the emergence of hallucinations/delusions, hyperarousal, and anhedonia, respectively.
118-1	22579-22583	Here	_
118-2	22583-22584	,	_
118-3	22585-22587	we	_
118-4	22588-22597	speculate	_
118-5	22598-22602	that	_
118-6	22603-22606	the	_
118-7	22607-22616	increased	_
118-8	22617-22619	EC	_
118-9	22620-22627	between	_
118-10	22628-22631	the	_
118-11	22632-22641	bilateral	_
118-12	22642-22645	MDN	_
118-13	22646-22649	and	_
118-14	22650-22655	right	_
118-15	22656-22667	postcentral	_
118-16	22668-22673	gyrus	_
118-17	22674-22679	could	_
118-18	22680-22687	reflect	_
118-19	22688-22695	altered	_
118-20	22696-22703	sensory	_
118-21	22704-22714	processing	_
118-22	22715-22717	in	_
118-23	22718-22731	schizophrenia	_
118-24	22731-22732	,	_
118-25	22733-22737	PTSD	_
118-26	22737-22738	,	_
118-27	22739-22742	and	_
118-28	22743-22746	MDD	_
118-29	22746-22747	,	_
118-30	22748-22760	contributing	_
118-31	22761-22763	to	_
118-32	22764-22767	the	_
118-33	22768-22777	emergence	_
118-34	22778-22780	of	_
118-35	22781-22795	hallucinations	_
118-36	22795-22796	/	_
118-37	22796-22805	delusions	_
118-38	22805-22806	,	_
118-39	22807-22819	hyperarousal	_
118-40	22819-22820	,	_
118-41	22821-22824	and	_
118-42	22825-22834	anhedonia	_
118-43	22834-22835	,	_
118-44	22836-22848	respectively	_
118-45	22848-22849	.	_

#Text=It is interesting to note that, though previous studies report positive correlations between increased thalamus-somatosensory cortex EC and psychotic symptoms no such correlations were found in the present investigation.
119-1	22850-22852	It	_
119-2	22853-22855	is	_
119-3	22856-22867	interesting	_
119-4	22868-22870	to	_
119-5	22871-22875	note	_
119-6	22876-22880	that	_
119-7	22880-22881	,	_
119-8	22882-22888	though	_
119-9	22889-22897	previous	_
119-10	22898-22905	studies	_
119-11	22906-22912	report	_
119-12	22913-22921	positive	_
119-13	22922-22934	correlations	_
119-14	22935-22942	between	_
119-15	22943-22952	increased	_
119-16	22953-22975	thalamus-somatosensory	_
119-17	22976-22982	cortex	_
119-18	22983-22985	EC	_
119-19	22986-22989	and	_
119-20	22990-22999	psychotic	_
119-21	23000-23008	symptoms	_
119-22	23009-23011	no	_
119-23	23012-23016	such	_
119-24	23017-23029	correlations	_
119-25	23030-23034	were	_
119-26	23035-23040	found	_
119-27	23041-23043	in	_
119-28	23044-23047	the	_
119-29	23048-23055	present	_
119-30	23056-23069	investigation	_
119-31	23069-23070	.	_

#Text=The observation of increased EC between the bilateral MDN and the right medial superior frontal gyrus is also consistent with a previous report of increased EC between the thalamus and medial prefrontal cortex (which includes the medial superior frontal gyrus) in schizophrenia.
120-1	23071-23074	The	_
120-2	23075-23086	observation	_
120-3	23087-23089	of	_
120-4	23090-23099	increased	_
120-5	23100-23102	EC	_
120-6	23103-23110	between	_
120-7	23111-23114	the	_
120-8	23115-23124	bilateral	_
120-9	23125-23128	MDN	_
120-10	23129-23132	and	_
120-11	23133-23136	the	_
120-12	23137-23142	right	_
120-13	23143-23149	medial	_
120-14	23150-23158	superior	_
120-15	23159-23166	frontal	_
120-16	23167-23172	gyrus	_
120-17	23173-23175	is	_
120-18	23176-23180	also	_
120-19	23181-23191	consistent	_
120-20	23192-23196	with	_
120-21	23197-23198	a	_
120-22	23199-23207	previous	_
120-23	23208-23214	report	_
120-24	23215-23217	of	_
120-25	23218-23227	increased	_
120-26	23228-23230	EC	_
120-27	23231-23238	between	_
120-28	23239-23242	the	_
120-29	23243-23251	thalamus	_
120-30	23252-23255	and	_
120-31	23256-23262	medial	_
120-32	23263-23273	prefrontal	_
120-33	23274-23280	cortex	_
120-34	23281-23282	(	_
120-35	23282-23287	which	_
120-36	23288-23296	includes	_
120-37	23297-23300	the	_
120-38	23301-23307	medial	_
120-39	23308-23316	superior	_
120-40	23317-23324	frontal	_
120-41	23325-23330	gyrus	_
120-42	23330-23331	)	_
120-43	23332-23334	in	_
120-44	23335-23348	schizophrenia	_
120-45	23348-23349	.	_

#Text=This finding could reflect a compensatory response to possible regional structural and functional deficits in the medial superior frontal gyrus that are typically observed in this illness.
121-1	23350-23354	This	_
121-2	23355-23362	finding	_
121-3	23363-23368	could	_
121-4	23369-23376	reflect	_
121-5	23377-23378	a	_
121-6	23379-23391	compensatory	_
121-7	23392-23400	response	_
121-8	23401-23403	to	_
121-9	23404-23412	possible	_
121-10	23413-23421	regional	_
121-11	23422-23432	structural	_
121-12	23433-23436	and	_
121-13	23437-23447	functional	_
121-14	23448-23456	deficits	_
121-15	23457-23459	in	_
121-16	23460-23463	the	_
121-17	23464-23470	medial	_
121-18	23471-23479	superior	_
121-19	23480-23487	frontal	_
121-20	23488-23493	gyrus	_
121-21	23494-23498	that	_
121-22	23499-23502	are	_
121-23	23503-23512	typically	_
121-24	23513-23521	observed	_
121-25	23522-23524	in	_
121-26	23525-23529	this	_
121-27	23530-23537	illness	_
121-28	23537-23538	.	_

#Text=Interestingly, the EC increase between the left MDN and the right medial superior frontal gyrus was negatively correlated with the PANSS negative score, while the EC increase between the right MDN and the right medial superior frontal gyrus was negatively associated with the PANSS general psychopathology score.
122-1	23539-23552	Interestingly	_
122-2	23552-23553	,	_
122-3	23554-23557	the	_
122-4	23558-23560	EC	_
122-5	23561-23569	increase	_
122-6	23570-23577	between	_
122-7	23578-23581	the	_
122-8	23582-23586	left	_
122-9	23587-23590	MDN	_
122-10	23591-23594	and	_
122-11	23595-23598	the	_
122-12	23599-23604	right	_
122-13	23605-23611	medial	_
122-14	23612-23620	superior	_
122-15	23621-23628	frontal	_
122-16	23629-23634	gyrus	_
122-17	23635-23638	was	_
122-18	23639-23649	negatively	_
122-19	23650-23660	correlated	_
122-20	23661-23665	with	_
122-21	23666-23669	the	_
122-22	23670-23675	PANSS	_
122-23	23676-23684	negative	_
122-24	23685-23690	score	_
122-25	23690-23691	,	_
122-26	23692-23697	while	_
122-27	23698-23701	the	_
122-28	23702-23704	EC	_
122-29	23705-23713	increase	_
122-30	23714-23721	between	_
122-31	23722-23725	the	_
122-32	23726-23731	right	_
122-33	23732-23735	MDN	_
122-34	23736-23739	and	_
122-35	23740-23743	the	_
122-36	23744-23749	right	_
122-37	23750-23756	medial	_
122-38	23757-23765	superior	_
122-39	23766-23773	frontal	_
122-40	23774-23779	gyrus	_
122-41	23780-23783	was	_
122-42	23784-23794	negatively	_
122-43	23795-23805	associated	_
122-44	23806-23810	with	_
122-45	23811-23814	the	_
122-46	23815-23820	PANSS	_
122-47	23821-23828	general	_
122-48	23829-23844	psychopathology	_
122-49	23845-23850	score	_
122-50	23850-23851	.	_

#Text=These negative correlations support our speculation of the present findings representing compensatory responses to the illness.
123-1	23852-23857	These	_
123-2	23858-23866	negative	_
123-3	23867-23879	correlations	_
123-4	23880-23887	support	_
123-5	23888-23891	our	_
123-6	23892-23903	speculation	_
123-7	23904-23906	of	_
123-8	23907-23910	the	_
123-9	23911-23918	present	_
123-10	23919-23927	findings	_
123-11	23928-23940	representing	_
123-12	23941-23953	compensatory	_
123-13	23954-23963	responses	_
123-14	23964-23966	to	_
123-15	23967-23970	the	_
123-16	23971-23978	illness	_
123-17	23978-23979	.	_

#Text=In addition, we found that the right MDN displayed increased EC with the bilateral supramarginal gyri, whilst the left MDN exhibited this same pattern with the left supramarginal gyrus.
124-1	23980-23982	In	_
124-2	23983-23991	addition	_
124-3	23991-23992	,	_
124-4	23993-23995	we	_
124-5	23996-24001	found	_
124-6	24002-24006	that	_
124-7	24007-24010	the	_
124-8	24011-24016	right	_
124-9	24017-24020	MDN	_
124-10	24021-24030	displayed	_
124-11	24031-24040	increased	_
124-12	24041-24043	EC	_
124-13	24044-24048	with	_
124-14	24049-24052	the	_
124-15	24053-24062	bilateral	_
124-16	24063-24076	supramarginal	_
124-17	24077-24081	gyri	_
124-18	24081-24082	,	_
124-19	24083-24089	whilst	_
124-20	24090-24093	the	_
124-21	24094-24098	left	_
124-22	24099-24102	MDN	_
124-23	24103-24112	exhibited	_
124-24	24113-24117	this	_
124-25	24118-24122	same	_
124-26	24123-24130	pattern	_
124-27	24131-24135	with	_
124-28	24136-24139	the	_
124-29	24140-24144	left	_
124-30	24145-24158	supramarginal	_
124-31	24159-24164	gyrus	_
124-32	24164-24165	.	_

#Text=With the supramarginal gyrus being thought to function in the phonological loop component of working memory, the increased EC between the MDN and the supramarginal gyri could be associated with impaired verbal working memory processing in schizophrenia, PTSD, and MDD subjects, possibly with regards to a compensatory response.
125-1	24166-24170	With	_
125-2	24171-24174	the	_
125-3	24175-24188	supramarginal	_
125-4	24189-24194	gyrus	_
125-5	24195-24200	being	_
125-6	24201-24208	thought	_
125-7	24209-24211	to	_
125-8	24212-24220	function	_
125-9	24221-24223	in	_
125-10	24224-24227	the	_
125-11	24228-24240	phonological	_
125-12	24241-24245	loop	_
125-13	24246-24255	component	_
125-14	24256-24258	of	_
125-15	24259-24266	working	_
125-16	24267-24273	memory	_
125-17	24273-24274	,	_
125-18	24275-24278	the	_
125-19	24279-24288	increased	_
125-20	24289-24291	EC	_
125-21	24292-24299	between	_
125-22	24300-24303	the	_
125-23	24304-24307	MDN	_
125-24	24308-24311	and	_
125-25	24312-24315	the	_
125-26	24316-24329	supramarginal	_
125-27	24330-24334	gyri	_
125-28	24335-24340	could	_
125-29	24341-24343	be	_
125-30	24344-24354	associated	_
125-31	24355-24359	with	_
125-32	24360-24368	impaired	_
125-33	24369-24375	verbal	_
125-34	24376-24383	working	_
125-35	24384-24390	memory	_
125-36	24391-24401	processing	_
125-37	24402-24404	in	_
125-38	24405-24418	schizophrenia	_
125-39	24418-24419	,	_
125-40	24420-24424	PTSD	_
125-41	24424-24425	,	_
125-42	24426-24429	and	_
125-43	24430-24433	MDD	_
125-44	24434-24442	subjects	_
125-45	24442-24443	,	_
125-46	24444-24452	possibly	_
125-47	24453-24457	with	_
125-48	24458-24465	regards	_
125-49	24466-24468	to	_
125-50	24469-24470	a	_
125-51	24471-24483	compensatory	_
125-52	24484-24492	response	_
125-53	24492-24493	.	_

#Text=We also found a number of effects which were lateralized to the left or right MDN.
126-1	24494-24496	We	_
126-2	24497-24501	also	_
126-3	24502-24507	found	_
126-4	24508-24509	a	_
126-5	24510-24516	number	_
126-6	24517-24519	of	_
126-7	24520-24527	effects	_
126-8	24528-24533	which	_
126-9	24534-24538	were	_
126-10	24539-24550	lateralized	_
126-11	24551-24553	to	_
126-12	24554-24557	the	_
126-13	24558-24562	left	_
126-14	24563-24565	or	_
126-15	24566-24571	right	_
126-16	24572-24575	MDN	_
126-17	24575-24576	.	_

#Text=In particular, the right MDN displayed increased EC with the left middle cingulate cortex.
127-1	24577-24579	In	_
127-2	24580-24590	particular	_
127-3	24590-24591	,	_
127-4	24592-24595	the	_
127-5	24596-24601	right	_
127-6	24602-24605	MDN	_
127-7	24606-24615	displayed	_
127-8	24616-24625	increased	_
127-9	24626-24628	EC	_
127-10	24629-24633	with	_
127-11	24634-24637	the	_
127-12	24638-24642	left	_
127-13	24643-24649	middle	_
127-14	24650-24659	cingulate	_
127-15	24660-24666	cortex	_
127-16	24666-24667	.	_

#Text=The latter is thought to play a key role in attention and awareness—areas of cognitive functioning that are impaired across psychiatric disorders.
128-1	24668-24671	The	_
128-2	24672-24678	latter	_
128-3	24679-24681	is	_
128-4	24682-24689	thought	_
128-5	24690-24692	to	_
128-6	24693-24697	play	_
128-7	24698-24699	a	_
128-8	24700-24703	key	_
128-9	24704-24708	role	_
128-10	24709-24711	in	_
128-11	24712-24721	attention	_
128-12	24722-24725	and	_
128-13	24726-24741	awareness—areas	_
128-14	24742-24744	of	_
128-15	24745-24754	cognitive	_
128-16	24755-24766	functioning	_
128-17	24767-24771	that	_
128-18	24772-24775	are	_
128-19	24776-24784	impaired	_
128-20	24785-24791	across	_
128-21	24792-24803	psychiatric	_
128-22	24804-24813	disorders	_
128-23	24813-24814	.	_

#Text=Therefore, increased EC between this region and the MDN could be associated with impairments of attention and awareness.
129-1	24815-24824	Therefore	_
129-2	24824-24825	,	_
129-3	24826-24835	increased	_
129-4	24836-24838	EC	_
129-5	24839-24846	between	_
129-6	24847-24851	this	_
129-7	24852-24858	region	_
129-8	24859-24862	and	_
129-9	24863-24866	the	_
129-10	24867-24870	MDN	_
129-11	24871-24876	could	_
129-12	24877-24879	be	_
129-13	24880-24890	associated	_
129-14	24891-24895	with	_
129-15	24896-24907	impairments	_
129-16	24908-24910	of	_
129-17	24911-24920	attention	_
129-18	24921-24924	and	_
129-19	24925-24934	awareness	_
129-20	24934-24935	.	_

#Text=In addition, the left MDN showed increased EC with the right putamen—a finding which is inconsistent with previous studies reporting decreased EC between the MDN and the putamen in chronic schizophrenia and in an at risk mental state for psychosis.
130-1	24936-24938	In	_
130-2	24939-24947	addition	_
130-3	24947-24948	,	_
130-4	24949-24952	the	_
130-5	24953-24957	left	_
130-6	24958-24961	MDN	_
130-7	24962-24968	showed	_
130-8	24969-24978	increased	_
130-9	24979-24981	EC	_
130-10	24982-24986	with	_
130-11	24987-24990	the	_
130-12	24991-24996	right	_
130-13	24997-25006	putamen—a	_
130-14	25007-25014	finding	_
130-15	25015-25020	which	_
130-16	25021-25023	is	_
130-17	25024-25036	inconsistent	_
130-18	25037-25041	with	_
130-19	25042-25050	previous	_
130-20	25051-25058	studies	_
130-21	25059-25068	reporting	_
130-22	25069-25078	decreased	_
130-23	25079-25081	EC	_
130-24	25082-25089	between	_
130-25	25090-25093	the	_
130-26	25094-25097	MDN	_
130-27	25098-25101	and	_
130-28	25102-25105	the	_
130-29	25106-25113	putamen	_
130-30	25114-25116	in	_
130-31	25117-25124	chronic	_
130-32	25125-25138	schizophrenia	_
130-33	25139-25142	and	_
130-34	25143-25145	in	_
130-35	25146-25148	an	_
130-36	25149-25151	at	_
130-37	25152-25156	risk	_
130-38	25157-25163	mental	_
130-39	25164-25169	state	_
130-40	25170-25173	for	_
130-41	25174-25183	psychosis	_
130-42	25183-25184	.	_

#Text=Interestingly, the EC increase between the left MDN and the right putamen was positively correlated with the Global Assessment of Functioning scores.
131-1	25185-25198	Interestingly	_
131-2	25198-25199	,	_
131-3	25200-25203	the	_
131-4	25204-25206	EC	_
131-5	25207-25215	increase	_
131-6	25216-25223	between	_
131-7	25224-25227	the	_
131-8	25228-25232	left	_
131-9	25233-25236	MDN	_
131-10	25237-25240	and	_
131-11	25241-25244	the	_
131-12	25245-25250	right	_
131-13	25251-25258	putamen	_
131-14	25259-25262	was	_
131-15	25263-25273	positively	_
131-16	25274-25284	correlated	_
131-17	25285-25289	with	_
131-18	25290-25293	the	_
131-19	25294-25300	Global	_
131-20	25301-25311	Assessment	_
131-21	25312-25314	of	_
131-22	25315-25326	Functioning	_
131-23	25327-25333	scores	_
131-24	25333-25334	.	_

#Text=The finding that schizophrenia patients with relatively higher EC values between these regions had a greater day-to-day functioning suggests that this effect might also represent a compensatory response to the illness.
132-1	25335-25338	The	_
132-2	25339-25346	finding	_
132-3	25347-25351	that	_
132-4	25352-25365	schizophrenia	_
132-5	25366-25374	patients	_
132-6	25375-25379	with	_
132-7	25380-25390	relatively	_
132-8	25391-25397	higher	_
132-9	25398-25400	EC	_
132-10	25401-25407	values	_
132-11	25408-25415	between	_
132-12	25416-25421	these	_
132-13	25422-25429	regions	_
132-14	25430-25433	had	_
132-15	25434-25435	a	_
132-16	25436-25443	greater	_
132-17	25444-25454	day-to-day	_
132-18	25455-25466	functioning	_
132-19	25467-25475	suggests	_
132-20	25476-25480	that	_
132-21	25481-25485	this	_
132-22	25486-25492	effect	_
132-23	25493-25498	might	_
132-24	25499-25503	also	_
132-25	25504-25513	represent	_
132-26	25514-25515	a	_
132-27	25516-25528	compensatory	_
132-28	25529-25537	response	_
132-29	25538-25540	to	_
132-30	25541-25544	the	_
132-31	25545-25552	illness	_
132-32	25552-25553	.	_

#Text=A strength of the present investigation is that, at the time of scanning, patients with schizophrenia were experiencing their first episode of the illness and were still medication-naïve.
133-1	25554-25555	A	_
133-2	25556-25564	strength	_
133-3	25565-25567	of	_
133-4	25568-25571	the	_
133-5	25572-25579	present	_
133-6	25580-25593	investigation	_
133-7	25594-25596	is	_
133-8	25597-25601	that	_
133-9	25601-25602	,	_
133-10	25603-25605	at	_
133-11	25606-25609	the	_
133-12	25610-25614	time	_
133-13	25615-25617	of	_
133-14	25618-25626	scanning	_
133-15	25626-25627	,	_
133-16	25628-25636	patients	_
133-17	25637-25641	with	_
133-18	25642-25655	schizophrenia	_
133-19	25656-25660	were	_
133-20	25661-25673	experiencing	_
133-21	25674-25679	their	_
133-22	25680-25685	first	_
133-23	25686-25693	episode	_
133-24	25694-25696	of	_
133-25	25697-25700	the	_
133-26	25701-25708	illness	_
133-27	25709-25712	and	_
133-28	25713-25717	were	_
133-29	25718-25723	still	_
133-30	25724-25740	medication-naïve	_
133-31	25740-25741	.	_

#Text=This means that the effects reported here cannot be explained by illness chronicity or medication—two common confounds in neuroimaging studies of psychiatric disease.
134-1	25742-25746	This	_
134-2	25747-25752	means	_
134-3	25753-25757	that	_
134-4	25758-25761	the	_
134-5	25762-25769	effects	_
134-6	25770-25778	reported	_
134-7	25779-25783	here	_
134-8	25784-25790	cannot	_
134-9	25791-25793	be	_
134-10	25794-25803	explained	_
134-11	25804-25806	by	_
134-12	25807-25814	illness	_
134-13	25815-25825	chronicity	_
134-14	25826-25828	or	_
134-15	25829-25843	medication—two	_
134-16	25844-25850	common	_
134-17	25851-25860	confounds	_
134-18	25861-25863	in	_
134-19	25864-25876	neuroimaging	_
134-20	25877-25884	studies	_
134-21	25885-25887	of	_
134-22	25888-25899	psychiatric	_
134-23	25900-25907	disease	_
134-24	25907-25908	.	_

#Text=This absence of chronicity, and medication-related effects may account for the fact that, in the present investigation, we found increases in thalamocortical EC whereas previous studies employing the same resting-state paradigm tended to report decreases.
135-1	25909-25913	This	_
135-2	25914-25921	absence	_
135-3	25922-25924	of	_
135-4	25925-25935	chronicity	_
135-5	25935-25936	,	_
135-6	25937-25940	and	_
135-7	25941-25959	medication-related	_
135-8	25960-25967	effects	_
135-9	25968-25971	may	_
135-10	25972-25979	account	_
135-11	25980-25983	for	_
135-12	25984-25987	the	_
135-13	25988-25992	fact	_
135-14	25993-25997	that	_
135-15	25997-25998	,	_
135-16	25999-26001	in	_
135-17	26002-26005	the	_
135-18	26006-26013	present	_
135-19	26014-26027	investigation	_
135-20	26027-26028	,	_
135-21	26029-26031	we	_
135-22	26032-26037	found	_
135-23	26038-26047	increases	_
135-24	26048-26050	in	_
135-25	26051-26066	thalamocortical	_
135-26	26067-26069	EC	_
135-27	26070-26077	whereas	_
135-28	26078-26086	previous	_
135-29	26087-26094	studies	_
135-30	26095-26104	employing	_
135-31	26105-26108	the	_
135-32	26109-26113	same	_
135-33	26114-26127	resting-state	_
135-34	26128-26136	paradigm	_
135-35	26137-26143	tended	_
135-36	26144-26146	to	_
135-37	26147-26153	report	_
135-38	26154-26163	decreases	_
135-39	26163-26164	.	_

#Text=We speculate that some of the decreases reported in the existing literature may reflect the effects of these two common confounds.
136-1	26165-26167	We	_
136-2	26168-26177	speculate	_
136-3	26178-26182	that	_
136-4	26183-26187	some	_
136-5	26188-26190	of	_
136-6	26191-26194	the	_
136-7	26195-26204	decreases	_
136-8	26205-26213	reported	_
136-9	26214-26216	in	_
136-10	26217-26220	the	_
136-11	26221-26229	existing	_
136-12	26230-26240	literature	_
136-13	26241-26244	may	_
136-14	26245-26252	reflect	_
136-15	26253-26256	the	_
136-16	26257-26264	effects	_
136-17	26265-26267	of	_
136-18	26268-26273	these	_
136-19	26274-26277	two	_
136-20	26278-26284	common	_
136-21	26285-26294	confounds	_
136-22	26294-26295	.	_

#Text=A further strength is that all four groups were scanned using the same MRI scanner and image acquisition parameters over the same period of time, and therefore our results cannot be explained by systematic differences in the acquisition of the data.
137-1	26296-26297	A	_
137-2	26298-26305	further	_
137-3	26306-26314	strength	_
137-4	26315-26317	is	_
137-5	26318-26322	that	_
137-6	26323-26326	all	_
137-7	26327-26331	four	_
137-8	26332-26338	groups	_
137-9	26339-26343	were	_
137-10	26344-26351	scanned	_
137-11	26352-26357	using	_
137-12	26358-26361	the	_
137-13	26362-26366	same	_
137-14	26367-26370	MRI	_
137-15	26371-26378	scanner	_
137-16	26379-26382	and	_
137-17	26383-26388	image	_
137-18	26389-26400	acquisition	_
137-19	26401-26411	parameters	_
137-20	26412-26416	over	_
137-21	26417-26420	the	_
137-22	26421-26425	same	_
137-23	26426-26432	period	_
137-24	26433-26435	of	_
137-25	26436-26440	time	_
137-26	26440-26441	,	_
137-27	26442-26445	and	_
137-28	26446-26455	therefore	_
137-29	26456-26459	our	_
137-30	26460-26467	results	_
137-31	26468-26474	cannot	_
137-32	26475-26477	be	_
137-33	26478-26487	explained	_
137-34	26488-26490	by	_
137-35	26491-26501	systematic	_
137-36	26502-26513	differences	_
137-37	26514-26516	in	_
137-38	26517-26520	the	_
137-39	26521-26532	acquisition	_
137-40	26533-26535	of	_
137-41	26536-26539	the	_
137-42	26540-26544	data	_
137-43	26544-26545	.	_

#Text=In addition, the present investigation has several limitations that are worth mentioning.
138-1	26546-26548	In	_
138-2	26549-26557	addition	_
138-3	26557-26558	,	_
138-4	26559-26562	the	_
138-5	26563-26570	present	_
138-6	26571-26584	investigation	_
138-7	26585-26588	has	_
138-8	26589-26596	several	_
138-9	26597-26608	limitations	_
138-10	26609-26613	that	_
138-11	26614-26617	are	_
138-12	26618-26623	worth	_
138-13	26624-26634	mentioning	_
138-14	26634-26635	.	_

#Text=Firstly, we cannot exclude the possibility that the increased EC between the right MDN and the right pallidum that we report as a distinctive feature of schizophrenia may be expressed in other psychiatric groups not included here.
139-1	26636-26643	Firstly	_
139-2	26643-26644	,	_
139-3	26645-26647	we	_
139-4	26648-26654	cannot	_
139-5	26655-26662	exclude	_
139-6	26663-26666	the	_
139-7	26667-26678	possibility	_
139-8	26679-26683	that	_
139-9	26684-26687	the	_
139-10	26688-26697	increased	_
139-11	26698-26700	EC	_
139-12	26701-26708	between	_
139-13	26709-26712	the	_
139-14	26713-26718	right	_
139-15	26719-26722	MDN	_
139-16	26723-26726	and	_
139-17	26727-26730	the	_
139-18	26731-26736	right	_
139-19	26737-26745	pallidum	_
139-20	26746-26750	that	_
139-21	26751-26753	we	_
139-22	26754-26760	report	_
139-23	26761-26763	as	_
139-24	26764-26765	a	_
139-25	26766-26777	distinctive	_
139-26	26778-26785	feature	_
139-27	26786-26788	of	_
139-28	26789-26802	schizophrenia	_
139-29	26803-26806	may	_
139-30	26807-26809	be	_
139-31	26810-26819	expressed	_
139-32	26820-26822	in	_
139-33	26823-26828	other	_
139-34	26829-26840	psychiatric	_
139-35	26841-26847	groups	_
139-36	26848-26851	not	_
139-37	26852-26860	included	_
139-38	26861-26865	here	_
139-39	26865-26866	.	_

#Text=For example, a recent investigation reported divergent patterns of thalamocortical dysconnectivity in patients with schizophrenia and bipolar disorder.
140-1	26867-26870	For	_
140-2	26871-26878	example	_
140-3	26878-26879	,	_
140-4	26880-26881	a	_
140-5	26882-26888	recent	_
140-6	26889-26902	investigation	_
140-7	26903-26911	reported	_
140-8	26912-26921	divergent	_
140-9	26922-26930	patterns	_
140-10	26931-26933	of	_
140-11	26934-26949	thalamocortical	_
140-12	26950-26965	dysconnectivity	_
140-13	26966-26968	in	_
140-14	26969-26977	patients	_
140-15	26978-26982	with	_
140-16	26983-26996	schizophrenia	_
140-17	26997-27000	and	_
140-18	27001-27008	bipolar	_
140-19	27009-27017	disorder	_
140-20	27017-27018	.	_

#Text=However, a direct comparison with our findings is difficult due to major methodological differences between the two studies.
141-1	27019-27026	However	_
141-2	27026-27027	,	_
141-3	27028-27029	a	_
141-4	27030-27036	direct	_
141-5	27037-27047	comparison	_
141-6	27048-27052	with	_
141-7	27053-27056	our	_
141-8	27057-27065	findings	_
141-9	27066-27068	is	_
141-10	27069-27078	difficult	_
141-11	27079-27082	due	_
141-12	27083-27085	to	_
141-13	27086-27091	major	_
141-14	27092-27106	methodological	_
141-15	27107-27118	differences	_
141-16	27119-27126	between	_
141-17	27127-27130	the	_
141-18	27131-27134	two	_
141-19	27135-27142	studies	_
141-20	27142-27143	.	_

#Text=For example, we focussed on a specific nucleus of the thalamus (the MDN) whereas Skåtun and colleagues examined ten sub-sections of the thalamus that were identified using independent component analysis rather than pre-existing neuroanatomical knowledge.
142-1	27144-27147	For	_
142-2	27148-27155	example	_
142-3	27155-27156	,	_
142-4	27157-27159	we	_
142-5	27160-27168	focussed	_
142-6	27169-27171	on	_
142-7	27172-27173	a	_
142-8	27174-27182	specific	_
142-9	27183-27190	nucleus	_
142-10	27191-27193	of	_
142-11	27194-27197	the	_
142-12	27198-27206	thalamus	_
142-13	27207-27208	(	_
142-14	27208-27211	the	_
142-15	27212-27215	MDN	_
142-16	27215-27216	)	_
142-17	27217-27224	whereas	_
142-18	27225-27231	Skåtun	_
142-19	27232-27235	and	_
142-20	27236-27246	colleagues	_
142-21	27247-27255	examined	_
142-22	27256-27259	ten	_
142-23	27260-27272	sub-sections	_
142-24	27273-27275	of	_
142-25	27276-27279	the	_
142-26	27280-27288	thalamus	_
142-27	27289-27293	that	_
142-28	27294-27298	were	_
142-29	27299-27309	identified	_
142-30	27310-27315	using	_
142-31	27316-27327	independent	_
142-32	27328-27337	component	_
142-33	27338-27346	analysis	_
142-34	27347-27353	rather	_
142-35	27354-27358	than	_
142-36	27359-27371	pre-existing	_
142-37	27372-27387	neuroanatomical	_
142-38	27388-27397	knowledge	_
142-39	27397-27398	.	_

#Text=Furthermore we examined drug-naïve patients with a first episode of the illness, whereas Skåtun and colleagues recruited medicated patients who had been ill for an average of 5.8 years (for schizophrenia) and 9.9 years (for bipolar disorder).
143-1	27399-27410	Furthermore	_
143-2	27411-27413	we	_
143-3	27414-27422	examined	_
143-4	27423-27433	drug-naïve	_
143-5	27434-27442	patients	_
143-6	27443-27447	with	_
143-7	27448-27449	a	_
143-8	27450-27455	first	_
143-9	27456-27463	episode	_
143-10	27464-27466	of	_
143-11	27467-27470	the	_
143-12	27471-27478	illness	_
143-13	27478-27479	,	_
143-14	27480-27487	whereas	_
143-15	27488-27494	Skåtun	_
143-16	27495-27498	and	_
143-17	27499-27509	colleagues	_
143-18	27510-27519	recruited	_
143-19	27520-27529	medicated	_
143-20	27530-27538	patients	_
143-21	27539-27542	who	_
143-22	27543-27546	had	_
143-23	27547-27551	been	_
143-24	27552-27555	ill	_
143-25	27556-27559	for	_
143-26	27560-27562	an	_
143-27	27563-27570	average	_
143-28	27571-27573	of	_
143-29	27574-27577	5.8	_
143-30	27578-27583	years	_
143-31	27584-27585	(	_
143-32	27585-27588	for	_
143-33	27589-27602	schizophrenia	_
143-34	27602-27603	)	_
143-35	27604-27607	and	_
143-36	27608-27611	9.9	_
143-37	27612-27617	years	_
143-38	27618-27619	(	_
143-39	27619-27622	for	_
143-40	27623-27630	bipolar	_
143-41	27631-27639	disorder	_
143-42	27639-27640	)	_
143-43	27640-27641	.	_

#Text=Secondly, although we can exclude medication as a potential confound, there are other sources of neurofunctional variability such as IQ and socio-economic status that were not monitored and might have contributed to the differences between patients and controls.
144-1	27642-27650	Secondly	_
144-2	27650-27651	,	_
144-3	27652-27660	although	_
144-4	27661-27663	we	_
144-5	27664-27667	can	_
144-6	27668-27675	exclude	_
144-7	27676-27686	medication	_
144-8	27687-27689	as	_
144-9	27690-27691	a	_
144-10	27692-27701	potential	_
144-11	27702-27710	confound	_
144-12	27710-27711	,	_
144-13	27712-27717	there	_
144-14	27718-27721	are	_
144-15	27722-27727	other	_
144-16	27728-27735	sources	_
144-17	27736-27738	of	_
144-18	27739-27754	neurofunctional	_
144-19	27755-27766	variability	_
144-20	27767-27771	such	_
144-21	27772-27774	as	_
144-22	27775-27777	IQ	_
144-23	27778-27781	and	_
144-24	27782-27796	socio-economic	_
144-25	27797-27803	status	_
144-26	27804-27808	that	_
144-27	27809-27813	were	_
144-28	27814-27817	not	_
144-29	27818-27827	monitored	_
144-30	27828-27831	and	_
144-31	27832-27837	might	_
144-32	27838-27842	have	_
144-33	27843-27854	contributed	_
144-34	27855-27857	to	_
144-35	27858-27861	the	_
144-36	27862-27873	differences	_
144-37	27874-27881	between	_
144-38	27882-27890	patients	_
144-39	27891-27894	and	_
144-40	27895-27903	controls	_
144-41	27903-27904	.	_

#Text=We also note that there were demographic differences amongst clinical groups—for example the PTSD participants came from rural rather than urban areas and were older than the other groups.
145-1	27905-27907	We	_
145-2	27908-27912	also	_
145-3	27913-27917	note	_
145-4	27918-27922	that	_
145-5	27923-27928	there	_
145-6	27929-27933	were	_
145-7	27934-27945	demographic	_
145-8	27946-27957	differences	_
145-9	27958-27965	amongst	_
145-10	27966-27974	clinical	_
145-11	27975-27985	groups—for	_
145-12	27986-27993	example	_
145-13	27994-27997	the	_
145-14	27998-28002	PTSD	_
145-15	28003-28015	participants	_
145-16	28016-28020	came	_
145-17	28021-28025	from	_
145-18	28026-28031	rural	_
145-19	28032-28038	rather	_
145-20	28039-28043	than	_
145-21	28044-28049	urban	_
145-22	28050-28055	areas	_
145-23	28056-28059	and	_
145-24	28060-28064	were	_
145-25	28065-28070	older	_
145-26	28071-28075	than	_
145-27	28076-28079	the	_
145-28	28080-28085	other	_
145-29	28086-28092	groups	_
145-30	28092-28093	.	_

#Text=These differences however cannot account for our main finding, i.e., the presence of trans-diagnostic EC alterations between the MDN and the cortex in all clinical groups.
146-1	28094-28099	These	_
146-2	28100-28111	differences	_
146-3	28112-28119	however	_
146-4	28120-28126	cannot	_
146-5	28127-28134	account	_
146-6	28135-28138	for	_
146-7	28139-28142	our	_
146-8	28143-28147	main	_
146-9	28148-28155	finding	_
146-10	28155-28156	,	_
146-11	28157-28160	i.e	_
146-12	28160-28161	.	_
146-13	28161-28162	,	_
146-14	28163-28166	the	_
146-15	28167-28175	presence	_
146-16	28176-28178	of	_
146-17	28179-28195	trans-diagnostic	_
146-18	28196-28198	EC	_
146-19	28199-28210	alterations	_
146-20	28211-28218	between	_
146-21	28219-28222	the	_
146-22	28223-28226	MDN	_
146-23	28227-28230	and	_
146-24	28231-28234	the	_
146-25	28235-28241	cortex	_
146-26	28242-28244	in	_
146-27	28245-28248	all	_
146-28	28249-28257	clinical	_
146-29	28258-28264	groups	_
146-30	28264-28265	.	_

#Text=Thirdly, because the data were acquired using a cross-sectional rather than a longitudinal design, it was not possible to distinguish between correlates of illness vulnerability and correlates of illness onset.
147-1	28266-28273	Thirdly	_
147-2	28273-28274	,	_
147-3	28275-28282	because	_
147-4	28283-28286	the	_
147-5	28287-28291	data	_
147-6	28292-28296	were	_
147-7	28297-28305	acquired	_
147-8	28306-28311	using	_
147-9	28312-28313	a	_
147-10	28314-28329	cross-sectional	_
147-11	28330-28336	rather	_
147-12	28337-28341	than	_
147-13	28342-28343	a	_
147-14	28344-28356	longitudinal	_
147-15	28357-28363	design	_
147-16	28363-28364	,	_
147-17	28365-28367	it	_
147-18	28368-28371	was	_
147-19	28372-28375	not	_
147-20	28376-28384	possible	_
147-21	28385-28387	to	_
147-22	28388-28399	distinguish	_
147-23	28400-28407	between	_
147-24	28408-28418	correlates	_
147-25	28419-28421	of	_
147-26	28422-28429	illness	_
147-27	28430-28443	vulnerability	_
147-28	28444-28447	and	_
147-29	28448-28458	correlates	_
147-30	28459-28461	of	_
147-31	28462-28469	illness	_
147-32	28470-28475	onset	_
147-33	28475-28476	.	_

#Text=Fourthly, our results are based on the MDN and may not be relevant to other sections of the thalamus, which is both structurally and functionally heterogeneous.
148-1	28477-28485	Fourthly	_
148-2	28485-28486	,	_
148-3	28487-28490	our	_
148-4	28491-28498	results	_
148-5	28499-28502	are	_
148-6	28503-28508	based	_
148-7	28509-28511	on	_
148-8	28512-28515	the	_
148-9	28516-28519	MDN	_
148-10	28520-28523	and	_
148-11	28524-28527	may	_
148-12	28528-28531	not	_
148-13	28532-28534	be	_
148-14	28535-28543	relevant	_
148-15	28544-28546	to	_
148-16	28547-28552	other	_
148-17	28553-28561	sections	_
148-18	28562-28564	of	_
148-19	28565-28568	the	_
148-20	28569-28577	thalamus	_
148-21	28577-28578	,	_
148-22	28579-28584	which	_
148-23	28585-28587	is	_
148-24	28588-28592	both	_
148-25	28593-28605	structurally	_
148-26	28606-28609	and	_
148-27	28610-28622	functionally	_
148-28	28623-28636	heterogeneous	_
148-29	28636-28637	.	_

#Text=In conclusion, the present study found limited evidence for schizophrenia-specific alterations, indicating that dysconnectivity of the MDN is not a unique feature of schizophrenia.
149-1	28638-28640	In	_
149-2	28641-28651	conclusion	_
149-3	28651-28652	,	_
149-4	28653-28656	the	_
149-5	28657-28664	present	_
149-6	28665-28670	study	_
149-7	28671-28676	found	_
149-8	28677-28684	limited	_
149-9	28685-28693	evidence	_
149-10	28694-28697	for	_
149-11	28698-28720	schizophrenia-specific	_
149-12	28721-28732	alterations	_
149-13	28732-28733	,	_
149-14	28734-28744	indicating	_
149-15	28745-28749	that	_
149-16	28750-28765	dysconnectivity	_
149-17	28766-28768	of	_
149-18	28769-28772	the	_
149-19	28773-28776	MDN	_
149-20	28777-28779	is	_
149-21	28780-28783	not	_
149-22	28784-28785	a	_
149-23	28786-28792	unique	_
149-24	28793-28800	feature	_
149-25	28801-28803	of	_
149-26	28804-28817	schizophrenia	_
149-27	28817-28818	.	_

#Text=Instead, we found a number of trans-diagnostic alterations, indicating that EC alterations between the MDN and the cortex are primarily a trans-diagnostic feature of psychiatric disorders—compatible with emerging conceptualizations of mental illness based on a single general psychopathology factor.
150-1	28819-28826	Instead	_
150-2	28826-28827	,	_
150-3	28828-28830	we	_
150-4	28831-28836	found	_
150-5	28837-28838	a	_
150-6	28839-28845	number	_
150-7	28846-28848	of	_
150-8	28849-28865	trans-diagnostic	_
150-9	28866-28877	alterations	_
150-10	28877-28878	,	_
150-11	28879-28889	indicating	_
150-12	28890-28894	that	_
150-13	28895-28897	EC	_
150-14	28898-28909	alterations	_
150-15	28910-28917	between	_
150-16	28918-28921	the	_
150-17	28922-28925	MDN	_
150-18	28926-28929	and	_
150-19	28930-28933	the	_
150-20	28934-28940	cortex	_
150-21	28941-28944	are	_
150-22	28945-28954	primarily	_
150-23	28955-28956	a	_
150-24	28957-28973	trans-diagnostic	_
150-25	28974-28981	feature	_
150-26	28982-28984	of	_
150-27	28985-28996	psychiatric	_
150-28	28997-29017	disorders—compatible	_
150-29	29018-29022	with	_
150-30	29023-29031	emerging	_
150-31	29032-29050	conceptualizations	_
150-32	29051-29053	of	_
150-33	29054-29060	mental	_
150-34	29061-29068	illness	_
150-35	29069-29074	based	_
150-36	29075-29077	on	_
150-37	29078-29079	a	_
150-38	29080-29086	single	_
150-39	29087-29094	general	_
150-40	29095-29110	psychopathology	_
150-41	29111-29117	factor	_
150-42	29117-29118	.	_

#Text=Therefore, the EC of MDN could potentially be used to assess the presence and progression of general psychopathology above and beyond traditional diagnostic boundaries.
151-1	29119-29128	Therefore	_
151-2	29128-29129	,	_
151-3	29130-29133	the	_
151-4	29134-29136	EC	_
151-5	29137-29139	of	_
151-6	29140-29143	MDN	_
151-7	29144-29149	could	_
151-8	29150-29161	potentially	_
151-9	29162-29164	be	_
151-10	29165-29169	used	_
151-11	29170-29172	to	_
151-12	29173-29179	assess	_
151-13	29180-29183	the	_
151-14	29184-29192	presence	_
151-15	29193-29196	and	_
151-16	29197-29208	progression	_
151-17	29209-29211	of	_
151-18	29212-29219	general	_
151-19	29220-29235	psychopathology	_
151-20	29236-29241	above	_
151-21	29242-29245	and	_
151-22	29246-29252	beyond	_
151-23	29253-29264	traditional	_
151-24	29265-29275	diagnostic	_
151-25	29276-29286	boundaries	_
151-26	29286-29287	.	_

#Text=Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
152-1	29288-29297	Publisher	_
152-2	29297-29298	’	_
152-3	29298-29299	s	_
152-4	29300-29304	note	_
152-5	29304-29305	:	_
152-6	29306-29314	Springer	_
152-7	29315-29321	Nature	_
152-8	29322-29329	remains	_
152-9	29330-29337	neutral	_
152-10	29338-29342	with	_
152-11	29343-29349	regard	_
152-12	29350-29352	to	_
152-13	29353-29367	jurisdictional	_
152-14	29368-29374	claims	_
152-15	29375-29377	in	_
152-16	29378-29387	published	_
152-17	29388-29392	maps	_
152-18	29393-29396	and	_
152-19	29397-29410	institutional	_
152-20	29411-29423	affiliations	_
152-21	29423-29424	.	_

#Text=Conflict of interest
#Text=The authors declare that they have no conflict of interest.
153-1	29425-29433	Conflict	_
153-2	29434-29436	of	_
153-3	29437-29445	interest	_
153-4	29446-29449	The	_
153-5	29450-29457	authors	_
153-6	29458-29465	declare	_
153-7	29466-29470	that	_
153-8	29471-29475	they	_
153-9	29476-29480	have	_
153-10	29481-29483	no	_
153-11	29484-29492	conflict	_
153-12	29493-29495	of	_
153-13	29496-29504	interest	_
153-14	29504-29505	.	_

#Text=References
#Text=Miller, A., McEvoy, J., Jeste, D. & Marder, S. in Textbook of Schizophrenia (eds Lieberman J., Stroup T. & Perkins, D.) 365–381 (The American Psychiatric Publishing, Washington, DC, 2006).
154-1	29506-29516	References	_
154-2	29517-29523	Miller	_
154-3	29523-29524	,	_
154-4	29525-29526	A	_
154-5	29526-29527	.	_
154-6	29527-29528	,	_
154-7	29529-29535	McEvoy	_
154-8	29535-29536	,	_
154-9	29537-29538	J	_
154-10	29538-29539	.	_
154-11	29539-29540	,	_
154-12	29541-29546	Jeste	_
154-13	29546-29547	,	_
154-14	29548-29549	D	_
154-15	29549-29550	.	_
154-16	29551-29552	&	_
154-17	29553-29559	Marder	_
154-18	29559-29560	,	_
154-19	29561-29562	S	_
154-20	29562-29563	.	_
154-21	29564-29566	in	_
154-22	29567-29575	Textbook	_
154-23	29576-29578	of	_
154-24	29579-29592	Schizophrenia	_
154-25	29593-29594	(	_
154-26	29594-29597	eds	_
154-27	29598-29607	Lieberman	_
154-28	29608-29609	J	_
154-29	29609-29610	.	_
154-30	29610-29611	,	_
154-31	29612-29618	Stroup	_
154-32	29619-29620	T	_
154-33	29620-29621	.	_
154-34	29622-29623	&	_
154-35	29624-29631	Perkins	_
154-36	29631-29632	,	_
154-37	29633-29634	D	_
154-38	29634-29635	.	_
154-39	29635-29636	)	_
154-40	29637-29640	365	_
154-41	29640-29641	–	_
154-42	29641-29644	381	_
154-43	29645-29646	(	_
154-44	29646-29649	The	_
154-45	29650-29658	American	_
154-46	29659-29670	Psychiatric	_
154-47	29671-29681	Publishing	_
154-48	29681-29682	,	_
154-49	29683-29693	Washington	_
154-50	29693-29694	,	_
154-51	29695-29697	DC	_
154-52	29697-29698	,	_
154-53	29699-29703	2006	_
154-54	29703-29704	)	_
154-55	29704-29705	.	_

#Text=Brain networks in schizophrenia
#Text=Thalamocortical dysconnectivity in schizophrenia
#Text=Voxel-based, brain-wide association study of aberrant functional connectivity in schizophrenia implicates thalamocortical circuitry
#Text=Disrupted thalamic resting-state functional networks in schizophrenia
#Text=Network community structure alterations in adult schizophrenia: Identification and localization of alterations
#Text=Low-frequency BOLD fluctuations demonstrate altered thalamocortical connectivity in schizophrenia
#Text=The role of the thalamus in schizophrenia from a neuroimaging perspective
#Text=Characterizing thalamo-cortical disturbances in Schizophrenia and bipolar illness
#Text=Altered resting-state functional connectivity of thalamus in earthquake-induced posttraumatic stress disorder: a functional magnetic resonance imaging study
#Text=The limbic thalamus
#Text=Activity and connectivity of brain mood regulating circuit in depression: a functional magnetic resonance study
#Text=SHort-term effects of antipsychotic treatment on cerebral function in drug-naive first-episode schizophrenia revealed by “resting state” functional magnetic resonance imaging
#Text=The p factor: one general psychopathology factor in the structure of psychiatric disorders?
155-1	29706-29711	Brain	_
155-2	29712-29720	networks	_
155-3	29721-29723	in	_
155-4	29724-29737	schizophrenia	_
155-5	29738-29753	Thalamocortical	_
155-6	29754-29769	dysconnectivity	_
155-7	29770-29772	in	_
155-8	29773-29786	schizophrenia	_
155-9	29787-29798	Voxel-based	_
155-10	29798-29799	,	_
155-11	29800-29810	brain-wide	_
155-12	29811-29822	association	_
155-13	29823-29828	study	_
155-14	29829-29831	of	_
155-15	29832-29840	aberrant	_
155-16	29841-29851	functional	_
155-17	29852-29864	connectivity	_
155-18	29865-29867	in	_
155-19	29868-29881	schizophrenia	_
155-20	29882-29892	implicates	_
155-21	29893-29908	thalamocortical	_
155-22	29909-29918	circuitry	_
155-23	29919-29928	Disrupted	_
155-24	29929-29937	thalamic	_
155-25	29938-29951	resting-state	_
155-26	29952-29962	functional	_
155-27	29963-29971	networks	_
155-28	29972-29974	in	_
155-29	29975-29988	schizophrenia	_
155-30	29989-29996	Network	_
155-31	29997-30006	community	_
155-32	30007-30016	structure	_
155-33	30017-30028	alterations	_
155-34	30029-30031	in	_
155-35	30032-30037	adult	_
155-36	30038-30051	schizophrenia	_
155-37	30051-30052	:	_
155-38	30053-30067	Identification	_
155-39	30068-30071	and	_
155-40	30072-30084	localization	_
155-41	30085-30087	of	_
155-42	30088-30099	alterations	_
155-43	30100-30113	Low-frequency	_
155-44	30114-30118	BOLD	_
155-45	30119-30131	fluctuations	_
155-46	30132-30143	demonstrate	_
155-47	30144-30151	altered	_
155-48	30152-30167	thalamocortical	_
155-49	30168-30180	connectivity	_
155-50	30181-30183	in	_
155-51	30184-30197	schizophrenia	_
155-52	30198-30201	The	_
155-53	30202-30206	role	_
155-54	30207-30209	of	_
155-55	30210-30213	the	_
155-56	30214-30222	thalamus	_
155-57	30223-30225	in	_
155-58	30226-30239	schizophrenia	_
155-59	30240-30244	from	_
155-60	30245-30246	a	_
155-61	30247-30259	neuroimaging	_
155-62	30260-30271	perspective	_
155-63	30272-30286	Characterizing	_
155-64	30287-30303	thalamo-cortical	_
155-65	30304-30316	disturbances	_
155-66	30317-30319	in	_
155-67	30320-30333	Schizophrenia	_
155-68	30334-30337	and	_
155-69	30338-30345	bipolar	_
155-70	30346-30353	illness	_
155-71	30354-30361	Altered	_
155-72	30362-30375	resting-state	_
155-73	30376-30386	functional	_
155-74	30387-30399	connectivity	_
155-75	30400-30402	of	_
155-76	30403-30411	thalamus	_
155-77	30412-30414	in	_
155-78	30415-30433	earthquake-induced	_
155-79	30434-30447	posttraumatic	_
155-80	30448-30454	stress	_
155-81	30455-30463	disorder	_
155-82	30463-30464	:	_
155-83	30465-30466	a	_
155-84	30467-30477	functional	_
155-85	30478-30486	magnetic	_
155-86	30487-30496	resonance	_
155-87	30497-30504	imaging	_
155-88	30505-30510	study	_
155-89	30511-30514	The	_
155-90	30515-30521	limbic	_
155-91	30522-30530	thalamus	_
155-92	30531-30539	Activity	_
155-93	30540-30543	and	_
155-94	30544-30556	connectivity	_
155-95	30557-30559	of	_
155-96	30560-30565	brain	_
155-97	30566-30570	mood	_
155-98	30571-30581	regulating	_
155-99	30582-30589	circuit	_
155-100	30590-30592	in	_
155-101	30593-30603	depression	_
155-102	30603-30604	:	_
155-103	30605-30606	a	_
155-104	30607-30617	functional	_
155-105	30618-30626	magnetic	_
155-106	30627-30636	resonance	_
155-107	30637-30642	study	_
155-108	30643-30653	SHort-term	_
155-109	30654-30661	effects	_
155-110	30662-30664	of	_
155-111	30665-30678	antipsychotic	_
155-112	30679-30688	treatment	_
155-113	30689-30691	on	_
155-114	30692-30700	cerebral	_
155-115	30701-30709	function	_
155-116	30710-30712	in	_
155-117	30713-30723	drug-naive	_
155-118	30724-30737	first-episode	_
155-119	30738-30751	schizophrenia	_
155-120	30752-30760	revealed	_
155-121	30761-30763	by	_
155-122	30764-30765	“	_
155-123	30765-30772	resting	_
155-124	30773-30778	state	_
155-125	30778-30779	”	_
155-126	30780-30790	functional	_
155-127	30791-30799	magnetic	_
155-128	30800-30809	resonance	_
155-129	30810-30817	imaging	_
155-130	30818-30821	The	_
155-131	30822-30823	p	_
155-132	30824-30830	factor	_
155-133	30830-30831	:	_
155-134	30832-30835	one	_
155-135	30836-30843	general	_
155-136	30844-30859	psychopathology	_
155-137	30860-30866	factor	_
155-138	30867-30869	in	_
155-139	30870-30873	the	_
155-140	30874-30883	structure	_
155-141	30884-30886	of	_
155-142	30887-30898	psychiatric	_
155-143	30899-30908	disorders	_
155-144	30908-30909	?	_

#Text=Resting-state functional connectivity in treatment-resistant depression
#Text=Anatomical and functional brain abnormalities in drug-naive first-episode schizophrenia
#Text=Abnormalities in whole-brain functional connectivity observed in treatment-naive post-traumatic stress disorder patients following an earthquake
#Text=Network-level functional connectivity in first episode psychosis: dissociating trans-diagnostic and diagnosis-specific alterations
#Text=The positive and negative syndrome scale (PANSS) for schizophrenia
#Text=A structured interview guide for the Hamilton Depression Rating Scale
#Text=Weathers, F, Litz, B, Huska, J. & Keane, T.
156-1	30910-30923	Resting-state	_
156-2	30924-30934	functional	_
156-3	30935-30947	connectivity	_
156-4	30948-30950	in	_
156-5	30951-30970	treatment-resistant	_
156-6	30971-30981	depression	_
156-7	30982-30992	Anatomical	_
156-8	30993-30996	and	_
156-9	30997-31007	functional	_
156-10	31008-31013	brain	_
156-11	31014-31027	abnormalities	_
156-12	31028-31030	in	_
156-13	31031-31041	drug-naive	_
156-14	31042-31055	first-episode	_
156-15	31056-31069	schizophrenia	_
156-16	31070-31083	Abnormalities	_
156-17	31084-31086	in	_
156-18	31087-31098	whole-brain	_
156-19	31099-31109	functional	_
156-20	31110-31122	connectivity	_
156-21	31123-31131	observed	_
156-22	31132-31134	in	_
156-23	31135-31150	treatment-naive	_
156-24	31151-31165	post-traumatic	_
156-25	31166-31172	stress	_
156-26	31173-31181	disorder	_
156-27	31182-31190	patients	_
156-28	31191-31200	following	_
156-29	31201-31203	an	_
156-30	31204-31214	earthquake	_
156-31	31215-31228	Network-level	_
156-32	31229-31239	functional	_
156-33	31240-31252	connectivity	_
156-34	31253-31255	in	_
156-35	31256-31261	first	_
156-36	31262-31269	episode	_
156-37	31270-31279	psychosis	_
156-38	31279-31280	:	_
156-39	31281-31293	dissociating	_
156-40	31294-31310	trans-diagnostic	_
156-41	31311-31314	and	_
156-42	31315-31333	diagnosis-specific	_
156-43	31334-31345	alterations	_
156-44	31346-31349	The	_
156-45	31350-31358	positive	_
156-46	31359-31362	and	_
156-47	31363-31371	negative	_
156-48	31372-31380	syndrome	_
156-49	31381-31386	scale	_
156-50	31387-31388	(	_
156-51	31388-31393	PANSS	_
156-52	31393-31394	)	_
156-53	31395-31398	for	_
156-54	31399-31412	schizophrenia	_
156-55	31413-31414	A	_
156-56	31415-31425	structured	_
156-57	31426-31435	interview	_
156-58	31436-31441	guide	_
156-59	31442-31445	for	_
156-60	31446-31449	the	_
156-61	31450-31458	Hamilton	_
156-62	31459-31469	Depression	_
156-63	31470-31476	Rating	_
156-64	31477-31482	Scale	_
156-65	31483-31491	Weathers	_
156-66	31491-31492	,	_
156-67	31493-31494	F	_
156-68	31494-31495	,	_
156-69	31496-31500	Litz	_
156-70	31500-31501	,	_
156-71	31502-31503	B	_
156-72	31503-31504	,	_
156-73	31505-31510	Huska	_
156-74	31510-31511	,	_
156-75	31512-31513	J	_
156-76	31513-31514	.	_
156-77	31515-31516	&	_
156-78	31517-31522	Keane	_
156-79	31522-31523	,	_
156-80	31524-31525	T	_
156-81	31525-31526	.	_

#Text=PTSD CheckList—Civilian Version (PCL-C) 16–17 (National Center for PTSD Behavioural Science Division, Boston, MA, 1994).
157-1	31527-31531	PTSD	_
157-2	31532-31550	CheckList—Civilian	_
157-3	31551-31558	Version	_
157-4	31559-31560	(	_
157-5	31560-31565	PCL-C	_
157-6	31565-31566	)	_
157-7	31567-31569	16	_
157-8	31569-31570	–	_
157-9	31570-31572	17	_
157-10	31573-31574	(	_
157-11	31574-31582	National	_
157-12	31583-31589	Center	_
157-13	31590-31593	for	_
157-14	31594-31598	PTSD	_
157-15	31599-31610	Behavioural	_
157-16	31611-31618	Science	_
157-17	31619-31627	Division	_
157-18	31627-31628	,	_
157-19	31629-31635	Boston	_
157-20	31635-31636	,	_
157-21	31637-31639	MA	_
157-22	31639-31640	,	_
157-23	31641-31645	1994	_
157-24	31645-31646	)	_
157-25	31646-31647	.	_

#Text=Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion
#Text=An automated method for neuroanatomic and cytoarchitectonic/ratlas-based interrogation of fMRI data sets
#Text=Region of Interest Analysis Using the MarsBar Toolbox for SPM 99
#Text=Psychophysiological and modulatory interactions in neuroimaging
#Text=Basal ganglia output to the thalamus: still a paradox
#Text=Abnormal asymmetries in subcortical brain volume in schizophrenia
#Text=Cortical-basal ganglia imbalance in schizophrenia patients and unaffected first-degree relatives
#Text=The diminished interhemispheric connectivity correlates with negative symptoms and cognitive impairment in first-episode schizophrenia
#Text=Relationship of lesion location to cognitive outcome following microelectrode-guided pallidotomy for Parkinson’s disease: support for the existence of cognitive circuits in the human pallidum
#Text=Functional magnetic resonance imaging evidence for disrupted basal ganglia function in schizophrenia
#Text=Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy
#Text=Mediodorsal and visual thalamic connectivity differ in schizophrenia and bipolar disorder with and without psychosis history
#Text=Mapping thalamocortical functional connectivity in chronic and early stages of psychotic disorders
#Text=Thalamocortical connectivity during resting state in schizophrenia
#Text=Neurobiology of posttraumatic stress disorder
#Text=Gray colored glasses: is major depression partially a sensory perceptual disorder?
158-1	31648-31656	Spurious	_
158-2	31657-31660	but	_
158-3	31661-31671	systematic	_
158-4	31672-31684	correlations	_
158-5	31685-31687	in	_
158-6	31688-31698	functional	_
158-7	31699-31711	connectivity	_
158-8	31712-31715	MRI	_
158-9	31716-31724	networks	_
158-10	31725-31730	arise	_
158-11	31731-31735	from	_
158-12	31736-31743	subject	_
158-13	31744-31750	motion	_
158-14	31751-31753	An	_
158-15	31754-31763	automated	_
158-16	31764-31770	method	_
158-17	31771-31774	for	_
158-18	31775-31788	neuroanatomic	_
158-19	31789-31792	and	_
158-20	31793-31810	cytoarchitectonic	_
158-21	31810-31811	/	_
158-22	31811-31823	ratlas-based	_
158-23	31824-31837	interrogation	_
158-24	31838-31840	of	_
158-25	31841-31845	fMRI	_
158-26	31846-31850	data	_
158-27	31851-31855	sets	_
158-28	31856-31862	Region	_
158-29	31863-31865	of	_
158-30	31866-31874	Interest	_
158-31	31875-31883	Analysis	_
158-32	31884-31889	Using	_
158-33	31890-31893	the	_
158-34	31894-31901	MarsBar	_
158-35	31902-31909	Toolbox	_
158-36	31910-31913	for	_
158-37	31914-31917	SPM	_
158-38	31918-31920	99	_
158-39	31921-31940	Psychophysiological	_
158-40	31941-31944	and	_
158-41	31945-31955	modulatory	_
158-42	31956-31968	interactions	_
158-43	31969-31971	in	_
158-44	31972-31984	neuroimaging	_
158-45	31985-31990	Basal	_
158-46	31991-31998	ganglia	_
158-47	31999-32005	output	_
158-48	32006-32008	to	_
158-49	32009-32012	the	_
158-50	32013-32021	thalamus	_
158-51	32021-32022	:	_
158-52	32023-32028	still	_
158-53	32029-32030	a	_
158-54	32031-32038	paradox	_
158-55	32039-32047	Abnormal	_
158-56	32048-32059	asymmetries	_
158-57	32060-32062	in	_
158-58	32063-32074	subcortical	_
158-59	32075-32080	brain	_
158-60	32081-32087	volume	_
158-61	32088-32090	in	_
158-62	32091-32104	schizophrenia	_
158-63	32105-32119	Cortical-basal	_
158-64	32120-32127	ganglia	_
158-65	32128-32137	imbalance	_
158-66	32138-32140	in	_
158-67	32141-32154	schizophrenia	_
158-68	32155-32163	patients	_
158-69	32164-32167	and	_
158-70	32168-32178	unaffected	_
158-71	32179-32191	first-degree	_
158-72	32192-32201	relatives	_
158-73	32202-32205	The	_
158-74	32206-32216	diminished	_
158-75	32217-32233	interhemispheric	_
158-76	32234-32246	connectivity	_
158-77	32247-32257	correlates	_
158-78	32258-32262	with	_
158-79	32263-32271	negative	_
158-80	32272-32280	symptoms	_
158-81	32281-32284	and	_
158-82	32285-32294	cognitive	_
158-83	32295-32305	impairment	_
158-84	32306-32308	in	_
158-85	32309-32322	first-episode	_
158-86	32323-32336	schizophrenia	_
158-87	32337-32349	Relationship	_
158-88	32350-32352	of	_
158-89	32353-32359	lesion	_
158-90	32360-32368	location	_
158-91	32369-32371	to	_
158-92	32372-32381	cognitive	_
158-93	32382-32389	outcome	_
158-94	32390-32399	following	_
158-95	32400-32421	microelectrode-guided	_
158-96	32422-32433	pallidotomy	_
158-97	32434-32437	for	_
158-98	32438-32447	Parkinson	_
158-99	32447-32448	’	_
158-100	32448-32449	s	_
158-101	32450-32457	disease	_
158-102	32457-32458	:	_
158-103	32459-32466	support	_
158-104	32467-32470	for	_
158-105	32471-32474	the	_
158-106	32475-32484	existence	_
158-107	32485-32487	of	_
158-108	32488-32497	cognitive	_
158-109	32498-32506	circuits	_
158-110	32507-32509	in	_
158-111	32510-32513	the	_
158-112	32514-32519	human	_
158-113	32520-32528	pallidum	_
158-114	32529-32539	Functional	_
158-115	32540-32548	magnetic	_
158-116	32549-32558	resonance	_
158-117	32559-32566	imaging	_
158-118	32567-32575	evidence	_
158-119	32576-32579	for	_
158-120	32580-32589	disrupted	_
158-121	32590-32595	basal	_
158-122	32596-32603	ganglia	_
158-123	32604-32612	function	_
158-124	32613-32615	in	_
158-125	32616-32629	schizophrenia	_
158-126	32630-32639	Cognitive	_
158-127	32640-32651	dysfunction	_
158-128	32652-32654	in	_
158-129	32655-32666	psychiatric	_
158-130	32667-32676	disorders	_
158-131	32676-32677	:	_
158-132	32678-32693	characteristics	_
158-133	32693-32694	,	_
158-134	32695-32701	causes	_
158-135	32702-32705	and	_
158-136	32706-32709	the	_
158-137	32710-32715	quest	_
158-138	32716-32719	for	_
158-139	32720-32728	improved	_
158-140	32729-32736	therapy	_
158-141	32737-32748	Mediodorsal	_
158-142	32749-32752	and	_
158-143	32753-32759	visual	_
158-144	32760-32768	thalamic	_
158-145	32769-32781	connectivity	_
158-146	32782-32788	differ	_
158-147	32789-32791	in	_
158-148	32792-32805	schizophrenia	_
158-149	32806-32809	and	_
158-150	32810-32817	bipolar	_
158-151	32818-32826	disorder	_
158-152	32827-32831	with	_
158-153	32832-32835	and	_
158-154	32836-32843	without	_
158-155	32844-32853	psychosis	_
158-156	32854-32861	history	_
158-157	32862-32869	Mapping	_
158-158	32870-32885	thalamocortical	_
158-159	32886-32896	functional	_
158-160	32897-32909	connectivity	_
158-161	32910-32912	in	_
158-162	32913-32920	chronic	_
158-163	32921-32924	and	_
158-164	32925-32930	early	_
158-165	32931-32937	stages	_
158-166	32938-32940	of	_
158-167	32941-32950	psychotic	_
158-168	32951-32960	disorders	_
158-169	32961-32976	Thalamocortical	_
158-170	32977-32989	connectivity	_
158-171	32990-32996	during	_
158-172	32997-33004	resting	_
158-173	33005-33010	state	_
158-174	33011-33013	in	_
158-175	33014-33027	schizophrenia	_
158-176	33028-33040	Neurobiology	_
158-177	33041-33043	of	_
158-178	33044-33057	posttraumatic	_
158-179	33058-33064	stress	_
158-180	33065-33073	disorder	_
158-181	33074-33078	Gray	_
158-182	33079-33086	colored	_
158-183	33087-33094	glasses	_
158-184	33094-33095	:	_
158-185	33096-33098	is	_
158-186	33099-33104	major	_
158-187	33105-33115	depression	_
158-188	33116-33125	partially	_
158-189	33126-33127	a	_
158-190	33128-33135	sensory	_
158-191	33136-33146	perceptual	_
158-192	33147-33155	disorder	_
158-193	33155-33156	?	_

#Text=Association of thalamic dysconnectivity and conversion to psychosis in youth and young adults at elevated clinical risk
#Text=Convergent and divergent functional connectivity patterns in schizophrenia and depression
#Text=Impaired cognitive control mediates the relationship between cortical thickness of the superior frontal gyrus and role functioning in schizophrenia
#Text=Neuroanatomical mechanism on the effect of distraction in working memory maintenance in patients with schizophrenia
#Text=The neural correlates of the verbal component of working memory
#Text=Altered striatal functional connectivity in subjects with an at-risk mental state for psychosis
#Text=Thalamo-cortical functional connectivity in schizophrenia and bipolar disorder
159-1	33157-33168	Association	_
159-2	33169-33171	of	_
159-3	33172-33180	thalamic	_
159-4	33181-33196	dysconnectivity	_
159-5	33197-33200	and	_
159-6	33201-33211	conversion	_
159-7	33212-33214	to	_
159-8	33215-33224	psychosis	_
159-9	33225-33227	in	_
159-10	33228-33233	youth	_
159-11	33234-33237	and	_
159-12	33238-33243	young	_
159-13	33244-33250	adults	_
159-14	33251-33253	at	_
159-15	33254-33262	elevated	_
159-16	33263-33271	clinical	_
159-17	33272-33276	risk	_
159-18	33277-33287	Convergent	_
159-19	33288-33291	and	_
159-20	33292-33301	divergent	_
159-21	33302-33312	functional	_
159-22	33313-33325	connectivity	_
159-23	33326-33334	patterns	_
159-24	33335-33337	in	_
159-25	33338-33351	schizophrenia	_
159-26	33352-33355	and	_
159-27	33356-33366	depression	_
159-28	33367-33375	Impaired	_
159-29	33376-33385	cognitive	_
159-30	33386-33393	control	_
159-31	33394-33402	mediates	_
159-32	33403-33406	the	_
159-33	33407-33419	relationship	_
159-34	33420-33427	between	_
159-35	33428-33436	cortical	_
159-36	33437-33446	thickness	_
159-37	33447-33449	of	_
159-38	33450-33453	the	_
159-39	33454-33462	superior	_
159-40	33463-33470	frontal	_
159-41	33471-33476	gyrus	_
159-42	33477-33480	and	_
159-43	33481-33485	role	_
159-44	33486-33497	functioning	_
159-45	33498-33500	in	_
159-46	33501-33514	schizophrenia	_
159-47	33515-33530	Neuroanatomical	_
159-48	33531-33540	mechanism	_
159-49	33541-33543	on	_
159-50	33544-33547	the	_
159-51	33548-33554	effect	_
159-52	33555-33557	of	_
159-53	33558-33569	distraction	_
159-54	33570-33572	in	_
159-55	33573-33580	working	_
159-56	33581-33587	memory	_
159-57	33588-33599	maintenance	_
159-58	33600-33602	in	_
159-59	33603-33611	patients	_
159-60	33612-33616	with	_
159-61	33617-33630	schizophrenia	_
159-62	33631-33634	The	_
159-63	33635-33641	neural	_
159-64	33642-33652	correlates	_
159-65	33653-33655	of	_
159-66	33656-33659	the	_
159-67	33660-33666	verbal	_
159-68	33667-33676	component	_
159-69	33677-33679	of	_
159-70	33680-33687	working	_
159-71	33688-33694	memory	_
159-72	33695-33702	Altered	_
159-73	33703-33711	striatal	_
159-74	33712-33722	functional	_
159-75	33723-33735	connectivity	_
159-76	33736-33738	in	_
159-77	33739-33747	subjects	_
159-78	33748-33752	with	_
159-79	33753-33755	an	_
159-80	33756-33763	at-risk	_
159-81	33764-33770	mental	_
159-82	33771-33776	state	_
159-83	33777-33780	for	_
159-84	33781-33790	psychosis	_
159-85	33791-33807	Thalamo-cortical	_
159-86	33808-33818	functional	_
159-87	33819-33831	connectivity	_
159-88	33832-33834	in	_
159-89	33835-33848	schizophrenia	_
159-90	33849-33852	and	_
159-91	33853-33860	bipolar	_
159-92	33861-33869	disorder	_
